var title_f12_62_13280="Scaphoid shift test 1";
var content_f12_62_13280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Scaphoid shift test: Step 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 480px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    To perform the scaphoid shift test, first have the patient position their forearm so it is angled towards you. Then grasp the patient's hand around the metacarpals from the dorsal side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin deWeber, MD, FAAFP, FACSM.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_62_13280=[""].join("\n");
var outline_f12_62_13280=null;
var title_f12_62_13281="Patient information: Black eye (The Basics)";
var content_f12_62_13281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/10/42145\">",
"         Patient information: Taking care of bruises (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Black eye (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/black-eye-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6700727\">",
"      <span class=\"h1\">",
"       What is a black eye?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A black eye happens when something hits your eye, cheek, or nose and causes a bruise above or under your eye. Bruises happen when blood vessels under the skin break, but the skin isn&rsquo;t cut. When the blood vessels break, blood leaks into the tissues under the skin and makes it change color.",
"     </p>",
"     <p>",
"      A black eye starts off red in color, and then turns blue or purple. As it heals, a black eye can turn green and yellow. Often, the swelling gets worse in the first day after the injury or when you wake up the next morning. Most black eyes heal in 1 to 2 weeks, but some take longer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6700742\">",
"      <span class=\"h1\">",
"       How is a black eye treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A black eye doesn&rsquo;t need treatment. It will get better on its own. But you can &ldquo;ice&rdquo; your black eye to make it feel better and help it heal. To do this, put a cold gel pack, bag of ice, or bag of frozen vegetables on the injured area every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and your skin. Use the ice (or other cold object) for at least 6 hours after your injury. Some people find it helpful to ice longer, even up to 2 days after their injury.",
"     </p>",
"     <p>",
"      You can also take medicines such as",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;) to help with the pain and swelling. But people who have certain conditions or take certain medicines should not take ibuprofen. If you aren&rsquo;t sure whether you can take ibuprofen, ask your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6700757\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if you have any of these symptoms with your black eye:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Any problems seeing, such as blurred vision or double vision",
"       </li>",
"       <li>",
"        Very bad pain in your eye, especially when trying to move it from side to side",
"       </li>",
"       <li>",
"        Bleeding from the eye",
"       </li>",
"       <li>",
"        Nausea and vomiting",
"       </li>",
"       <li>",
"        A slow heart rate",
"       </li>",
"       <li>",
"        Trouble breathing through your nose",
"       </li>",
"       <li>",
"        Your nose looks crooked.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6700772\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Most people don&rsquo;t need tests for a black eye, but your doctor might want you to have an eye exam. Plus, if you are having trouble seeing or moving your eye, your doctor might take a special kind of X-ray called a CT scan. The CT scan will show if any of the bones around your eye are broken. It can also show if you have damage to the eyeball itself.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6700789\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42145?source=see_link\">",
"       Patient information: Taking care of bruises (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?12/62/13281?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16985 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-ACA0B7D5D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_62_13281=[""].join("\n");
var outline_f12_62_13281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6700727\">",
"      What is a black eye?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6700742\">",
"      How is a black eye treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6700757\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6700772\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6700789\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/10/42145?source=related_link\">",
"      Patient information: Taking care of bruises (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_62_13282="Acrochordon - close view";
var content_f12_62_13282=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acrochordon (also known as skin tag or soft fibroma)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFFAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0GFRtDHOQe/epC7bflz6c9KsStGnyqwJ9KhZlLc529K8/lPbuQiRt2CSMDINWSFdlyc9ulVp4s85HcUiShIyATv8AwqfUqzZNlFkYEDAqJc3EwVQdoP4VXjbefmHftUxm8ttqAZIxQmOzRbuvLEIjUgMO4qnG6sfm5z79KRjuALnJxUkUSuVJxjOfpTbuK1kRso3KqAY7EVYkVY4yDgt/KnSeWg+Rhtx1qJSAMnlvrQJaszJZNsyfKfcjvVqNWjCuc4zVs2sflmWT8M1BKjeWu0gg9hUWtqzTmutBzTqUCr9PqaBtj2s+TVmCKMW6EYLnrz0qpIjySYX6e1Oz3BNbILm7MjBADtB4461SQvI5GOR2FX1jEL/vArHvg1o2NsrBnmAVOozSs5A5KJmbCyp5gAUCpS5iBZW+UHFT3PlsORkDpVZk3/IFbj3xScRKWupEbh3YseVPHripUVpCvzqMnn2qeG2SPdlRnqBTLi2ww8oEEDJ460lGRTkr6ENzMPm8sEY4GKWMu7LvYsO+e1SLAAnzJT2kWNPugE099RN9B806rgouSMfL7U437NGpRQvbpVPbJKw3A4GeKlS12gNIBjOKd2ibK2obi25pTtzyR0pI2V327Se2Knkjh2uQcn64xRawKPnwQD3xSTYhmyMMVbAXHBB70RRNKxC4werk9KsNGoyDhgvUVXleRk8uEbVzkY5zRew76WGLsSVlI38YB9KuR5nKhyFRRxxjJqGG1KbDJgb+mT1qOTeq7S3y9hirWi1Ibu9B0l4YFdoRyRjdjpWWnnSTFsEOD36Y9RV+ONGcBiBGvBzT4g4P7sYV+P8A61LcewscCKvnNJjB4GOT9KrSp9pkLJCVQcljV1NoH79gSM4B6fjSm58x0jdVWBDllTvV2T0Iu1qM+z/ZrdQ/yyMAwBHUetVZJJJMRuNzdiPSrLzPf3DEcHPA7AVDeXMFuhhtsmXBG7Hc1VtNBJtsigRYpcnAU8ruNP8AKyzESIxXLYBqsHJjJIGFA+Zj1qOe9HliOJtiY5wOv+TU8yS1KcW2XHnSOMBVALcH1qGfMgVNgJ+nTmoUV9yO4wCMDcOCaeild7ysoY4AGc5x6UnJvQLJIBM5d4LeNlGACx/i+lDWsilTIy9jtA/rU0mpOo2xRxoVPBC4NVI75Ydz3Ay+MDI7+tD5WCujUvp5bZokCruVeD0yDWdfXj3WGdETHdVxmq7XM11vkO7Le+c+30qvM0m4PIuyNgMLkZ9KltsaiupYKFo8OuBu6d//ANVEyhURFB6dPTNEKBnO8mKI9cfx+lTtFK2JZAyxk9SOpos3qJzSKMdskjbhI7MoyxPQeuTV2Is9wUhcxKR94cYwKjvn2QhkyPm5GeMVGkhyWGF3LgnPQYqkuXUhycthZJsMuSWXOT1z+NMmlEhkYlvMzgZH4VAwBBcnAU4qlcM+7KOw5ByOaTl0LUeqNcX32aB0jjHmHCBsYx3P41WhknnmMagZc5wOap20ElxOFkk8qH+JnrUu5bUMIrUfInAcDBxirV3qTKyehNcPDbQCKN98jBSX7gjnFZkt4jK73ALluhPU0phMrJtLAehGKI7WEOr3bkDdxGnJ49fSiTewk11NuHfgEsc989cVKk6rkYy1VpHBwuSQPTihkEYyQTnketStDdxRae5xE3dm/wAKy/LYyogJJPJx2pw3kbuf5U+ONwDIDg9qmTuaRVkXLJRG7K/J9DSv+8OSME8ZB6VVhldGLtnJ9PWtGz2qfPmxj0oSurEydmQywbFR3zt/Kk84sxMSnGO1Ov7hrmUbIzt6UqwMsZ6D2IxTa7E+pWlZm+7kj27VMypCiMHLZ6802dVOcAj1OKghQFto3Edsms7W3KTurFqW48xOThR0WqjXEjSbBwg59j71LtDtsVcE9TVpIY8FpFHyUO8mCaSI1kCFWIJHGaUzjexVcD0Bp88u5VCRhQPzotYA4JccdcVfoJNbsdGQIS8nLHpxmlZmdSC7Y44NKMMvGCBxjvShAU38fL196aZDY1U3EDoh/WrKIqgHPI9KhViOATwMY6VJCSrBWJxjrU6Jhe5KDtT7nPc05I2YbjkD1q1B5RXJGB1yelRzPLI5EYJC9eMVRnfUhwQwUdB0Paq0y5m3dsdqvNC4Cs7rz0AOcVC0IDj5smk1qWmRQpKdyxkbR1qUwSPKAg6AYANWY0OzGOAOfcURB5H224AX09aF2EylNbrGMS4JYcinxzkIFVM4GBmrF1bv5gEiMoxjjmoIY1wwJIP8HGKT0ehS1QiCJxlixPPCjFDsByFwuOpPSppPLRVUdTwRjNV5GTa27kdOKsTV2NOXUt/CPU1EiE7gOeepqWL57dpMZQHBOaZbT+Y4ZVARckDGOaGgIZdigryT0AqCRneNkjDITgZXotXZQ6yjzsKWOQByTU000drH86jzCPlQH9TT5eonLyKsVrIEVXkyWG457AetV2khVBhmJz0boadJM7KSzhXfhvYelUeWkKqxfHTFJ2Q1qTPcOw2Km0842jtTTHJI6oiEnHyg45ppj2EmRlTsRnJqB75VmJ+YYBXIOMfSlfuNRux2oK1vL5VxLvkHBVe3tUSeWg3Mo39AFOcn3qEyxvGbiVy2SQgP3mPrSj52CDgt/EeOOtK63LlGyNGWeQWKIHG5jv21Cqbx84yRjPaoPNUIFYZY8fSpGBVsqwy2OnSqbT2MndEu2PzC5wEU5AOeRVaGIz3LRxEn8eBVhYVfIJIXGSM8kCnPKPJCQgRIBltozn8afKTzMikeMLsVSdpxnOM+tVlhEk5UB+Tk7vSra2TmIyDeI+5xyTUSeaxZYgQSOcdx6UNMV10L8D/Z4cpjjBzgcVTa486T99K+R0HpThFIJPLuGSNjxzyB+VVxHGjlZufmyMdcVauRp1LgjC2rzygKhO1ARktVEEZQRkAsfl4yPxqWV2uBw42JnBJPH0qt+5EiCSQ4HJzziolvoXFiywSOJCz7mB4PAyaS0tCr5nU4x1I6Ui3itJhTlc46Y4qKWQxuVRsZyOvak7LULt6FieQFQRGqgZyQM0ltdqTl1QJwCVHTFVWhYDDNll9WzmmR280rBIY3ZiO3T8aXM+g7LYv/AGxGlXgMc8YPCjP86cjF5ZJGB2ElvlGePeqKwrGspPDocAA8Z71ImoFLWSCM7TIfn5/Kr5+5PLfY29kcYABBbvmoxex+biUfKoyMiq87bmGAMH04qOC38xmd8+vNQ7nUl3LImR5ic7U7CpjcLKdqEFRWbIiiZQFI/GrKS5X5Rt7UtepVi4ghXLM3HTFI08I4GW9h0qkEZ5NobOeRVpYIlIDuQwHanr0Ja7lmGfYnKDnoar3k7FVUHBP+e1SrHAql9+T2HenNZC7jLfd2+/alZvQWi1ZUgeQHyxyzfrVtIsNmXhF5+tR7WtmBiAyvXml8yViWJJJ56dBRtoxS7ocUYlmjO3HTPpT0jbjeQOOTQD8wDEAdeeCavp5TRqer9fpRZXJbexRjX5+RlQDxirDtuRQsZUeuaElIdmQqcHPI7VE95JK53YXnoO9NaIHdj441jYllJY1YAyuFGMdqgS4LKrABh0FWI484yQCRyScgVKfYHYhkkUMqjk5zVi2UsysVwrHHNQOYojiIk4PU1PEz7QxBY9OD0oWrE3YlM7RZCqCvuKZ9ocSBgMMe4oOFGH4b+tIkxVNpG4Z4NXsQOO+RhvGDjp0zSOMthOMdeelPKyOPkDE564qSFTGmZFYnpyOlAnboVVabIDHrxzVqIEHHHbpSJteRvNk2kdh1NSp5XLMjADooPNTZleQryOrDfL+BqJlXeuCCTyaR5AVJKBQeN1QC8WJ8iMMegqhqPYsvEiRbm5f6dKp3EQ+zhVI8wHPHcVNLeCaIeYvlse3rWe022QDbxx1p3Kin1K0hlj/dsxXHG3HBPrVuKYGJtgG4clsVnX4ZpBK7LGD0LGnpPbRxGMN0GSD/ABVOxpJXSJJbopnJG88bj1qvk3M43yEuO2c1Xvb4RRqkYQytjPGcVWt5GmnUbiCPwyaHLoTyaFy6ZCzAks/TGOn0qV3S3UKhJYLuIHrVaKHblp43LAfKvqT3qEQszjlsDOcHtRbsSvMQs08xy7uzdMDmp5bVbVP3rbrgkkJ/jSxNLaA/ZZIuV4cjJ/PtUUsmyNpDG292ADls5x1OaXKP2liqLVnfesbb+h4/Sp2g8pFaZhl+h3fd/AVIbxg5/etu68dhTbZkVvPmUMvYHufX3pKKQObZNDa/Z40mlGfMyQp4OMdaYlxHHKjhMkHPzHOahuLh7nzZJCTyAeg/T0psFhLLFJKoWOEfxN3Poo71VnvEhu+5anuxK7OFIOCGI9TVeNpCSFyQOWx2pt/cQwRCG3XnI3N1Jx2qCG8bHlxHG7k7f4qblZ6iS00NyeeKOFVnZ84yqjhfqazJrhCdyngHPHHbpUFzuZy5YPGCBkeuOlU5GMgCqoCjgYHvQ5vsCgrXReF6zKDF97+8OSKVIRI4aWR8Hqe+am0z7LZhGcI7bTkHnJ7VFJPLEwbYgkHPPOfamlpqS99CzdSCKyS3hjRduSWznNZsqIyqDJ8zcnjIP41HeXkkhzOcN0GF2ipIQgG6dsDbwoHJpuSbBRtEmS0SOz86T7zNtX39aqneu9YY1BOck8n86kuZGnwIk2xjgZqzFHDajfOzPKeRGBgUnHmYJ2VyvbxzrggHCjOPf0NSzXd0imCM+UrDlfY1IZREoEv32O447e1MVEnLuf3aA4BJxVqNloQ3zPUpGdxEIQhJJOeO9Ii7ctKh3dFIomREP7pS/wA3eofNkcsCuB/cx3rNrozS/Y3oY8BjIefSmGRg37sHBPPNWJMMCwIyDwKmhh8i386XG4/dFBve2rKjQuOXjZSe/NTLEoUpjCHuafcaqZiVYL0wMelVUd5ZSAORyeelJtDV+pYspVtS2PmPqRSSETSYXPrV6AJMF3KBjqfWmywxq2YlwR39aTi7E85WUJA6l8OfY1Ykv28kxx/KpPOagiCbmy2PrzzViMQeWQ4Ib9KFohNlAtKzYO4A8gnvVq3nVYmjXcW6CrUMESqzytwBwCaRcgMIyvPt2ocQ5r6Eca+WB5uSp6CkaXByM4PbNSzeYSqMcgdDT7e1kmPyYBxnkVNneyC6SuytbAzSBVyE61NcxFvuAlF7/wCFS+UcY2kHPQUhnuI12N93sCKb0VhJ3JbQrbqBIQ3v6VLNMJZAVACkYHaqK7wd/rzWjatD5D+bgswx06ClF3VgkrO4kEW6TLgBug9DT5JHFuSAFQHoPWopiEACHJzx64pY1Aj3kAihb2QPa7DMkhG4/KcfQ/WrQSOIDY6sx/WqklyhQIQM+uc0+d41gWRCytjnHPNNWQmmyzFcTq7MjEDvmlad5OQGdexPOazWufKgKsyuwPHPb3q9pF156mMkLu5ZvQe1Und2bFKPKr2HRxZbLnBPJNR3cwidUXOCMsT2qeeSC3Ri0mW/hFc1Leqx5Y5J2gH3qpNIdOLk7mmGdED5ZkbjdjvVS51BYldUjJkbgnrgVbUyCy8qVi0QBfbwGbHesO9V7smKNiitxsXv9amUuXY2pxvqx/26Ejc1x5ki8bRzim7p3XfvCRHkuxxVKPRYoR98tIOd31rDvZbq1uzGzM6McqfSsvaW3R1RpxlpFm5ql7b/ACRwFi2PmYg8n2qCOQmQTn5ioGFY5yfpXPTT3BzISxUHOB1qSG8Hk5EuHPb1NCld3YShyqxtx3Wblm+UsAcDHSpIWQr58jnhgAv94+lc3eySQgFWyScg1Ztrom8iLyM+CD64+tVF2ZzzVzoJZVLPJJlBu2orHk+9It5+7dI2ADcY9c96r3N3DJKQSZGI5zwM+1VnkZSwLKoBwAQOPpVsx3L6rJMh2uqbe/pSwiQDCDe6rxk4A9/eqazyySBtnlqFwiqMD3q9BaSqpeaQRL/zzz8xpJcz0FJ2QlmCZQbpVc5zgnhqa0cs8xWBFCqxLcYA9farhEUFqZRjc5IXnt1NVvtUjDyyVPouMYp2toZt8zuPhCBtkS+ZIfRcqGpt1d3D7vtIZnxjgfd+mKSCcxyA4A2/N+NOG+QedIeC3LeprSNmQ9NSjBBJPKyRoGBBLEnoPXNPNk5t0d2HldQdvOKdcTLny7eIxHk79xy317Gqj3cw2wzoGKg4kU53n39KlqK1Ki23YlZ13KASkOOFJ5J9cU24YFSIkIHPJ6mmWrbzvlTgcA471LO0SYKE52/Nk5wO1IvZkNqgzkL8x4wTxmrKsB8053sDwg6/U1Vt/MM21SSGI6DGatSwz+WXcgxE4BJ60lsD31IIt0k6h+QMsPUCrcg3Algqp+pqGKSOP5Yo0MhO0ljmpJXZ5843EDGRyKcfdIk22V5SY2AXIb6dKdGJAvmMGZxng9Kla2YDfI2c8k+noKjvJy0Plxkhf4lp7asH5ETu7qGdwuTwCc1Gs0lw5QOZW7KFyBThbZiMkpIiUDAPenTXq28eLUKpA5IFNu240i2tulvFvunAPUL6/Sqd3N8nUAjuBVTzZpyGkV3w2QPerS24kBeY4X+6DzS+LYhrlepvErbzkD5sdPSlZzKMyE56bR2qGARsMs53HJOemaWGVclWXP8AtAVCdtzravsSTRCGIkqST1Wq9uWLsqkgkc4FWzEbh8BscZJJqdYbdF+eTaT145ocbu5PNbQZDKImQOTIucnHrVme6EzuR8qKAABVdpIo3BiXcDwDV+2tozGstydqH+HuTTS8yW+rMePDOxj3cetXIlSJFLOCePl6k1LdvHJNtjjEa44x3qrMjrtKBSQM471NuV9ynr5D7twsuCTjoBnpTrdZGCorBU7s1H2GUjfJux9KhfduCE8n3zS1vqCs9jRlmhtmUKwmPU+lNkvJSFYgIGHGPSqAjZ2CqQQOOvX1q0sRJLyFQg7Ua9BadSaG4jUZcnPv0GalluQxKo2V6c1nR2klxl4vujqOo/Cr50/yoGMsqIxGQueT/hSvJoppJleZxv454xipolUruJKqBnHvS2QKnMG3eRnL80+WOVgJH29eTmmoivqPliVYFdJRyM884p5VxEUDLgjO4HIqocKuSck8ADpTGEmVVF4znK84FAW7ksscjOFTnjJFL55eJUIYDqc460xhJAw2kOCATnrWddSSSkqcjbyMHgUOLXqaR94ivWaJgXI69QeMVVGpPFMXjb5T196ZelhZsJCGBOOtYNxetFJ8jAAjHzAH8qyl7u50QhzI3tX1otEQCM9OOwqlDfhpYmmUlRyF6CsJbotG7tjJJHStvQdEkv1S5ud/lgnYueKm7e25qoRgtTa+0XOpODbrsB4Zj0AHpW/ZaekMMe4bpBwc06ztUgjWNE2gHmtKL5VI6DvWsYNu7OSpUtoihLpySjczHJ4wKzL7QrWWJkJZt3r1ro3V/mVcc+1QtA5AJ42+tVKlczjVa1ueb3/hW5gLPZTZ46SDrXKXltd6Wc3KMDn73b8K9xlgVQMEDPY1ha3p0V5H5LxqyMO4zUSpuOx008Rf4jxufUJJDyxPoc1bh1DCptJ+bGfwqTxN4XvNOmMtqhktgCQRyRWJay7rhXICuBwvQA+9TFNFVLNXR1gvCGVZCS5IIB9Per1q0LbnuJQo4wi8k1zQbe6yBuvOOuPrWhZgBN0rgkZxkdcVutEcbsdfaGOaK4nQ7FWMKme7etUllEsjEOWXbuYg5zWMt7O0ZCyKq4xtHp61LbyyFASgEYwMngH0Bocrk2sbIdpcKjAgdvep/KMaYnALjHPpVZLr7HbiS3iBkZseaVJUewz1qmk7E5eTJJyWzmnoZPyNaRRnKkKSMD5aqASBiMqWA45600yiUM8k3ygfTNNimDOjBVwDk4HJwabJRoWeUVy43EjBDGq1xGgK8bW9M9fakklErM/lsFJ4zxUcgCnGdxzkH/Gk9rFJNE0k4jQPFEQ4H97cD/hSSSpgrHEFcnJHXjFQfxAkHGeoqS6uxHtaIBSVwT1zTuKw+3mWNWeVcyY+QDkD3pksrPICMjaOc1liGbe80MjqCQ2PvKfbB6fhTlmldm3ADZyCp+U//XovZBZvc0EcgFo8EjknGahW8m3sFf5CcHioI2U27SI4CEkMV5zTLRHuHYRnCJySe4qW30Liluy8b2QxbI1YRBsjPf3qzbGBJI3uvunqBzUTGAQ7VLY9FFUZJIVDIobjv0p6x1E7S0JNQu3upcRkpEGwqdsVFFbyyTdcAGptOtop7gbxhTxn3qzfRCC4McEg4OARTSvqw5ktEVZpWgkzAfb2FQtd3DMOAWPUgdKkdMS5BLevuakEWFDMg2gciizvoQpLqbZkVjgYYfrVi1eOOI7gSx7VTixbyfvAd5HX0q0HGD8vynuRUWT1OmWmxIr+dPGgVR2qW5th5xi3gkfzqN9qRggjd1qS2kjQeZLlueuegqnZEb6oWOBbMkHc75ztPbNSCQyMTJn2wf0qrPcGebJ3bm5z/KrnnLbMFjKu45Lr/KoixyTJzZMLbeEOewqnFerHIxaMH/e7VZN5JKoeWXknABqArDI4JXn+8T0qnvoKO1mFzezSLh2b0Az1qGJd0bMTg/zoaBGcR5yc9j3qWTybWJlcbpc/IwPT2xUat6l27B5KqBnPTPPcVPGDLGAchMjjFURdGRflDE9DkZq2u21hd5LjMijMaA5yfWncHCwy4kcviNtoUEHBIzVRpGjkJkYkHpSPehlJIKv1Ldc1XedZgfmLEnJ4xUyfY1iuhoQXDYLgFV/Opri5YhI9rY6gBeT71jzu0SiNORnOM1ZWcuwa5kcKBgY54pRZTgtycSMWALfN1xVj7c9qreSAwOAWxzWZLeSO6iNQqrzuA+Y1MowwEqhCBks3vVEuK6ksdy00uM5JPrxU0jIBJyN33Rz1NBjsZIdon8ic/wALDKmsHVp2spWLPlMYyvNVfl1uJe89FYdroMRkBYcjJ/wrjL1/NmUMvOM9Kvalr0W0h8kfTNZVvKLu5RYmO8g4BrGpNS2OulBrRmx4etHu5/MkG6FTkA+td9pEsluPLlwYu2OorC0ry7OOOEbSqgFj6mtCK5ViTgsfQdualJJXHL3tOh1EU8ZZmXaRjAycYq2jx4B3D25rjWlkaY5ilSIdetSWV00F7tKyNCTgE0/b2MXhubVHYedyRGPoTUxjCRo0j7nbsKyILlRjBww9eKtrKrPy6kjnk10xqRe7OWdKS2JJY+CCMHrk1ReAPgDH1q61wrAA+nHrUQlVQfJC9OSfWnJpkxi0tTJvLMuGVk+XGDXmPjLw6LTzLuzjwWPzAfw17GrK2fOJZCRkKKw/EllFPaylAxQ+tYzX2kbwnrZniEN05d41fYMbeR1FXbe52oc5Pof61H4g082l8CAQH459KqW5ZGyX5H4inFuSuE4pGxFIdm0kgZz0xWjDtZszOFXHBAzn2rHhnQvuYu7ducVcjmVzsU7jjtWiSRzy1NFZneTahO052LmtOMRW1qpnwbpz2/hFUNKVUk8+RTtA4xz+NEt1512WwOuTtHA/Cr2VzO+ti5LcvLEY9qYHPKjn8aiMhVgmSPQ+pogQyuf3irGScluAKenlk7iSVGcuT/Ko1eoXSYIXklQiNs9KvTTJbcELLJnLAniqEt18vyswHt3FEFtJcuWiTewycE4oVlshu+5K99KxBUjrkrjvUXmNJlGjBJOSwHemugQr5vD8HbThcCaYK0YXHXbxn3zRezswWqJ2kwTFGxKkYYD1qKUlQyKAdxwTnjrUPnrCzA7ju4qnJLJKxIOPYUrjsSS2n2aTNnIGI5aP+E+tEMhd9i4RjzjqfrUCyHfkA5Hb1qxHateNuUbdvIZT0/Ghbia0LZiaLB+8x7imS7gC5QKSP4u9NivXsZgNQZMMcRygfKfY/wB00+ZnvJByG9NvT86tq6ITsx8d+qKqpgAdqlV/NkLuvcHr0qOK1QDL8EDHqar3USxAMWYg9OaSTQ3ZmnJdW0LB0PmHuPSqsl+hzuUhm6Z6CsxWCKxOT6VC0zuMEZ4xyafNK2pPKjvHMaTK7SF5AMY/h/L+tON2Fb51CqTwB2qJ4FjziRWHHNMyiJkursTjk0ndGys0acBiZWlkAAHCj/GoLi3Zl37NkTcbucVVF08UgLQl/r3q3PqdzMoeRB5Q+6o4APvQ3dWYJNSugX7p8sZ2nnjINRCVUbc0IBJ+6OlNRmXO3JdvQYAp8MM0pAGFYdcn9aVuxVn1EnmO1hs2nqv51CSWTY5cDrkcZFXhbW6qGmuAxB+6vSpHuWRR5ccRHq4yf/rily3GpdjOZGjUSQyEMpydp6fjUQkaRQGG+Q9yvJ+tTzsJuJblFQ/wRpzUiSmOHMcW5ieJs8jjpis3HsaKVvULGWOFstE8nB4QHP1zU7q0xaSRAA4PUYxUT3Vy8QAmcY67eBUOZEXdI2WI4qrq1kLfUjRHTc2EU54OOtMmgcIJpThHYqoH8R9qtiaIktLsKjHyg1PeXUdziSZVTHyJt/gGOuO9GjWpSvFlZoHjhiaVgR97AAz+NM3fMvAZWB+gqJ7tQyxtIHz1K1JE0ZiRiu58ng9h61Kab0L+EWKLLgsVVlOBzwDUV3KgDRyEtg9xnFJcTuq78rj3HB/wqle3qsFMUZCEfMSfv+tXbSxCd2Q3V5nMcJL8/L7fWudvdTZ4irvkg524/rRfTCJ26gdSc4xXP3cxaTKA89Ca55tvRHXTinqV724OHOMHoKb4eu1j1Fdxw204BPeqt8zqwSTAbsB19q6Twr4Mlup4bm+ZkTcDsB5/GnZKNmaKV3c6DTriS6mXywxz1PYV6Do9mPsqMy8kfMfWqMFhFFEI1RV57ccVoWD+S3lZOOzZqIR5XeQVZ88fdNMRqpG1QT64ppQM5yoyMdqsQqHThvlA60rxqoIVsk9810uKOFSd7FSWNSQhUf4VhyxvaawEXe3mD6ha6N0GAT26VVhj3zu7c44HHIrlrU+ZpI6KdSydyxF0w6gmldcJhcAkdxmrMUaquW5Hpik29So4rupxtucM5XIGkAypXg8GsvWGzZsq/e7cda2JEBTOPm9+9Zd5GskTKc4x0FTVj0Cm9Tyb4gW832GNol2yI2QQMZFcLaTOArEnryBXtHi3Tkm0uTHPljehNeRyWDG/KRtgP8x9KzgmvdOmbTXMWbW5GcbWbjg5rXsJY1IdtpZgcf41z1ukWP3s5THZVyc1dW4tlRRGzFuhft9K2tbU5JNM6CC6naCXa+IwNrH/AAptud79ACMmseCdfKAQkc4IzWha3UuPLg4c8Fj1oViGi8soygmBIB6Doae8pmYhBhW7D0rNfzA+WzuU5+tXYEaKVJWGVXnFJp7BzLfqX/3ajMznj7yjqKtfa1SERopXB698Vl/ahLK0soU7j93NQCdllI4Ynj6VL02Glfc1mjMzk7/kHOT60sUuyPaiAMDgknk1TVnIXByxP0pWid3PzYK801e9waFcbWYSeuQfWpPtEaW6qqgPnBNREuW8s5OeuR0qJljQlZCVI6Ed6OpJaRZbhSF27QeWrRSaKCMqoLNjqO9Y6TDcFUkJTmmAOQ3y1SdloS9dCWdvPBVlXYRggjI96qNbzab81hIpRufIc5A/3T2q2JUNoQuCc561XwJfmJJXPNG2g7X1Eh1BXUvLmKYnBWQ45/lT5rlf4SHb61HNHHt8varA9iMimHTlVAzQ4H5UWdrhddSB7hS53kEDvnGKbJe2sIXMi5Jx61MtlbqhYhcg5wauW0VsVYsqLgdgKEmNtLY6CVZJCChYg9RRGxifPlZbHer39p2ckZ+yENEvAB6sfes94967hLkt17UpaG0VdFh7x0VM8qDjHvUb3X7xVUgdB161FHaypjIBX1zkU1lt4zxIzy55IUYpatArJmzC8abXu5ztJ6Jzipmu45Jf9HyIwCvXkj61zbFi2Azb/fvVmNSUVidgJxtJ5P4Uc9tLD5b6mzGMMNxBJ5JbsKgu79C7JCMIuBnP3vesuS5mMrIGkJPLMe/5dulS29qgDPN8xUZAIpOpfRDUFHVk1vKZQzSIrdcED196f9oeRV5X0GTUlvZyOYyyBI/XHWtCe2t7MARuhblWZRuYj+lLluDmjNVpY5P3uFY9s9RSXVyZ3RVUogG0Hv8AWtGM2rR4YGQkH888D3qIwxW/mC5Ta38CZH6mm4va+gk0yjDFIysnkyPIR8gXkfU1NcWpRilwSsgUHA5AHT8KhmuLiJ/Lt5Gwfl+Q81Ei3BcrJvK5G/I+Zqiy2NLssw6YshXBOSMc9h602aC3i8z/AEos46JtyCPrUt3Pc3CL5Fu6gfKFAwcVkXUVxbgrNE6nqORx7VVktkK7e7GXM7HIJAXsMcCsa9uJIj+8PyEfKCauveQrC3l4ZivO48r7Vzl8xkyfMyT2zk1LehpBakF5MsiEkk7ux7Vi3k+1yx6H3p15KER053dDWRIGZV6je2B71EYXd2buVtEdh4A0ePUrw3Nwm6KI/KOxb3r1mOKOGNQoXHXOcVj+EtITS9FtoGxuKh3ye5rTdWVAoBOeAO+aUmt2NK+iL1ufNyE4J4Bq/b2cZALcsPWqumQGMDdyxOa2FwEPByOwpxXMrsipLldkQeWMBUJAHUZ61Mq5xn5qbgK4xnd3FSq25CMYrSMLO5jKQSoFUY7jINJaJlTjPWmGXMZjYnpxmm2EwDspOecipbXOhWfIzREaKMsSfanK8CdckelEKbwePm9aWRfLUGZQRjGcV3RVkcMndlW8lMrfIAiZ+UVmXB5KsPz4rRnA6xkkHjB71n3Q4UcZJ59aiauaRdjn9XB+yzIy5464615TqkMkPnyQ/K4BGPavXtUTG5DkrjBrzvW7cRXbrjgjkVyS92Z3Q96DR54s+W+ZQc8gipY3OAOnrTbq3FvfyRYbGcgj0NOiDzPjKqp7nitrN6nG3y6F6C4VW/djacYyRmtS2vWjJdgGYjC1mwQqJtocEY5IpDOwYlOnSm1KOqJvGR0Nq6MFkmf5ycbfai6nklVVMh8vnArC+0SElwc9qsQzZA3ZyaXNdC5dTStthV2PJXtnrV6O/gjTiBSe5IzWLFvJbb3H5VpW8UUSHzGJY8g0JOwm0ty1LqElwAVjVVXjjpU1tKp3F8McVnENI5CYIHGAKlijeJvmIQUaiOksFtktZXnYF9vygVlrCtzdKnTcahFwiQkPy2eKWCQBxs4ane4krFi9tUhdkRuhzz0qgyYPAyTx3q80ckzEL8wPf2pLz93EF24ah6gtClGRgRrkN+lWrlUhhAMg3kdM9KzjI3mAjgjnIFOkkLKA4ye5NK6W5WpdskdjvC5C/wB7tU88jTnbJIFUdqyVuHUGNXIBFPi5PzHB9TTVrA1dkjqFOM98CpbhYUZRbSmZdoJOwrhscjn09a6NYDfaVpK6beWcX2UbnjklWN1lz9/nr2/Ks7xRewXGqk27xzMIkE08YwskgHzMPxq2tLmafQlNhHeXW20LpMThSuAce9Th30+4ZdQTz4o8qZI+31qdVit18u2Zy2SGYD5m+tE8CrtieZduM8gkE1knodTJbi+N2q+TGFjCjbjpRbWkgkUPbswI5CHnHtWc9u9qpntNzJ3jYbQ3+7WlZau1zChLsrKNgwcFR6UWvuJO2w0WVyUZ1tX3E/eIACimpEDOu0qWxzngfjUk7u+AJW3ejHI5oitTJtaRwp/uscbqUik+5No1qz3YkdQ6ZI6cZ+tWneSCbMUixBjkKV5/WmOZLf8AdG4gwv8AAjZJPrx3qJ5I3VQWeRhngD5fqc0LayE77ky6g6y/vn3N0U+hqWGCe4uDkZDckkVSRbWNvMkTLDqqt61Ibh4WVTkxlQTGe9LVfEF/5TQM0cAUCGNlx34NQsYSuWjwxHygnk+maghdriXESnPJx6LVuSITvsXnaPmIPAx7960SbRndIgggRUe5yvl5ACjjee+PYVXe+mXIWRjH0IPWrWoJbvHIYZgdigfIMKDnGAKw5WLYy4IXkqBis9nZGkdVdlmbUHkRVLnagITNZ14GjDSys8b/AMOT1qncXAizgkN2PpWRfX81xJmaVmycDmm59zRR7Db2Mg7gwPPSsu5VYmDHAbGc/jT7m7cKcHAPasq9uWK7gwOecY6VDtubRuiG9/emQ5xzxngmovD9rJqHiKyt2LMrOCec4APeq11cgoQSeua7D4WadINSe/mU7ShWMH0z1ovyRux7yPX47dUZVQhtgBb0+gpJcNPGM7Vz09qsWsahcMcZ56dafIm51KKdoIzWc480WaRlZlyBFXaB94849qvxoDyMe1VYht4GSPxzVwYCKCcsentW1Pa5x1ZakTACQ5HANLcL8u5Bx0oCM27PIPrUc3mIm0dDjtVXsrkrVlWdwqE45ArFjimTUROspVSfmXrkVtSIG5Y9Kq3ULltyHAHU+1cVS1R3O2lJR07mzZSTHBXv6irFz5sgw4yB6is7RL1WiyOXXgj0rfRgbZiqgnr9K9TDtThueXibwnsc/MrLjaQAapXGeXHUVsXMWYixHJ7Gs+cAxMOhwaU4WLhO5gagxJxkbT39K4vUmE91KuDsxjpXV6rN5eI16jnLViWFqkkjmdfMIbmuL4pWO6HuxuzyzxMrWlymxhyMH+lZSzs2Mkdfzr0bx94YjmsmvLQMCnzMnXP0rzBEw+GyMcDNdEbpWZx1GnK5oRu+07TgkZNW4NoA8xiPUZqkhAGFAOOKnWNj0B59qTBWNCMgDEZIXPStAmKONdp3Me1ZkYIO0ZJH61JErGRtwwKabM3G5sQ3IMXlxhQ3cjrUiuZDgKSPTFY6MUfIOR6Vo2rys4GQBzTUnsDii/vVFUg7X9c1GZXkyznLVW34bLHOP51Ku4rknHOMUczI5SaLMkgLA7PX0q95kcS/uxlumKrKxAEYHPripxBJJgkY/Ciwrli2vHWJgSOnpyKhl3S/eJOeTmkWAvIRnJzjpxVqG2kjXOQxPFVFX0Ym0iCSCOFF2gFiOPaqko3EAhc1dkXClnYlqorHKHJLEjPp0pS7Dix0cCZy5JPbNEgVTgYFSxxCNA788ZNRwS20N4klzCbiEHLR7iu4emalaF3OwsoL2LRtMl0nRba8iliLTSywrI5fcc9e2MYrlfFFxNHqZW9tI7O5CLmJIwgA7HA4qxNq+hxnC6DN9BfOP6VganNbXV801nam2hIAEbSmQ5HXk1blZWRMIO92eiRsIZJERFViCA5OeMc0W8DXU2J1AAXGRyAfeoftEaSBNnmMcjcSQM/Srtq/lW5ZZ4kjGWwCMknoPesk77m8k0tBkqKCBKXdj3Awq/48Vi6mgilLW5+dW+Ujo47cVsSB2VHaVQGHyjqfxqF7Fi29pgkbciR+gI7DFVJcz0Jjpqyvp0qOqyXCkOc/u2459T7VsNMJSESMldu1mYdvbPvWbdxRMR5Dkuo4kbgn/wCtTQJY1jF65jDDKEL8rCjVKwb6liG2QXIMjp945Xvj69qbOu5lB+ZMYX5scUjQwncq3kYXA4CMPzq3HZxtbJi53O3BQLnv29KIqw5PuVxHFFAZCHZS23APXjOPaq6ussu4bwT3J7fWtCCyCTKJm2RqMsS3H/66q3YjYsfmVGOFP9KGrgmW4JkWcrA+FYZYA+3Ipt/fhwI1IjRRkKB/XvVExtbmOSPa2/HAqOd/nIcAvjnjOKL2VhWuyGWZdpeTO1W/MVTn1HeOVAJ6EdD+FSXKSSDDbljx1IxWdcRpCpU72lHV/wCED2qXGxpGVyNnEkpVeWPTiqd+Ut7b904MpB3Hrj2FLfXWwsEYY24JSsd1Z4yRIoHu3T2qLpaGyXUoyzP2Jye9UJX3EkLuP6CrNyVGcMCR+tZ8kzKrojfKeOnWnHzHJ2NvwboKa5qbfbGbyIhkhfXsK9o0fR4YUXywVRRtUDjgVy/w20sWtiqygCSRgW4746fhXo9uoMX3QpHpUW9o9Sr8iFii+UB1BAzVe5Z1ljRT8u7BArRtoi5GT97io70J9oWOMZ29/erqxtAmE7yLVsQAWIyAM804yb85xnNRQnC+gPb1qxBGXddo+9VU1dWRjOybbJYvmxxwRk5qvcxkLn3q48LRt0wKtmJHg4+8R+VacnMrM5nV5WmjB2nAG35R7UmNu0EhgeoI61alXYNoGOeuapSRkEE8ZNZ8h1KVyhKv2O+MkZwkvJHv2rcjvAI8ITlutYOtErCu0Zwc1c0+RjCAuDnrUYeXLNxRtWpqdNSZp31wsiKFQqAMZrIuHAVgTyecgda0rrAhGPun9KybnLAkL24rsqJ9Tigknoc5rrMvBG4554qfS7SSGyW5XBByCvUGmXqC4vUidgqkgEk4rXhsiQ8MTboo/myo7ntXNQjzSbOmpLlgkzKnjaVGUKCp6jr+FeQ+NdF+w6n5sS4il5wOADXtskZj/wBkkZOK4fxxaefp0hYgyLkgDk1VSLi7mcXzqyPN4BDAowRIfT0pQ8ksoIwoPaqEchBO0fKOtX7Qhslh+J4qrmDTW5o2rLAA5XJNMkkZnYj7x7UwygFQfrUjtHngkmk2mrBFWYkDkHDdMZ6VbSRnYhFySeKggQMSWX9atIyIeCCe3NKKLbGKxjfByPWtCyBkwX54781lqGeUliQOuavxuIwApP0pcuonsakskUQXZw3HQUn25yuGYYHf1rNAd8knGPWogsjPnPyjsKrmdyFFM10c4zuJLEnk9ParH2plyd5APas22YOxVj07/wCNWZyvk7UIPv3pp32IcSw5haPLElvTPNPiGV2r9K512lj65OOKmj1GTGOhHJqee25Sp3Nq8QIAMcms94QQDjBz1NQteyS/eH496YJSByeaL31LULD3hHmDYS7HjHXP/wBenamtlFFGLSW4afgSCSMKAccgHPY+tdjp+pWUGk21zb3NvHc29q0MUJXEi3Dtgyk46bec9q5zxjPFeawrQypcMsMcc068CaQDDMP8fahqy0BSu7GrKSX4U8/lVi3AhVSW+QDhzyc+wq9oZihjLm3kurgjjK/KtT3Onxz/ADStHAEH3WfLE+wHeiMPMuVToZ8U4Q7nLFepx1P4VNdajuhWJMiJm3hDz2q1HZ2kk+23ckqgyWU8nuBVe5JtpFlgCbh8vzKGBqWmuoRaZBb2087JtUZIyM8Aj3qfU5S1tHG21YlGVB5JPrTC13dRB224bg/wjjpj2qeKG1tpFEsnnsvUA5U1aXYTfcxk8wMFlJKZ4kxj8K1XljaFVKbcchweTTryZp0WNWIiHCovAWpYNP3geaW8sYJfGMZqVDVpDlP+YqbxcKI0JwTz3x7/AM6R5FRQoxtBxmtm/wBNtrKBALzBYcqq5OPeueuY3ckxg7RyDnFOUeUIyuSm78hWWMcscZPJFT3zpaQQFdpmcbnJG7A96zYVeFt8pG5ecEg1NIkbL51w4jU8j3pK4OyZBPqJlzvRWx1+lUr27toovlZWZgchhkD2qO7eNfmiZnX06dqwrpg0mMHHpSlKSKikyG/myAACARn61jzuWJ9PpV+9dSqj+Feg9BWa++bd5Yx3NQ0aptIhmMRjZwcNwAO9Q6Lam/1eCPGVDhmPsKiukZVORk478flXUfDzTzLLJdHIUHYvH5mqk+WLYR96SR6Z4dWRhjGAWyCK7WFQFC47c1j6XbbIFXbgdjitcApgAms6EWtWaVpJuyL1ksbRyLk7uoNUb0MbwZGMkc1qWPlrbTO4BbbgD0rG1q9ME9qZBhG4Oe1bYhr2dzHDpuo4ouxsMD5jV22d0kXjjHFZ8UgYAxYYHkVejkBfL8YFKlJWTRNWLNObe8W48gc1SW4VRhuO9Et62zYp+QVRcF5Sc4GOlOrU190xpUtPeLjoskJYMN1V3iOGPOMc5pYMK6B8lc9q0blS8BZcFauK5ohKXI7HO3UQkGCPzqtp2LadlYjpwOtaNw+0nC5JHSsK/kaM+ZEuxxz61zP3JcyO+n70eVm/PcbowNuAQcdqzWJ8w7hkKCelQ2up/aYi2/5wMFT2plxMyIVUYLd66/aqcbowdJxdjCvy02pLEi5I5BzjFb+kXE+nQywTRiRDzzwQawbGEHVv3jkgHJJ610N0gkfEO4rwu5upqMNF6y6lYhqyj0I55VlbcqkFjyQOlc7rVvuLMOI2HTv9K6SXIiUY2sOCR9ay9Qi81GXOMAnpWtWN9znpyszw3WbI2mqXEYI2lsgiq434weK6LxnGY9QSVV+VwAfY1mQx713MRgevaslZoU04y1IYI97gHpU6xqsmCwx7mkZd8uEGR6Cn/Zwr/Nj0pNWEn2JUBJxHyM9amaIKp39euKWIbBhVx6Z7U4qzvljwe9HKVzEJfACrk54q5BtSBR3qSG3jBLOBz0GaGCBuOQPSqS5RSmnohmZHcKQcDvmrsaZT7uePSmBg6/KvHuetTtMkKcct29qTI2K5RgxcfSovMkwSeee5qTzSxJXv1IpACOqgAnkVL2He5Wcs7k7cDOMmgIC2cAZ9PetUmLyxwDjsO1MhiViScHHOO1LluPmsQ7f3Y6K2OTUKKzN65Nawt1f5QoJJ49BSzQiJRkcnj6UWBSR1+jW00/hp4NMjRonsmEiptDm43j72eenTtXPeKrZZNYDr5LTGJBcGIjaZgPmxitGQWVjpmlyNoi3ktxFvebzZACdxG35T145q5rtnZRWN29tYGze1SGThyQfM6o2f4h14rV6oxTs7lDzpI0a3hujjjPP3vWpFiIVzmQqMcr0/E1ks0fnoHXag6kdcelasN/8AZJlkiAfKYIYdiP1rJWbuzpaeyJ4rySADyothI6+1MnmW6mjES4GMHnqazJZpJsBspjoOmaa91IFSIlSAc7gOaV7+gWsdLez28FnFbR7fORiZDx+XvWVe+Sku6Fjjryf0qraRy3LhVUBPvMxpL6NN6qWPBOeeKcm5ChaPUsWdwJJV38KG4FbcmpJ5bJA22M9Qa5mEbZN/miQIOMcf/rq9p+nGaN7m7mMMAPQnlj7CiHMtgnyvVk8lwgJIJkOfwFVZh5jB4W4OeDyMU5WhRWIBGR8ue1VvnRXkE21e6njOaqzIulsIr+WGbbyBgEnpWXf3ErE+YQMj64FXMtIjITuXNMbTtkHnTFVZskBu9Ci3oh86RhSynOVchvrVC5DqTlxnFXr1lRSkacnO5s9fpWVOzGLJYjA6Y/lUSVmbQ2K8r5yCuScZ5zVK9dWb5BtHSrAGAxLAHHeqV0wbO1+DUlNlORHdwE6dq9i8DaUYbG1iI2lV3MMdzXlWhwG61mzjblfMBI9q928POFldckY9u1Ko72RpSW8jprYIqE9CMAccVNG21ASAcHHTrUe0Fcr09SKljXHBHIJxn0raOiM3vqP84wpJJEflI5BHQ1mTRjUJVaQFlXgZpb4uH2ROdp+8KtWcYROSSa5qkvaPl6HTCPs1zdSSJBGAkYwB6VoWq+aQM4NVIiPNx/EOg9avQKVyw5J6VvSio7HLWlcS5jTzCEGMU3yGwrkYHqasFMwFmH7zPNQzXQZVhAPvVSaWpjFt6IcYPNbbFjI70BjEhSTLI1X7dAtugUjcRzUd75ZboDkc1soJK5kqnM+V7GS4w6sAAOgrH1TYHPt1xWldnJKpnAPU9Kxr2NkdlZt2ev5Vyz3asejRWzMnTyyXspTtwD71Ylc5DNwCevaqMkwtrnJwF759arXmsw3DLEh4HUDoKwhVUIuL3OudJzlzJaG/4etzNdyTEKSc/Me1bLKsc2RyE5J9TWbo91HFYMFbgr29ferUbFolJ4B/h9f/AK1elQso6Hl17ueo2VsRswPv81Zlyqskr4ygO0Z71oXTFhuYZ44wOKzrw/uo+AMD5h6mqlqzFaHm/i63864ZTyQoxXHx5GUyR7V6Fr8bG4L7sjO3pjBri5YEW4Y5IAJIx61yJam9XWKkRQsIiSp/HHBp0k+X3ZHTimPEGfA4/GpEtSx2g7qvVmCsiNZ3aQBjVqO4KuoLD8KiEG18d+nSpre2BJJ5Pr2pJMtyTLXn8ZIOQOKTdu5P1qKSMfw1cs4GflgBgDijVkuy1I0Z8sFXA6U9Ecj5iM96044YoVzwSenPU1BN+8Y9sDNPlsiea5DGwUkYG7pQcyk7cn+lMVCXIzkk5OOmav2rqm0kZ70krlbBaQHgN+AqSSMRn5SR60olDMSo9ximlt+ctg8im0JavUfbyeWG+nenTTh2xjjPpVQu27B5IHT1qxBBuGQDk9QKhO4SVtTsdDEVjpwD6hqccz2jXrR2zKECA4wAR96sbxKqwz+Rb3Fy9jMqXK+c+4yFh98+/b8K0rR1sLTTXvdW8pvLaSGL7L5oEbEgqxyMg4PFZOtut7ftMtwLiPYFVhD5QUAYChewFay2Mo7la4lWWcsirtJyFxwo9KfZzIr4K+c+Aec/L6Vbjkto4tqpz05HSql5MI5w8RUMxwMdqyOvXY0zGZnZrkLuIyBj9M05dOdYlmaAiMnjHNZwvQuMsWOec+lXrfUTL5abnbavCg9BVxlHqQ4SezGTT7YtqAqDxkdT+FIbZ5cMzrGwHc5NMEsMt0JJXCqOSCeTUskiqS0QAXHHehS5nclxcdEIFMbBo4lLLyrY54qG4lmuZ/8ASJDg9d3ali1N0kUhRlRxkVHLMTgsp3kccYxUtpgk+oizLFODIcqOme+O1T3M8Es6v5wZ2524wFrPkinkUkphV6mmW0MLyFrqXYF/hB5NOPZBJLct3V4FlZoNqsOwrMmvmkYu+ZGHQUt/5QQOi4yehPaqBvTEcqACowvFDk1uOMU0QT3KM2ZCOOcCs2ZxOQAvygVYliMh3vtIJ4HvSSyRwBlddz4+XHapafc0TM2ZCBgHAPr2qhLGS3JX8KvXMobGB8w4rOuNynCkZqbLoO7NbwVCP+EkjI6RqW9ulex+HIzJNvGdg+935ryPwBtXU7hn5Jj/AC5r3PwtDtsA0oUbzuHaplrKxvB8sLm3AgMTAj5guRUxEbwDJw3YAc5ptsAsiZIx0p9zAImcO+0n7pB4NdVrRucvNeVjIkhUXTFWLepNXMrhQOCOtVkXLDAI+tXoYuS5OQR0rkgtzsqPRD1RQQwHOPzq/bBSqkjviq0WC23PHarsWEIKEYHUGuunG25w1ZXRdlCranaAa5512zlhzn9K07mbKYU8GsuU7ec8H1qa7vawsNFq5eNyNo2gnGM4plxIqqSOc+/SoIHCDPr+tR3B3BucZ5p87saqmlIqzyDksDgkZNUtUb59y9AMe9XgoVkZwSD/AAms6/GWckYA9Kwlom2dcbaJHI6+pkKKgPJ6dM0+x06NI8Pw5GQPUd62F0yZ5lnc4yMhTzirMtoAiHGP8K5qVOUpOTR0VK6jFQTMj7O1vhowxUckDpWnaXschU5LZ4I6Ux0dF2kdR+dZN5K1lKXXO0nORxmumMvZ69DlklU06nSJLvOSD1wFFZuoSYn+ZchODz1NVbHU2jjeQ7FDKQvGT9aqvOZNxdgq+vv/AFrqjPmVzklDlMzWNsiSls7N2QBxXB6jJ/pxToB1x9K7zUH2pKDk7uma86vWMl7JIucbsAYrGWjKbvEtxhQBtHbmr8DRJGMnJPpWVE+cYJyParcCYySeORg1SmjnlEWbDHK4GeetNDucDoMdqe69cDK0yNgBjjPpUstLQngUZJPXsferSTiNSoAB96oqxHPXnpU0Ug3YYZz60ITRaM7MCuDgj0qEylchevripi6rHx1xjPpUDuj5ORnpkU2JKzHxSAL8x5H4Zp4kLMAOlVHk+YqAOnUVJayqVPOT3NJalWL0coVPmGO/HWnKzyEgcCqcrc+vbrSwXiopGPoaTfQpRsrlpUZWAbnHNbNjtCEsw47VzktyWJI4wOnSrGn6jFDOhuo3lgz86I20kegPakpKLCUXJHpMcV62j6f/AGbp9jcQ7CX+0hXYMSc9SMDpXNa5LNDesl5b29vMEUmOEALjt0OKqjV/DzLuGk3ZP/X3/wDWrF1O6tri8ZrCCW3gwAI3k3nPfmtJTW6MoU2nqjoEtJSA0uQv15NT2VtbtOjPt2Dt1ojmklBI5B5zV2CCBU33EyoB91FpwjEqc5Nl3U7DTjpbEkLKBlM9z6Vyskc1vEpj+VWGBtHWtO7lQ7dsm9e2RVbzN0QGNqA/Mc0T5XcINpFCKHBPnghR69avwSwIVZVBZRyp6U++uYZ2jVB91dpbFUPkEy7VOPWs3aL0NF72rLLz+azBI0UE5wBzU9sYE3SXRJK9FFV/LAjbaQD3NM8p3G0jLHjg0Xs7ktXCW5aW52fdjJ+77VCSELqFDAdDjOKszWawgGUlWAyeOtViw3ny/lU07ifkQahAFgDyOCzc7V7VieWZVZUByBkEjpWjcgNI28naffioH8tYzs35Iwe1Ju7KjoZcm5MLnIHP0qs6NKcsTk+tbHkqU+UZyOpqvOiqgHfB6VNilIyZbUlPMLquB2qt5IYMzHgdc1alVuecioSpEZU9cdKaSHc0fA+w+I44sHEgx9a+hNPXZaxqAQo6CvA/h5A8niy3Mce/y8u59BX0BZqdg5yCeKUY3lcpyajYvxRpJGQOCo4YdqoXrFMpO5x2qzCxgcOCD7UX7pNGxKpv549a6Jr3dDKm/f1M5SDkLnHY+1XbXI+Xkk96z4Fbartge1WkbaSWzgiuSirnXWfYuhiuCuKsJK0e4gFlYetU1O5gBhgeasKrKpIHUd66ldHHJDppEYDZ8p6VlXdwFkEXXsfarNzJ5ahcgseAM1jCKXz/ADMkg9c1x16jbSR2YakrXZopOqd898U15ZWIcD5agkOzCuh3E1PFayypyx2+npQqjloi3FR1YAPPuZjgj3qCCJmkJkXCjofWtGO38uPJIOPWiRSqB0TPc5Faqm5WuYyqJXSKpTcAfcVFNGu1wc5A4q1Oz+WrMNox0xVZpsxuO5GOea6GkY8zZQdC0Jwv3fT0rC1qLzLQ8DgkV0SAopxkE9eO1Zd2qlJEY/Kcnms5xurFQlaRxUV3KrBGfheAParZundcggoOST1rO1DfGxZcZBOfpWfLczsCrY2DoRwPxrGlJ35DpnFNcw/W9SfaY48kjqR0zXPCMShW/iPoa2JBiM+Yu4sMkegxVW3ZFiwVAxngcVvKHI9TknK8bIqx27Ko4yDyTUvzrwvXuauBhg9NvvQNmOcZHOO1Q0jNMgjGFIkGDULKN+cHmnTyfPhMH2pYMk5fOPelexokLgJjd1PSo2f5jt5xVp/LAIxz1qHZyAoH40eg0h0Uhb73Pp70/cu0lAc+mKVtqct1H60xip9qHa2orajo/mJGRnFOWNYjleAaqvMUPA59aaLkuQB+NClYtxLbNuXjg9M0+3ti4ZieBVaNix571dil8tDkAn+lF0S0yGaPaPvZ5xkUtoLf7XF9t837MD+88ojfj2zxmlkcOCc9fyNJCm45IPymlpca0Wp1djo+k3Vv5tlpviSaLOA6IhB/HFc54gt0sNTaGKG7t49isEu8CTn1A4x6V1dprNubWwtvt8tskllJYumGAikzuSTjrkkdOa5fxfPDea4Dbz/aXWCOOecA4llVcMwz24qpWS0Jg25anSmeSIKpjwoH4/Sq9xc5kHykL0IqZFluZPMbaoPOal+y28WTLJ5rH7o6AVWrJ0TM9PMkYJFuIJyWY/yrQmt1jjGMH1GetRAozHYDtznOfzqZVGABnr/nmo6j6aFX+Mx7cZ9qdDGXOyKMlx7VsxWaFCS3OOMiqXmTWrFk25J44q7W1JvpZA1t9mTEzZYgAimRqIQH2fJnOalmSUlZJDuzzSTGaYYIGz0FDsLUrT3BlyT9wZzxVIqj5x8uTj1NJPKyTbcYJpiuikMQSx9O1TzdB8mg9rRfIG5AO+ah+zxlWU8EjtSSzNIw3ucAYHpUF05QEqcjkGlJpO4RTKksbiQgEgAVTaDzJAGJGPWrizYG4nJOM+tRMSzZ/n3pOzKKV4FiIVVrOnyen8q1mgaV8svQ9CabdRJGdoYFsZzimrjujpPhTYPHeXN2+duAi/1r1yzkGzaoJX+Vee/DXH9nOpHzGT9K7q3kEUwGQVPpV00Kfka6xwON5YrnsKqXtqFQujqQORk9aar9SM4PUCqt4/zKDnb0/Ctpv3b2Jpp8xFp7rOrICA4PAPp7VZPClSD1xmubmn8u6eSJyrgkge1akOoPIm54HPT5hXnqahud8qd9Ua8RKhSG+YdalluWKZAOe1ZFreSXdywKMkS+nOa3Io1YhQTjrwK1hJ1fhMqkVT+IpxXG1W3xbmPQ1SlLo42IWJPr0raFuDE0h+XB4HSqcW0ykspOOoHNKpSeiuFOqtWkRomSm7kdzWhZMEm2OcIehpi2+VLBSFpkqSKqgDp0J61rCHIZzqKasa5FusR3/hmsvUJRvKQcJ3qCZpGxvORTDhBuySTxzXQ530MFTtq2Q3crMgVuB6DtVQ/IwOFx1Ge9WJE3lmcDb1NZ9xKM8sTnt6VhOVpI0irofJITznBbgD1rOvWWMSBlPA//AF1YaXDDeCR2FZOoSEB3yFBBByaub0JitTmtRUSMxBxkZOKyUjXypY3zkgY7YrV1OQLzk9MEZ61lvINhck78YwKwgtdTpk2olCV/9HLhhljjHpVFsqRknJ9ak3NNMxIyi8Yx2p7APyV681tValZGCViJJOcdhTgWIyT+FSxReg5JzUpXacn161ikPToV2jPJx056YqRBhSB09qcF7e/HFPjj4YMRuz29KGCKbbiTk9O1Oico2SPxqyEDNg5JHTNPe1JAJ70rFXXUpyTF2PTHQUwKwBJzWjHYjcSy8ZqX7LgYHH160uVj5omQYySCRjPpzUiwkLhRzjmtM2hAYHk9Aaa0AXIHPvSSKuijbxNu5B9TVmQZHyjjoasrbyBMKO/JxViSAhV3c+vvVpEN6mGxOcVJExGOSPqa02s1JzjHHXqals4jZ3C3CpG0iHKrIoZfxB61FtS7qxqzIdU0jSI9M1OxtTZqfMhmmELLLuJMgJ65GPpiqXiN4brV/PglS4cRRpNcIMCaULhnH1P54roNKilt9IsWn1DRYFmUmNLiyDybQxGSdvI96i8S6JcK8t3Jc2U5QRrKtrH5YRWHynGACD6itZJ2OeLSkADrHhGGxf0p7tGY8dW9cVVkxGpQFstyRT4YvKQNI+GPQVKbLaQ+L5U2hR0yWHOaljnFuwHDgjJA7e9ELLGhGF29MGmrF5hdo1IA65qyUiwt9GyjYGOe1QvMHlPyfKOgNUrpyqKEXDdDRAWRCzths4A9aTmxqCLck7TuAMgA4wO1S3F0lrCUQgsRyc1RSZlkyqZLdTmnLAJW3Ssec9+tOMuwmkZc7tuDk5PtTd3GW5zz7VPJATOwXp2HbAqWC2VSTIcr0wamzKK1vZm+mKjC4HOe9R30DQEwNyBxwa0wSpLREq49KqyRsxLy/Me2aqyWhnzO5jJCobaTkCpZgqRfLyfUetW4rcs+WHH5VNdWqKoP8RHapS0HJmHhsAqeTUXktK4BOB1Oa0HgcPlQCPpUbLzkj/6xpW1G2rHU+BGWKOaE8qHzn1ruPMCz8kgZGMcZFeZ+HL5bW/CMMLIMZPrXc/akVV3lXUHKqDkmtIS7itdGs06hjsbaB1z3qlqNyQVYEBSTtUHk1myzzks23AbJC44+lWdMt2aRXk++fQdKzlUlL3TaMVFXZNYWHmv58xUDrtrXKfu0TruGMelN2j5NoIA6+1LMMTcNz9e1XCioomVZy1YsCJHuye3HbJrVs3GAVHz5rPt2Ubg5wh6UqyGAkEnoOnX8a2hFQ2Mpyc1qX791AVFJPrUcGHGSoAHYVUecHDfw9BVmCQFVCnp04qU05XHyvlsaVsAwCg/J15ps2C+CCCD271V+0YA3dR6mqd1dTFj5TfLjrWrkramLi07klyTtHPHpVckOoAHTPPvTi5eH5yFwOfeqgOwsc5PasXG7ujVSsrMW5LqNj4CnnFZd8dmCCOOTVy7uA43FiSeoznFc9q9+kbeWp5bjdms5pGlO7LMjgq5dssRnINZFw5kk7Mq5+tEt3shYxldoAzzg/hWZczbEbcdpPK49O+ap6rUL2Znamd5ZFGGJz9Ky7hh5BLE5IPOat3EivyMcdaoGP7VP5I4QfNJ9PT8aF7pTd9CLTrZ2tgzKfm55NTPFtYdSp/StUPHAuwY6Y4FV5MM+eNvUelTbsZqTbuytHE2/A6HsamMA2gdeOmakfcqDy8ZpqscdAKkokt4gEZmpk6gFlAHX0qVD8n3+TQqjcPQih2aBFaNG6lTge9WQEx8wyCO1S4UdAMfypgT94QCR3pLQp2Y1WBIUd6nhAZ+ODjmmRwksMDkdamZNpzzyOlNSdtSHG+wsiKF4AHtUccJJUsO/apEB3gkYxwTV6FOF+Xk/pSvcexAECZLDBIxioHGSAAcNzyelaZhXaRnJ9qjeERgE8gjjNU9FoCd2U4oiOo9qmkRTHgnk8DNO3hQVx1449aovLvuPkLYHAFJOw7XOy0yzhvNJs5NUtbYCNDFbySXfkF0B+7jByASeeKg1e7nQ3dlLaJbzy+Wh2tkLEg+RV9u+aiE+m3tnZrqMl1BNbRmINCgdXXJPQng81FrkzSXsRWKSGBII1hEhyxjA+Un3PJqnLQzUNRkkJjBLDeeO9JdRYSOVmDMeQOpWqz3EqIMknjJPrUtvK8gUBMk9M9BRzIqzEaNictwG/D9a0bPEcYRN2Dwc1XuN6R4kHzAdsc1HayNhgSMg9hmhSsxOJpNDE4YtjIrKMDs4KjIzxVq4kYBRGW3Y6kVctDHHDlyGcjnvTbTdgTaKlpZ7X3SjOeOelVpx5cjAcKScD0rRuLsb+uF+vesi5Znbepb5TRJpbCV3uIwcZLgCondjkYA4x604TPLJtJPPTjPFLAAsgL9RU3uVsPRSq4x85PcVHJbzSLnB6dMdquLdRRSDoVqK41DcSUUDmrbVtSLO5TmzEm0Jg9vWoESS4xtHzHvSTkyHczfketSrL5afJgH2qNxvQbNA9t3Bz6GqMkYG49B3z1FW3kkkcbj044ps6qo65z1wKE9CepkSBkl3KehFdL4evmnuLcu25skHtWI44wFz70W8jWciyISGBBJFK3U0UuXQ9D/1kwQk4HOBxmtKyfMn3tpA4rldK1ATFZMlsrjHpW0lyYmV8ZHcetaRs2EtFY2t22MdxnPuKfKQyM3GVwfwql5vnReZDnB4KmkMs0fzyrgAdT0ra5jZliKbYuxm4PQVYeZX2jPzHkmsl7kMxBHHY5601ZXYYBGPWk9dioo1lcMpKkkntmmpJKCDyBngVlecfMVUkwetaMLqyHe3zds1zJNyaRvJqKuXS7MOCCQeamWWJMEL+8x096zwWwRyMdxURkfBYdR/KulRscspcxfuZ/Mc52jHGBWfcSDIGAO5zTHJcAdPSq946xLl2+br07U3JEq+xX1KYQxnB4x2rlr2XzpQUyxHHTNM8Q6iBOYfOCbuSSKofb0t4VS3IaVvvOeSPYVgvfdzqSdNE6yBpEVEAY8c9QfxqhNcAlg53H36VXlvFYSGRS0jdCePqazZLonEUQ8x+4HOPqa1so6slNvYsTXOFZEXcW4Vcdas6fCYFIbaXcDdiq9nbtFueRg0jD/vn2FaK7dgJY5H0rBy1KltYY0WW3EHJyaG4GRg8/lT/MVSefpUDtkDbjuam66Eq/UaXPABB7805Rnqf/riowcD3HNODgZIB69KTZokPjPzEnke1PLbR+vpTAcnnApWUY4OOPTtSvpcaVxQ5ZcggfTrVm16/wB4njNUY8nGeQfT0rQt5NpBA5xyaSab1CUbFwqqKOGByM5PWmY8x8sPTp1qJp+mTwe2MVLC65HzZ9zVuS2RHK9ybZgMcCkLsoO0jilMu5OwY9h1qF3DBsdaAHfaiRtPBPc08S7gAeRnrWY0gWXJPU1aVx/D9088VFzTlF5YsVAIFM0qKKbUY1nl8iJj80mC20dc4HWlkfZGx/SjRbd7y8ht4VDSyNhQeBn39KdrsT8zpvsOk7QP7aPI/wCfRv8AGo9cMNxdxC1k86OOCOLeVK5KjHQ1INPsEPlyazAJVODthcqD6bv60S2L2dyYpSj5AZXQ5V1PIIPpWttLGXNre5VjtPMHI+X+lXGgChRGpGP1q/aTQQHbJjDepqO7liMf7t1C4zjNPRE3dzKuAFU5O9iOlFuqRsN/BPX61HJOjXqIMc88c1YuFDOcA5OfyqUWyfPmqp7demD1pwt1WJs5Vs5U44qFHKx/KR6dKR7s+UQy8HjGM1RNhotGmkwoyKl/s8hTuJ2j1qa1uFQqduGJ9alurn5R3Bppol3voVE00+W8iEgdORWfcW5dsDJArSN45AjTdyPXiqcs4jB6Ekd+lTKzLjcqy221SMHaOhqFIMk7UxkZxmrz3KkKqgZ/OpIwWjLcAf7XWhWYpNoyZIHOFIAXOBUM0Plgrw1asjAnH+FVyPN3ZUAf5zUyVgUirDGfLB/pVWUOSevPJIrULDysAceh4xUaLmQcf/Wp36CuZ0cec7sY7+1V7mJtpWLg+p5rXu0HBHAP4VWCMWUkcDkChaaCIbMtZkFSQDz17V0EGqRTQ8YWQdVJrKdBIhGMcZ6VHFa7sEkg9hRqtioz6M6NrksUVDhxz1qWa8MaIZrgFj1UNnArBjExAjBHAIGeaq3HnRDEgAGPvbf61XTUuLV9DojfoxJWRRznr0qOTUdhO6WMD19a5SQksCBuYc8ZNZOp3jysUjB3AcL2FS5ytZGqhF7ndWmribU4o0+bcDlgeBXUwhVzuJz9OleWeF5suolOJMbc9/avQLHUwF8qcjjowooXi3zE4pJ25djZ8x8bc/PxzmoyW2kO+QODg9aijkWYEiRSSeuallMSId0y8H1rrTRwNO41pMk5GAO5rA8SX6Q25d3AbGAKsatrcFnE4Rg7Y4I7V5nrupvcyNJIxKjkdsn0rnqye0TpoUrvmZUWS61G8upQd8aPjHepA1wrbUgdnPHQ1veG9MMGnq0qgTTfO4Pb0FbS2QXOMDjmsoS5dDepJX0OPWxnc5uXKg9UXv8AU1YgtQgARAgHXAxXQXFt/cXr701bfAHAb29Kl3ZKkZL27Kc9cHrRHCxbnqeea6H7OJAAAMngU5LMKc9z3o5RXMUWnyZZTimm1y5GOema23jwcAHGOOOlQeTzj8s0OyAzvsOeSp+tRPbEHHQfSugSEsoB449KcbLjIHTuaOW5Slqc8lsQ2Tz9TUzwlu5PoMVoyQlGI25I6n1quQB9OnNTtoaPuUktsnGc1OkBU8HAA55q2pQfKR79KSWRT0Q4J6Hinyi5rlB4iMYLYFORHwMdD6d6tvFlQwwMnkntV22hQR9MmocSk0Zm1jg4wRx070xlYMc/Wt3aqrzjP0qlcbSxOME89OKLLuCMSRSHOTx6elWIzlAQenv0qWaImMsFPHr3pluMOQ3fjgUlcrREU5LKw7fpVvRLp7G6iukwJYzldw4P1plzHhPTJpLK5ezmjmh2h4zuG4bhn6HrQpOLuJwUkdGuo6PKQ8mlYc87VuiE/L0p9zqRuJzMQiIoEaRp0VQMACmXniTU5ZfPsLVktmUEqbVWCtjnBxyvpmsC/wBSuL+4M05G8gDKoFGB7Ct5VUtjCNF3vb8TVnZyAoLHkZ9qgmZwxXd06471cwQcscjHHHaopinksduD0HHIq5JEptFfTIZJpZHwc+oFayWzox8w/WotKuRaWoGwMzetSC5Mz/MMA980JRFJybJsIRlB16Zp9usW9mlUfQDpVpVW2hDFs5GCe9VlmjLFm43dKt2WqMndogIBchFHqM1EWzIVPHt6mr+6JuFGeODUKwxv0HTgnvUPUpPuRRx5XIDevFVLm2Y/MeP5VsgpEMd26CqtwfNyc4HTpTt0ZN2mY/kkMWHzcc46Ck82VUKjv0zWkYyV4Bx9OtQSADLYwen1qWh3uVoULIMnGTj6U+bbEuQAT2GakXcd+3A45PrR5HmISc49MVQjOLZkwc5/madG2HYucnqeKke3fdnop6809YWIJ61LTvceg4CKRevA9aT90GO0gAVUdWVdqHHNN8uQjcCcdqV32Hy3J5nKn5QGU8EZGfqKcmGGM4Xrz1Bqk25ZeVOfT3qxFk4yCD1z6UXE4F4hIYx+fNVnmO/oCO1EcEjne/JPT3qzHCBwyjIJGabcmCSWhApIjOxAG6HAFcnrdokV47SI3z/NweCO/wCNdwmwZUgAfXrVXUbCO8g8ttqsvKNjJBpxlyvUq3Y4C2dIHDQlueea6az1qOYASkq/QHtWXqWmXlrIB9jMqsfvRrnv0FQf2bcBhi1uQ5P3Qh5reUYy2H7S3xHUm9kA3RyDpzis671TywQ0jMTzjOay4tL1aWT9zp05Y9dx2qKtWfhHVp5x9ueO2iPXDbjj2xWb5luC5HqZ1zfSXUnlqzsW4EajJNb+leFyPLudQGZF5WIchPr6mug0jQbLSsmCLMh4MjHLH/CtN1CgDtmsmmy+dW0M9LYg7tpAHWnspAI29e5NXV6nOOP1qKQgtwu7POfepsS2Z0iK7EdTng0yG3ORnkVoYAXI2gHuR3qfYqLzgD2FCT6hcqxoiKc7evTFO2jzBjoOmahYsCccYzQjMckjoORQpWY7E0qDkdh71VMYJJCnAHrVrcTn5cH6dqYELSE4xj9abkmJIfBtA+7jH61JIMx7due+KekBAJYDGOpp00YCEg54496LhczHh38E8E8c1E1sjAEDPPFXmwQAuB6UpTs2c9KlxNFIrCEAEhR9cdRVW7jJHAAPY1fyR8vp0qPGWwCOvNJrQpGRtm27GPA9+9XbZCP4vwFaItkMbZIJHXHSkEaxtt+7SsxqSKbxvt5yPr0xUJtiwBfg98Vqz52MYxl84BqPaFjXJ57n1+tK1x8xkmNt4B57c1QuFMbZ6jORW7MinII5HYVVnt1k4K8dqOUd7mW7+ZEELZ54PatLw+sEOpWsl4oMCyAupXcPrjuM4NZ19GISqkYHtW14XMF3fWkNwR5TOA4Jxkdhn3NCWqFJ6M1Xg1ySUyrr0DR5yHW82rj/AHe30xWN4l8q51bzLd0lYRossiDCyyAfMwHvW7KsN9PLYXtlb6ffA/uXRdi5/uMPfsareJbX7PfxR+WsTLbRbkAx823npVzV0Z05JSVyCSTzEVFHK9aq34O5Il4z61bstqgbx7ke9QySR3N4Co4zgEetaNaEXsyNehVecjAxxzUqRkLhc575q2lqsSBjkN3FOaHIBJUYHOKFHuDlcqNK+AoY4HbNA3MQQcAdxTkiLOecjt6mrIh8sIc9sn1osxNktpbMNrZ6de1LMwiBUcc9RUJvGiI4BUdxVW4uvMYHHPPShtIlRbdybfgOzMSex/pTWkdiNowB3qOJTIwA6Ht2NaH7qNDlRvxt4oV2KVkV5ZfLTpnjPHY1T3qTk8k+3SrqoJXx1BJyD2qK8tVj4BxkZzTd7aCTVyujAtwenp29qtopKEcYJxnNUkhMeAxGR1FTNOsaHCg54x70lLuU4kpTld23A65HFS+Unl4IHT86hgzJFvYkYGcYqG5m2HGeSenpVKdtWS4tuwk8KDOOvr7VZt4Y3hxjP1rORmkfgnGeMVcEvlxgDnHp2oi1e47NaEVxboSAByTyT3qFoQrfMOPrSmcEMckt9eKauX+8xA9BUyauXFOxoW+wKwOf8+9RsVEhxwOh5qvFuYZ5x2pzA8t68Uue+pPJqPlVSoAOOvNKid8jnnNOjhZssACP1p7xOpHGQRxUtFXsIWYEbiAcjGOtWIpHQ8NxjpUMEW9mLcgcYPFaSQjyxgDpgUJSYpJdSHz2IJAOQaaJSc5BGOamWNSSCq56UrW4C5XlevWm7tiVkQrLk5I6jj3qLzizDA74xU80Pygxjn27VUKBGPBBznj+tLmaLUUSPzgn738qljUKmA3IoikBZto5HtimsWcgDIKnk+tLmS3CwyZvmyRkEYpOZFCkHBAzTliZ2weD2HSphDIhDAAD+HjFO99ULYha2UKN3yk9qYsSseO3GKsytn7x6fpSoqqvBJOelDGRCHnG07hVxbVQm7APHaoo2+bPHHXtUkt7hCcDPSmrdRO/Qhd9pKjPtiq8zlh8xO3GabJIdwLk465z0pAdzAA5GM0m+w0u4+GMk7hgf0p8nUDb2znrUiZIXK4P171EwDFsZz600+orFeUBlPbnORTI48ENgE464qdhwRzjrn0poHlsACCD3paXuWthdzomF4PfNQSSseR1HOamc/LgdMdD3qtIM9Fx7jtUTZUUIHYkkscduaUngYOCetOjiJGcgg+1OZN5XkbalalOJBtIyDk+9IUPU5AzzVgJhjgc4PX/ADxT44zIvzDaw6/Wqt0QjC1SPeMMPlA4qGzjaLHYnoPWtPUodhUjLDH581a0cR/2hZs+BhsKSOAxB2k/jihR11CUtLonGk3srL5rxCc4/dSTDzPYYJ6+xqvdxzZIm8zenyneTkY7c1uWaRC8ieV7YQqgSWOQjzN2PnDL1Lls8/SodcUfaVUk+aIkEnPO7Hf3xjNW4aERnrYxpcxxvtPTNJoT7g5IGc0UVp9oT2LE8zGRQOBmkWZmyg496KKmW5I6HKv1z71NcszEqx4FFFWhPcrMoJyRyakFughfAoopRS1Jk3cbg24ypz26VA9wzyAYAGaKKnoXHUsRyY3HHIFQvM7zYJ4HOKKKECHzfdz3qi3U/nRRQwiaNovyKqkio7m3y/Lds9KKKf2QXxFcp5S8E+tWYYgxySaKKlFMhlhVc4J5NTW0S7RwOeOlFFN7i6DwirJj0NWTGowQOTRRQtgLaIqRqQOSOaZOoKk+woorToZv4ijvIBC8cVZhmcK4yOB1oorLqaMWWQhgV4OakEp27cds0UUdBMIHLsc+1JKg5PcNjiiijoMjRcsCexqdVGSfpRRUdALMCDaxIzjmpJcbNxGRg8UUVq9jNbmfP91fQ9qjiA3gY4z3oorKW5qhW+6GOPvYxS4BbGBRRQ9gRHdReWpCnofzpluo44HpRRS6ldC1t2oG71BNlV65JGf0ooqnsLqRB8L93vTy3OAAB396KKmJQyXGcY4qMLux0HXPFFFOQ0OTgAjoccUTtsRmAyRyfeiipZSJIWLjJ6mnA7ffJ5ooraJlIoapjAYAZx/WmKoa15HaiiomESxYavfB1Tz87RtDsoLgf72M/rSOzszsWJGDkHqTnrmiii90hpJPQ//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A pedunculated, soft papule is present in the axilla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_62_13282=[""].join("\n");
var outline_f12_62_13282=null;
var title_f12_62_13283="Intimal hyperplasia in PAH";
var content_f12_62_13283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vascular changes in pulmonary arterial hypertension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pulmonary arteriole in pulmonary arterial hypertension showing both mild medial hypertrophy and marked intimal hyperplasia, leading to partial obstruction of the lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eugene Mark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_62_13283=[""].join("\n");
var outline_f12_62_13283=null;
var title_f12_62_13284="Ipratropium (nasal): Patient drug information";
var content_f12_62_13284=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ipratropium (nasal): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/7/21620?source=see_link\">",
"     see \"Ipratropium (nasal): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/45/19155?source=see_link\">",
"     see \"Ipratropium (nasal): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9426949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atrovent&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8120006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alti-Ipratropium;",
"     </li>",
"     <li>",
"      Apo-Ipravent&reg;;",
"     </li>",
"     <li>",
"      Atrovent&reg;;",
"     </li>",
"     <li>",
"      Mylan-Ipratropium Solution",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F14943900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ipratropium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698280",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nosebleed.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695661",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spray nose spray up the nose only. Keep out of eyes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12171 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-D07AEDFCF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_62_13284=[""].join("\n");
var outline_f12_62_13284=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9426949\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120006\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14943900\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031239\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031238\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031243\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031244\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031246\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031241\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031242\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031247\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031248\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/7/21620?source=related_link\">",
"      Ipratropium (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/45/19155?source=related_link\">",
"      Ipratropium (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36469?source=related_link\">",
"      Ipratropium (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/51/39732?source=related_link\">",
"      Ipratropium (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/59/4021?source=related_link\">",
"      Ipratropium (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_62_13285="Septal rupture post MI";
var content_f12_62_13285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60314&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Septal rupture after MI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pathologic specimen showing rupture of the interventricular septum (arrow) after a myocardial infarction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Edwards, WD, Pathology of myocardial infarction and reperfusion. In: Acute Myocardial Infarction, Gersh, BJ, Rahimtoola, SH (Eds), Elsevier, New York 1991, pp, 14-48. By permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_62_13285=[""].join("\n");
var outline_f12_62_13285=null;
var title_f12_62_13286="Perforating dermatosis 2";
var content_f12_62_13286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acquired reactive perforating dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_62_13286=[""].join("\n");
var outline_f12_62_13286=null;
var title_f12_62_13287="Adjuvant treatment of intermediate-risk endometrial cancer";
var content_f12_62_13287=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant treatment of intermediate-risk endometrial cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/62/13287/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13287/contributors\">",
"     Heidi J Gray, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13287/contributors\">",
"     Wui-Jin Koh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/62/13287/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13287/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/62/13287/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13287/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/62/13287/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1596987936\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer of the endometrium is the most common gynecologic malignancy in developed countries and the second most common in developing countries. Endometrioid carcinoma is the most common histologic subtype and typically presents at an early stage with abnormal uterine bleeding. It is associated with a good prognosis. Other histologic types of endometrial carcinoma (eg, serous, clear cell) may not present with uterine bleeding, and are typically diagnosed at more advanced stages. As a result, these other types are associated with a poorer prognosis.",
"   </p>",
"   <p>",
"    The stage at diagnosis (",
"    <a class=\"graphic graphic_table graphicRef51307 \" href=\"UTD.htm?42/33/43549\">",
"     table 1",
"    </a>",
"    ) and histologic subtype of endometrial carcinoma are used to assign risk for recurrent or persistent disease into low-, intermediate-, and high-risk. This review will focus on adjuvant treatment for patients with intermediate-risk endometrial cancer. An overview of endometrial cancer including clinical features and an approach to diagnosis, an overview on the approach to adjuvant treatment, and treatment of low- and high-risk and advanced endometrial cancer are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=see_link\">",
"       \"Overview of endometrial carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=see_link\">",
"       \"Endometrial carcinoma: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=see_link\">",
"       \"Approach to adjuvant treatment of endometrial cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7542?source=see_link\">",
"       \"Treatment of low-risk endometrial cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41991?source=see_link\">",
"       \"Adjuvant treatment of high-risk endometrial cancers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22825?source=see_link\">",
"       \"Treatment of locally advanced, recurrent, or metastatic endometrial cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1596987971\">",
"    <span class=\"h1\">",
"     DEFINITION OF INTERMEDIATE-RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;After surgical staging is complete, intermediate-risk patients are defined by the following: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cancer that is confined to the uterus but invades the myometrium (a subset of stage IA or stage IB) or demonstrates occult cervical stromal invasion (stage II). These groups have a higher risk of recurrence than do patients whose tumors are confined to the endometrium. This group excludes women with serous or clear cell cancers, who are considered to be at high-risk and are discussed separately (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41991?source=see_link&amp;anchor=H181148975#H181148975\">",
"       \"Adjuvant treatment of high-risk endometrial cancers\", section on 'Uterine serous or clear cell carcinoma'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A subset of women are considered to have high intermediate-risk based on certain pathologic criteria: &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The Gynecologic Oncology Group (GOG) defines high intermediate-risk based on age and any of three pathologic factors: the presence of deep myometrial invasion, grade 2 or 3 histology, or the presence of lymphovascular invasion [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/1\">",
"       1",
"      </a>",
"      ]. Women have high intermediate-risk risk disease if they are: &ge;70 years with one risk factor; age 50 to 69 years with two risk factors; or age &ge; 18 years with all three risk factors.",
"     </li>",
"     <li>",
"      In contrast, the Post-Operative Radiation Therapy in Endometrial Cancer (PORTEC) trials define high intermediate-risk by two of three clinicopathologic factors present: age &gt;60 years, outer half myometrial invasion, and grade 3 histology [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/2-4\">",
"       2-4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We use the GOG criteria to define the high intermediate-risk group, but either set of criteria is being used to determine clinical trial eligibility. (See",
"    <a class=\"local\" href=\"#H1596988128\">",
"     'Combined modality treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the absence of the criteria for high intermediate-risk, all others are considered to have low intermediate-risk endometrial cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5418407\">",
"    <span class=\"h2\">",
"     Lower uterine segment involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of cancer within the lower uterine segment (LUS) may identify patients at risk for nodal involvement, although whether it represents an independent risk factor for survival is unclear. We do not consider LUS involvement an intermediate risk factor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7542?source=see_link\">",
"     \"Treatment of low-risk endometrial cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1596988020\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adjuvant treatment options for women with intermediate-risk disease include observation or radiation therapy (RT). Our approach depends on whether or not risk factors are present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest observation following surgery rather than RT for women with low intermediate-risk disease because they have a good prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/1\">",
"       1",
"      </a>",
"      ]. The risks of adjuvant RT outweigh the survival benefits in this population. (See",
"      <a class=\"local\" href=\"#H215726495\">",
"       'Low intermediate-risk'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      We suggest RT rather than observation for women at high intermediate-risk disease. These patients are at an increased risk of a local recurrence, and this risk is significantly reduced with adjuvant RT [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/5\">",
"       5",
"      </a>",
"      ]. However, adjuvant RT does not appear to impact overall survival. (See",
"      <a class=\"local\" href=\"#H1596988042\">",
"       'High intermediate-risk disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      There is a lack of data to inform the role of adjuvant chemotherapy (alone or in combination with RT) in women with high intermediate-risk disease. Some experts prefer to offer chemotherapy to women with a subset of high-intermediate risk endometrial cancer (ie, grade 3, &gt;50 percent myometrial invasion, with evidence of lymphovascular space invasion). The use of combined modality treatment is currently being evaluated in clinical trials. (See",
"      <a class=\"local\" href=\"#H1596988128\">",
"       'Combined modality treatment'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evidence to support these recommendations is discussed below.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215726495\">",
"    <span class=\"h2\">",
"     Low intermediate-risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with low intermediate-risk disease, we suggest observation rather than adjuvant RT. Given the overall good prognosis of these patients following surgical treatment, there is very little benefit to be gained from adjuvant RT. This was demonstrated in Gynecologic Oncology Group trial 99 (GOG 99), which randomly assigned 448 women with intermediate-risk endometrial cancer to observation or adjuvant pelvic RT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/1\">",
"     1",
"    </a>",
"    ]. The administration of adjuvant pelvic RT resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lower incidence of first recurrence compared to observation only (hazard ratio [HR] 0.46,",
"      <strong>",
"       90%",
"      </strong>",
"      CI 0.19-1.11), which was not statistically significant. There was no difference in the incidence of distant recurrence (1.5 versus 1.4 percent, HR 1.28, 95% CI 0.42-3.85).",
"     </li>",
"     <li>",
"      No difference in the risk of death due to endometrial cancer (HR for mortality, 1.04,",
"      <strong>",
"       90%",
"      </strong>",
"      CI 0.56-1.93). However, the overall incidence of death was low (3 versus 2 percent, respectively).",
"     </li>",
"     <li>",
"      A significantly higher number of patients with moderate to serious (grade 2 to 4) toxicity, including hematologic (14 versus 5), gastrointestinal (64 versus 5), and cutaneous toxicity (15 versus 9). There were also six patients treated with RT who experienced a serious gastrointestinal obstruction, compared to one patient in the observation arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1596988042\">",
"    <span class=\"h2\">",
"     High intermediate-risk disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with high intermediate-risk disease, we suggest RT rather than observation. RT can reduce the risk of a local recurrence, although it does not appear to improve overall survival (OS). In a 2012 meta-analysis that evaluated the role of adjuvant RT among women with stage I endometrial cancer, there was no significant difference in overall survival (HR 0.88, 95% CI 0.63-1.22) or endometrial cancer-specific survival (HR 0.80, 95% CI 0.54-1.18) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the benefit of adjuvant RT on lowering the risk of a local recurrence was demonstrated in GOG-99 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/1\">",
"     1",
"    </a>",
"    ]. Pelvic RT resulted in a reduction in the risk of a local recurrence compared to observation (2 versus 9 percent, HR 0.42, 90% CI 0.21-0.83). Despite this, there was no statistically significant reduction in the risk of death (HR 0.73, 90% CI 0.43-1.26), although the study was not powered sufficiently for this endpoint.",
"   </p>",
"   <p>",
"    Because of the apparent lack of a significant overall survival advantage with adjuvant RT, some experts prefer not to administer adjuvant RT in this population. However, others prefer to administer adjuvant chemotherapy. The role of chemotherapy or concomitant chemotherapy plus RT specifically for women with intermediate-risk endometrial cancer is discussed below. (See",
"    <a class=\"local\" href=\"#H1596988092\">",
"     'Chemotherapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1596988128\">",
"     'Combined modality treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The evidence to support these recommendations is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H568079343\">",
"    <span class=\"h3\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT can be administered as vaginal brachytherapy (VBT), pelvic RT, and in specialized centers, using intensity-modulated RT (IMRT).",
"   </p>",
"   <p>",
"    We recommend vaginal brachytherapy for the treatment of women with high intermediate-risk endometrial cancer. While pelvic radiation (RT) decreases the risk of a local recurrence, it is associated with more toxicity, including long-term urinary and bowel symptoms. IMRT is an attractive alternative to VBT, but is not yet widely available. A discussion on the technical aspects of RT for endometrial cancer is covered separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19343690\">",
"    <span class=\"h4\">",
"     Vaginal brachytherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We prefer VBT alone for most patients with high intermediate-risk endometrial cancer, because it results in equivalent locoregional recurrence rates compared with pelvic RT and has a more favorable toxicity profile [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/3,7-11\">",
"     3,7-11",
"    </a>",
"    ]. In the PORTEC-2 trial, 427 women with high-intermediate risk disease were randomly assigned treatment with VBT or pelvic RT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/3\">",
"     3",
"    </a>",
"    ]. At 45 months there were no statistically significant differences between VBT and pelvic RT in terms of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Locoregional recurrence rate (5 versus 3 percent for VBT and pelvic RT, respectively)",
"     </li>",
"     <li>",
"      Distant metastases (8 versus 6 percent, respectively)",
"     </li>",
"     <li>",
"      Five-year disease-free survival (83 versus 78 percent, respectively) and overall survival (85 versus 80 percent, respectively)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    VBT was associated with a significantly lower rate of treatment-related diarrhea and other bowel symptoms (13 versus 54 percent, respectively)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215726707\">",
"    <span class=\"h4\">",
"     Pelvic radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As demonstrated in the PORTEC trial, pelvic RT results in a significant reduction the risk of a locoregional recurrence compared to surgery alone (5 versus 14 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H378527123\">",
"     'Unstaged intermediate-risk patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, pelvic RT is associated with both early and late-complications [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/1,13,14\">",
"     1,13,14",
"    </a>",
"    ]. Early gastrointestinal (GI) side effects (eg, diarrhea or rectal bleeding) may occur in up to 60 percent of women, and severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    complications can be seen in up to 8 percent of patients. In addition, in the PORTEC study, the rate of late complications (predominantly affecting the GI and urinary systems) was significantly higher in the group treated with RT compared to those who underwent observation (26 versus 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22570?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of radiation therapy for gynecologic malignancies\", section on 'Treatment-related toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=see_link\">",
"     \"Gastrointestinal toxicity of radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215726916\">",
"    <span class=\"h4\">",
"     Intensity modulated radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns about long term toxicities and the lack of a survival advantage with pelvic RT in women with intermediate-risk endometrial cancer have lead to exploration of alternative modalities of treatment, such as IMRT. Unlike conventional RT, the prescription dose used in IMRT is conformed to the target tissue in three dimensions, thereby reducing the dose of RT delivered to normal surrounding tissue. Preliminary experience with IMRT has been promising with low rates of both acute and chronic toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/15\">",
"     15",
"    </a>",
"    ]. However, its use is limited to centers specialized in IMRT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22570?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of radiation therapy for gynecologic malignancies\", section on 'Intensity-modulated RT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1596988092\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is low quality data that adjuvant chemotherapy is an alternative to RT in women with high intermediate-risk endometrial cancer to justify the morbidity of treatment.",
"   </p>",
"   <p>",
"    In one trial, 425 women with endometrial cancer that had at least 50 percent myometrial invasion were randomly assigned to treatment with whole pelvic RT versus three or more courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (CAP) chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/16\">",
"     16",
"    </a>",
"    ]. CAP was not associated with any improvement in progression-free survival (PFS) or OS. However, among women with high intermediate-risk (grade 3 endometrial cancer, cervical stromal invasion, or cases with positive peritoneal cytology), CAP resulted in an improvement in the five-year rate of PFS (84 versus 66 percent, hazard ratio [HR] 0.44, 95% CI 0.20-0.97) and OS (90 versus 74 percent, HR 0.24, 95% CI 0.09-0.69).",
"   </p>",
"   <p>",
"    Further data are needed before chemotherapy can be administered instead of RT in women with high intermediate-risk disease. We encourage participation in appropriately designed clinical trials. (See",
"    <a class=\"local\" href=\"#H1596988128\">",
"     'Combined modality treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1596988128\">",
"    <span class=\"h3\">",
"     Combined modality treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because RT reduces the risk of a locoregional recurrence but does not address the risk of distant recurrence, there is interest in use of a combined approach of chemotherapy plus some form of RT. However, there are no data to support its use for women with high intermediate-risk endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/17-24\">",
"     17-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combined modality treatment is being compared in two ongoing randomized trials being conducted in the United States (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00807768\">",
"     GOG 249",
"    </a>",
"    ) and Europe (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00411138\">",
"     PORTEC-3",
"    </a>",
"    ). A further discussion of combined modality treatment is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41991?source=see_link&amp;anchor=H176023614#H176023614\">",
"     \"Adjuvant treatment of high-risk endometrial cancers\", section on 'Treatment approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H378527123\">",
"    <span class=\"h2\">",
"     Unstaged intermediate-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who did not undergo formal nodal staging as part of their surgery are technically unstaged. For these patients, the data suggest that pelvic RT can be safely administered without a re-operation to complete staging [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H215726707\">",
"     'Pelvic radiation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This was demonstrated in the PORTEC study, in which 715 women who had undergone primary surgical therapy (without node dissection) were randomly assigned to observation or to adjuvant treatment with pelvic RT [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/2,4,25,27\">",
"     2,4,25,27",
"    </a>",
"    ]. With a median follow-up of 13 years, the use of pelvic RT resulted in the following outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/25\">",
"     25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No significant difference in 15-year overall survival compared to observation only (52 versus 60 percent, respectively, p=0.14).",
"     </li>",
"     <li>",
"      A significantly lower locoregional recurrence rate (5 versus 16 percent, HR for observation 3.46, 95 percent CI 1.93-6.18) but no statistically significant difference in the rate of distant metastases (9 versus 7 percent).",
"     </li>",
"     <li>",
"      There was no statistically significant difference in the rate of second primary cancers at 15 years (22 versus 16 percent, p=0.10).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H118956009\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with low intermediate-risk endometrial cancer have an excellent prognosis, with recurrence rates of about 5 to 6 percent without any adjuvant therapy. Patients with clinical features that define high intermediate-risk endometrial cancer have a recurrence risk ranging from 5 percent (with adjuvant radiation) to 30 percent (if not treated after surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13287/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, survival can be expected to be above 80 percent, with or without radiation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1596988184\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttreatment surveillance of women with endometrial cancer is similar regardless of risk. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=see_link&amp;anchor=H11157097#H11157097\">",
"     \"Overview of endometrial carcinoma\", section on 'Posttreatment surveillance'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/55/19314?source=see_link\">",
"       \"Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/12/8388?source=see_link\">",
"       \"Patient information: Endometrial cancer treatment after surgery (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1596988205\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with intermediate-risk endometrial cancer are at risk for locoregional relapse. Therefore, many patients undergo adjuvant treatment to reduce recurrence risk in the pelvis. (See",
"      <a class=\"local\" href=\"#H1596987936\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intermediate-risk patients are those with endometrial carcinomas invading the myometrium (a subset of stage IA or stage IB) or demonstrating occult cervical stromal invasion (stage II). These groups have a higher risk of recurrence than do patients whose tumors are confined to the endometrium. Several prognostic factors are used to stratify women into a high intermediate-risk endometrial group. The GOG uses the following risk factors: older age, outer half myometrial invasion, grade 2 or 3 differentiation, or the presence of lymphovascular invasion within the cancer. (See",
"      <a class=\"local\" href=\"#H1596987971\">",
"       'Definition of intermediate-risk'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women without high-risk prognostic factors (ie, low intermediate-risk disease), we recommend observation over adjuvant RT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H215726495\">",
"       'Low intermediate-risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with high intermediate-risk endometrial cancer, we suggest radiation therapy rather than observation alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We recommend vaginal brachytherapy rather than pelvic RT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1596988042\">",
"       'High intermediate-risk disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19343690\">",
"       'Vaginal brachytherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with high intermediate-risk disease, we suggest not administering adjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, some clinicians prefer to offer chemotherapy to women with a subset of high-intermediate risk endometrial cancer (ie, grade 3, &gt;50 percent myometrial invasion, with evidence of lymphovascular space invasion). (See",
"      <a class=\"local\" href=\"#H1596988092\">",
"       'Chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with unstaged intermediate-risk endometrial cancer, we suggest pelvic RT rather than observation or repeat surgery for nodal staging (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H378527123\">",
"       'Unstaged intermediate-risk patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there is interest in a combined approach of chemotherapy plus some form of RT, there are no data to support its use for women with high intermediate-risk endometrial cancer. Combined modality treatment is being compared in two ongoing randomized trials being conducted separately in the United States (",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00807768\">",
"       GOG 249",
"      </a>",
"      ) and Europe (",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00411138\">",
"       PORTEC-3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1596988128\">",
"       'Combined modality treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Posttreatment surveillance of women with endometrial cancer is similar regardless of risk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=see_link&amp;anchor=H11157097#H11157097\">",
"       \"Overview of endometrial carcinoma\", section on 'Posttreatment surveillance'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/1\">",
"      Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/2\">",
"      Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000; 355:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/3\">",
"      Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010; 375:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/4\">",
"      Creutzberg CL, van Putten WL, Koper PC, et al. The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. Int J Radiat Oncol Biol Phys 2001; 51:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/5\">",
"      ASTEC/EN.5 Study Group, Blake P, Swart AM, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009; 373:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/6\">",
"      Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev 2012; 4:CD003916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/7\">",
"      Alektiar KM, Venkatraman E, Chi DS, Barakat RR. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys 2005; 62:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/8\">",
"      Jolly S, Vargas C, Kumar T, et al. Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer. Gynecol Oncol 2005; 97:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/9\">",
"      Solhjem MC, Petersen IA, Haddock MG. Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial cancer. Int J Radiat Oncol Biol Phys 2005; 62:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/10\">",
"      McCloskey SA, Tchabo NE, Malhotra HK, et al. Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation. Gynecol Oncol 2010; 116:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/11\">",
"      Becker M, Malafy T, Bossart M, et al. Quality of life and sexual functioning in endometrial cancer survivors. Gynecol Oncol 2011; 121:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/12\">",
"      Creutzberg CL, van Putten WL, Koper PC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 2003; 89:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/13\">",
"      Nout RA, Putter H, J&uuml;rgenliemk-Schulz IM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 2009; 27:3547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/14\">",
"      Randall ME, Wilder J, Greven K, Raben M. Role of intracavitary cuff boost after adjuvant external irradiation in early endometrial carcinoma. Int J Radiat Oncol Biol Phys 1990; 19:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/15\">",
"      Beriwal S, Jain SK, Heron DE, et al. Clinical outcome with adjuvant treatment of endometrial carcinoma using intensity-modulated radiation therapy. Gynecol Oncol 2006; 102:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/16\">",
"      Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008; 108:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/17\">",
"      Klopp AH, Jhingran A, Ramondetta L, et al. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecol Oncol 2009; 115:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/18\">",
"      Alvarez Secord A, Havrilesky LJ, Bae-Jump V, et al. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol 2007; 107:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/19\">",
"      Frigerio L, Mangili G, Aletti G, et al. Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study. Gynecol Oncol 2001; 81:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/20\">",
"      Greven K, Winter K, Underhill K, et al. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 2006; 103:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/21\">",
"      Lupe K, D'Souza DP, Kwon JS, et al. Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer. Gynecol Oncol 2009; 114:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/22\">",
"      Onda T, Yoshikawa H, Mizutani K, et al. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer 1997; 75:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/23\">",
"      Lupe K, Kwon J, D'Souza D, et al. Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach. Int J Radiat Oncol Biol Phys 2007; 67:110.",
"     </a>",
"    </li>",
"    <li>",
"     Hogberg T, Rosenberg P, Kristensen G, et al. A randomized phase III study on adjuvant treatment with radiation (RT) &plusmn; chemotherapy (CT) in early stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991) (abstract). J Clin Oncol 2007; 25:274s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/25\">",
"      Creutzberg CL, Nout RA, Lybeert ML, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011; 81:e631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/26\">",
"      Parthasarathy A, Kapp DS, Cheung MK, et al. Adjuvant radiotherapy in incompletely staged IC and II endometrioid uterine cancer. Obstet Gynecol 2007; 110:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13287/abstract/27\">",
"      Scholten AN, van Putten WL, Beerman H, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005; 63:834.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16741 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.150-9E46D5F071-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_62_13287=[""].join("\n");
var outline_f12_62_13287=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1596988205\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1596987936\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1596987971\">",
"      DEFINITION OF INTERMEDIATE-RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5418407\">",
"      Lower uterine segment involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1596988020\">",
"      TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H215726495\">",
"      Low intermediate-risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1596988042\">",
"      High intermediate-risk disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H568079343\">",
"      - Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H19343690\">",
"      Vaginal brachytherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H215726707\">",
"      Pelvic radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H215726916\">",
"      Intensity modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1596988092\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1596988128\">",
"      - Combined modality treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H378527123\">",
"      Unstaged intermediate-risk patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H118956009\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1596988184\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1596988205\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16741\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16741|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/33/43549\" title=\"table 1\">",
"      Staging uterine carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41991?source=related_link\">",
"      Adjuvant treatment of high-risk endometrial cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=related_link\">",
"      Approach to adjuvant treatment of endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37992?source=related_link\">",
"      Endometrial carcinoma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=related_link\">",
"      Gastrointestinal toxicity of radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21624?source=related_link\">",
"      Overview of endometrial carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/2/22570?source=related_link\">",
"      Overview of radiation therapy for gynecologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/55/19314?source=related_link\">",
"      Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/12/8388?source=related_link\">",
"      Patient information: Endometrial cancer treatment after surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22825?source=related_link\">",
"      Treatment of locally advanced, recurrent, or metastatic endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7542?source=related_link\">",
"      Treatment of low-risk endometrial cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_62_13288="Active surveillance for men with early prostate cancer";
var content_f12_62_13288=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Active surveillance for men with early prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/62/13288/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13288/contributors\">",
"     Laurence Klotz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/62/13288/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13288/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13288/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13288/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/62/13288/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13288/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/62/13288/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITION OF TERMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active surveillance (expectant management) for men with prostate cancer involves the postponement of immediate therapy, with definitive treatment used if there is evidence that the patient is at increased risk for disease progression. Active surveillance is an accepted option for the initial management of carefully selected men with localized, well-differentiated prostate cancer thought to be at low risk for progression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Active surveillance differs from the older concept of \"watchful waiting\", which was based upon the premise that some men would not benefit from definitive treatment of apparently localized prostate cancer because of the prolonged natural history of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/3\">",
"     3",
"    </a>",
"    ]. For patients managed with watchful waiting, the decision was made at the outset to forego definitive treatment and to provide symptomatic treatment (either androgen deprivation therapy or local palliative maneuvers) if disease progressed locally or at distant metastatic sites. Watchful waiting was largely seen as an alternative to definitive local therapy for elderly men with a limited life expectancy and for those with substantial comorbidity.",
"   </p>",
"   <p>",
"    The key considerations in choosing active surveillance for the initial patient management include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Selection of patients who are at low risk of progression",
"     </li>",
"     <li>",
"      Frequency and type of monitoring during active surveillance",
"     </li>",
"     <li>",
"      Criteria for switching from surveillance to definitive therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of active surveillance for patients with localized prostate cancer will be reviewed here. Other approaches to the management of patients with early prostate cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of active surveillance as a treatment option in carefully selected men with early prostate cancer is based upon several assumptions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prostate cancer is often detected when it is not clinically significant.",
"     </li>",
"     <li>",
"      Patients who have indolent prostate cancer can be distinguished by clinical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pathologic parameters from those who will have more aggressive disease that will lead to symptoms, metastases, or death.",
"     </li>",
"     <li>",
"      All definitive treatments for patients with prostate cancer, including those directed at minimal disease, are associated with significant side effects and costs.",
"     </li>",
"     <li>",
"      With appropriate surveillance, patients can be reclassified as being at higher risk for disease progression and receive definitive therapy without substantially decreasing the chance of cure.",
"     </li>",
"     <li>",
"      The psychological burden of living with prostate cancer without active treatment has less impact on quality of life than receiving unnecessary, definitive treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to most other malignancies, the growth rate of many prostate cancers is slow and appears to be relatively constant over time. For many men, such disease either never requires treatment or treatment can be postponed for a prolonged period without significantly decreasing the chance for cure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=see_link&amp;anchor=H31#H31\">",
"     \"Screening for prostate cancer\", section on 'Overdiagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence supporting the concept that many men have asymptomatic prostate cancer that is indolent and does not require immediate treatment comes from a number of sources:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autopsy studies have shown that there is a high incidence of occult cancer in the prostate of men dying without a known prostate cancer. The frequency of such tumors may be as high as 30 percent in men under 40 years, and may approach 70 to 80 percent in those 60 to 80 years of age. At least one study has suggested that the prevalence of occult prostate cancer may be decreasing since the introduction of the widespread PSA screening for prostate cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=see_link\">",
"       \"Risk factors for prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Epidemiologic studies since the introduction of PSA-based screening indicate that the number of cases of prostate cancer is substantially higher than was seen prior to the screening era. Extrapolations based upon the frequency of a serum PSA &gt;2.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in men 50 to 70 years of age and the rate of a positive biopsy in that population subset suggest that there are over 500,000 undiagnosed cases of prostate cancer in this group [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A high frequency of occult prostate cancer was observed in the Prostate Cancer Prevention Trial, in which men underwent routine prostate biopsy at the completion of the trial [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/7\">",
"       7",
"      </a>",
"      ]. Among those who had received placebo, 15 percent of those without an elevated serum PSA or abnormal digital rectal examination had occult prostate cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=see_link&amp;anchor=H8#H8\">",
"       \"Chemoprevention strategies in prostate cancer\", section on 'Prostate Cancer Prevention Trial'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION FOR ACTIVE SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of those patients whose disease will not progress for an extended period is a critical issue in the choice of active surveillance for men with prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple criteria have been proposed for identifying patients with a favorable prognosis who are candidates for active surveillance, and the clinical criteria applied at different sites and in different studies vary somewhat [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/4,8-15\">",
"     4,8-15",
"    </a>",
"    ]. All such criteria incorporate an early clinical stage, a relatively low serum PSA, and a Gleason score consistent with well- or moderately-differentiated tumor. Other parameters that are frequently incorporated include the number of positive cores on the original biopsy, the percentage of positive cores, the extent of tumor involvement within a biopsy core, the PSA density, and PSA kinetics.",
"   </p>",
"   <p>",
"    Although controversial, several sites have recommended a repeat prostate biopsy before committing to a plan for active surveillance, in order to identify patients in whom the original biopsy may have missed evidence of increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/16\">",
"     16",
"    </a>",
"    ]. In most patients, delaying this biopsy for six months to a year may not have an impact on long term outcome, even if higher grade disease is eventually identified.",
"   </p>",
"   <p>",
"    Such eligibility criteria, known as the Epstein criteria, were initially developed and validated based upon pathologic findings from radical prostatectomy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. Although these criteria are useful in identifying men whose disease is likely to be localized and low grade at radical prostatectomy, long-term clinical correlation is required to determine how effective active surveillance is in a clinical setting. A study using contemporary biopsy techniques found that 93 percent of men meeting the Epstein criteria on biopsy had organ confined disease at prostatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/18\">",
"     18",
"    </a>",
"    ]. However, 20 percent had more aggressive pathologic features including Gleason 7 disease or extraprostatic extension. Despite these findings, no patient meeting these criteria had a clinical or biochemical failure at six years after surgery.",
"   </p>",
"   <p>",
"    In a prospective experience in Toronto, eligibility criteria consisted of clinical stage T1c or T2a prostate cancer, a Gleason score &le;6, and a serum PSA &le;10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/19\">",
"     19",
"    </a>",
"    ]. This corresponds to anatomic stage prognostic group I in the seventh (2010) TNM staging system (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 2",
"    </a>",
"    ). For patients over age 70 years, slightly less stringent criteria were applied (Gleason score &le;7 [3+4],",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PSA &le;15",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Observational studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Nomograms have also been developed as an alternative to a single set of criteria to predict the probability of indolent prostate cancer for an individual patient [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. The applicability of these nomograms is limited by the characteristics of the population in which they were developed, and the results may not apply to asymptomatic younger men detected by PSA screening [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link&amp;anchor=H15#H15\">",
"     \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\", section on 'Nomograms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The application of these criteria or of nomograms for helping a patient to decide whether or not to pursue active surveillance must be carefully individualized. Although age alone does not preclude active therapy, active surveillance may be particularly appropriate in older men and those with significant comorbidity, due to the long natural history of prostate cancer and concerns about treatment-related toxicity. Treatment-related toxicity (impotence, incontinence, acute surgical complications) appears to be more frequent in older men, making an active surveillance approach more attractive in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endorectal coil MRI may eventually be useful as a supplemental way to optimize patient selection for active surveillance. A prospective study imaged 60 consecutive patients who had been selected for active surveillance based upon standard criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients were subsequently reclassified as needing definitive therapy if a confirmatory biopsy revealed any Gleason 7 tumor, 3 or more cores positive for cancer, or more than 50 percent tumor in any one core. Any MRI finding of a tumor &gt;1 cm in greatest dimension was deemed positive, since this corresponded to a tumor volume of 0.5 cm",
"    <sup>",
"     3",
"    </sup>",
"    .",
"   </p>",
"   <p>",
"    MRI findings obtained upon study entry were correlated with those of the confirmatory biopsy. Among the 13 patients who had a lesion &gt;1 cm on their MRI (22 percent), repeat biopsy identified 10 who were reclassified based upon their repeat biopsy. Among the 24 patients (40 percent) where the MRI demonstrated a lesion &lt;1 cm, 16 were not reclassified on repeat biopsy and 6 were reclassified as being at increased risk. Overall, 20 of 22 patients who had a normal MRI at baseline were not reclassified on repeat biopsy. These findings need confirmation before MRI can be considered to have a role in determining the appropriateness of active surveillance.",
"   </p>",
"   <p>",
"    In older patients, a comprehensive geriatric assessment may be useful in determining whether a definitive intervention, active surveillance, or watchful waiting is most appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines that have attempted to identify patient groups for whom active surveillance is an appropriate option include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Urological Association (AUA) considers active surveillance, interstitial brachytherapy, external beam radiation therapy, and radical prostatectomy appropriate treatment options for patients with low and intermediate-risk prostate cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/1\">",
"       1",
"      </a>",
"      ]. These guidelines concluded that the available data on outcomes and complications were insufficient to recommend any one form of treatment over another for any risk category of disease. These guidelines recommend that all men with clinically localized prostate cancer be informed about all three of these treatment strategies, with a discussion of estimated benefit as well as harm from each intervention. We agree with this recommendation.",
"     </li>",
"     <li>",
"      The National Comprehensive Cancer Network (NCCN) 2010 guidelines define a very low risk group, which includes the criteria for the TNM anatomic stage prognostic groups I in the 2010 TNM staging system [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/2\">",
"       2",
"      </a>",
"      ]. In addition, these patients must have fewer than three positive biopsy cores, with &le;50 percent cancer in each core, and a PSA density &lt;0.15",
"      <span class=\"nowrap\">",
"       ngl/mL/g.",
"      </span>",
"      In this very low risk group, the NCCN recommends active surveillance as the preferred option for those with a life expectancy less than 20 years. For the low risk group (anatomic stage prognostic group I), the NCCN recommends active surveillance for those with a life expectancy less than 10 years, and considers active surveillance an option, along with radiation therapy and radical prostatectomy, for those with a longer life expectancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SURVEILLANCE STRATEGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal strategy for men who are being managed with active surveillance has not been defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H696570543\">",
"    <span class=\"h2\">",
"     Evidence of progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary parameters available for monitoring include the serum PSA, digital rectal examination, and repeat prostate biopsy, but no clinical studies have defined the appropriate testing intervals and the criteria to trigger active intervention.",
"   </p>",
"   <p>",
"    Repeat prostate biopsy is usually recommended based upon a concern that histologic grade will worsen. The probability that higher grade disease will be detected is 8 to 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/26,27\">",
"     26,27",
"    </a>",
"    ], and these cases may represent a higher-grade component of the original tumor that was originally not sampled rather than evolution to higher grade disease.",
"   </p>",
"   <p>",
"    In Toronto, the monitoring plan and criteria for active intervention include [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of the serum PSA at three month intervals, to calculate the PSA doubling time. A doubling time of three years or less is used as a criterion for intervention.",
"     </li>",
"     <li>",
"      A repeat prostate biopsy is performed at one year, to rule out higher grade disease that may have been missed on the original biopsy or developed as a consequence of tumor progression. Following this, biopsies are repeated every four to five years to look for evidence of biologic progression to Gleason 4+3 or higher. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=see_link&amp;anchor=H12#H12\">",
"       \"Interpretation of prostate biopsy\", section on 'Gleason score'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach is consistent with the 2007 American Urological Association (AUA) guidelines as well as those of the National Comprehensive Cancer Network (NCCN), neither of which delineate specific intervals for retesting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H696570550\">",
"    <span class=\"h2\">",
"     Prevention of progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    , a 5-alpha reductase inhibitor, is being studied to determine whether this approach can prevent or delay the progression of prostate cancer in patients being managed with active surveillance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=see_link&amp;anchor=H6#H6\">",
"     \"Chemoprevention strategies in prostate cancer\", section on '5-Alpha reductase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the REDEEM trial, 302 men were randomly assigned to treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    or placebo for three years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/29\">",
"     29",
"    </a>",
"    ]. All patients had low-risk disease and met strict criteria for active surveillance (T1c or T2a prostate cancer, PSA &lt;11",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    a Gleason score &le;6, &le;3 positive cores on biopsy with &le;50 positivity on any one core). Repeat biopsies were performed at 18 and 36 months. The primary endpoint was time to progression (defined by an increase in Gleason score to &gt;6, involvement of &gt;3 cores, &gt;50 percent involvement of any one core, or treatment for prostate cancer [RT, radical prostatectomy, hormonal ablation]).",
"   </p>",
"   <p>",
"    In an initial report, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    significantly decreased or delayed the risk of prostate cancer reclassification to higher risk disease (an increase in volume or grade of disease) compared with placebo (54 of 144 [38 percent] versus 70 of 145 [48 percent], hazard ratio 0.62, 95% CI 0.43-0.89) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/29\">",
"     29",
"    </a>",
"    ]. Furthermore, there was no evidence of an increase in the number of patients with high grade prostate cancer on the final biopsy.",
"   </p>",
"   <p>",
"    The results of the REDEEM trial require confirmation in larger numbers of patients with longer follow-up. The trial was relatively short term, and has no data on clinical progression. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data on patient outcomes with active surveillance come from observation studies. Large, randomized trials that compare active surveillance with immediate intervention are in progress. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Randomized trials of active surveillance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Observational studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several large observational studies provide important information about the clinical course of patients managed with active surveillance, although additional longer-term follow-up is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/28,30-37\">",
"     28,30-37",
"    </a>",
"    ]. These studies consistently found a low rate of progression to metastatic disease or death from prostate cancer with active surveillance; in addition, the majority of patients did not require definitive therapy within the time frame of these studies.",
"   </p>",
"   <p>",
"    The results with active surveillance are illustrated by a prospective study from Toronto, in which 450 patients were initially managed with active surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/28\">",
"     28",
"    </a>",
"    ]. From 1995 to 1999, patients with a favorable risk profile (Gleason score &le;6 and serum PSA &le;10",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    were offered active surveillance; less stringent criteria were used for patients over 70 years of age (serum PSA &le;15",
"    <span class=\"nowrap\">",
"     ngl/mL",
"    </span>",
"    or a Gleason score 3 + 4). From 2000 to 2005, enrollment was limited to the favorable risk category, regardless of age. Definitive treatment was recommended for a PSA doubling time of three years or less, histologic progression, or clinical progression.",
"   </p>",
"   <p>",
"    The following findings were noted at a median follow-up of seven years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 10-year overall survival for the entire cohort was 68 percent, and the 10-year prostate cancer specific survival was 97 percent.",
"     </li>",
"     <li>",
"      Definitive therapy was needed in 135 patients (30 percent), approximately one-half due to a short PSA doubling time and one-fourth due to histologic grade progression.",
"     </li>",
"     <li>",
"      Biochemical progression was observed in 50 percent of patients who underwent definitive therapy and in 13 percent of the entire cohort.",
"     </li>",
"     <li>",
"      Five patients died of prostate cancer, two of whom had refused definitive therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional evidence supporting active surveillance rather than radical prostatectomy or radiation therapy in selected patients comes from the Health Professionals Follow-up Study, in which 3331 men were diagnosed with prostate cancer between 1986 and 2007; treatment was deferred for at least one year in 342 (10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/30\">",
"     30",
"    </a>",
"    ]. The untreated group included both men managed with active surveillance and those in whom definitive therapy was not planned because of age or comorbidity. One-half of these patients remained untreated at a median follow-up of seven years.",
"   </p>",
"   <p>",
"    Patients deferring treatment were significantly older and had earlier stage disease, lower serum PSA, and lower biopsy Gleason scores. Multivariate analysis, adjusted for age, time of diagnosis, clinical stage, PSA at diagnosis, and Gleason score found no significant difference in the risk of developing metastases or dying of prostate cancer between the active surveillance and treatment groups (hazard ratio 1.03, 95% CI 0.65-1.23).",
"   </p>",
"   <p>",
"    Many men who require active intervention represent a subset of patients who were under-sampled originally. In a series of 470 men initially included in an active surveillance program at Johns Hopkins, patients underwent annual prostate biopsies to identify evidence of progression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/31\">",
"     31",
"    </a>",
"    ]. Overall, 51 patients (11 percent) underwent radical prostatectomy. In addition, three-fourths of men who progressed did so within one to two years after the original diagnosis, suggesting undersampling of more aggressive tumor rather than progression of indolent tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Randomized trials of active surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive assessment of the role of active surveillance in favorable-risk prostate cancer patients requires a direct comparison between immediate treatment and active surveillance including definitive treatment for evidence of progression. There are no results to date from randomized trials that compare definitive treatment (radical prostatectomy or radiation therapy) with a contemporary active surveillance approach.",
"   </p>",
"   <p>",
"    Two large older studies, the Scandinavian Prostate Cancer Group 4 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/38\">",
"     38",
"    </a>",
"    ] and the PIVOT trial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/39\">",
"     39",
"    </a>",
"    ], compared immediate definitive therapy (radical prostatectomy) with delayed treatment for metastatic disease or symptomatic locoregional progression. Both trials provide insights into the natural history of prostate cancer, but neither trial utilized an active surveillance strategy with definitive therapy instituted if there was evidence of progression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link&amp;anchor=H1302078#H1302078\">",
"     \"Radical prostatectomy for localized prostate cancer\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the Prostate Testing for Cancer and Treatment (ProtecT) trial that is being conducted in the United Kingdom (NCT00632983), patients are being randomly assigned to active surveillance, radical prostatectomy, or definitive radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients assigned to active surveillance have their PSA monitored every three months during the first year and every six months thereafter. Additional testing is carried out as indicated, and the therapeutic plan is reassessed as clinically indicated. The primary outcome of the trial is survival time, as assessed from the initial presentation.",
"   </p>",
"   <p>",
"    The trial commenced enrollment in June 2001, with a planned enrollment of 2050 patients. Enrollment was scheduled to be complete in 2008, with the final data collection date for the primary outcome to be complete in December 2015.",
"   </p>",
"   <p>",
"    A second trial, the Standard Treatment Against Restricted Treatment (START) trial (NCT00499174), was prematurely terminated because of inadequate patient enrollment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main advantage of active surveillance is the avoidance or deferral of treatment-associated side effects. These advantages are difficult to quantify. A detailed decision analysis that focused on hypothetical, otherwise healthy 65 year-old men with low-risk, localized prostate cancer used quality of life as the endpoint [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/41\">",
"     41",
"    </a>",
"    ]. In this analysis, active surveillance was associated with a higher quality-adjusted life expectancy than initial treatment with external beam radiation therapy, brachytherapy, or radical prostatectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A decision about whether to choose active surveillance or immediate treatment for early prostate cancer also needs to consider other factors that may affect quality of life:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are managed with active surveillance have the psychosocial burden of living with an indolent cancer without active treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/4,8\">",
"       4,8",
"      </a>",
"      ]. This anxiety can be a significant factor in causing many patients who are being managed with active surveillance to seek active treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/42\">",
"       42",
"      </a>",
"      ]. In the Toronto cohort, approximately one-third of patients sought active treatment for reasons other than disease progression [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Observational studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are properly educated about the indolent course of good-risk prostate cancer may be better able to avoid some of the psychological complications associated with active surveillance [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/8\">",
"       8",
"      </a>",
"      ]. Improved communication with the medical staff may improve both the acceptability of active surveillance as an initial approach as well as continuing participating in such a program [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/35,43\">",
"       35,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One observational study found an increased risk of erectile dysfunction in 231 patients who had annual 10 to 12 core prostate biopsies as part of their active surveillance program following the diagnosis of early prostate cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/44\">",
"       44",
"      </a>",
"      ]. This observation requires confirmation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/15/3315?source=see_link\">",
"       \"Patient information: Choosing treatment for low-risk localized prostate cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=see_link\">",
"       \"Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active surveillance for localized prostate cancer entails observation rather than immediate therapy, with curative-intent treatment deferred until there is evidence that the patient is at increased risk for disease progression. This approach is based upon the prolonged natural history of the prostate cancer and is an attempt to balance the risks and side effects of overtreatment against the possibility of disease progression and a lost opportunity for cure. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Rationale'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link&amp;anchor=H167060109#H167060109\">",
"     \"Radical prostatectomy for localized prostate cancer\", section on 'Survival impact of radical prostatectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The three standard therapies for men with organ-confined prostate cancer are radical prostatectomy, radiation therapy (either interstitial brachytherapy or external beam radiation therapy), and active surveillance.",
"     </li>",
"     <li>",
"      For men who place a high premium on avoiding the side effects of definitive treatment and who accept the possible increased risk of late metastasis or death, we recommend active surveillance (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal criteria for patient selection have not been defined, but generally include the clinical stage, serum PSA, and Gleason score from the diagnostic biopsy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patient selection for active surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the prospective cohort in Toronto, the eligibility criteria consisted of clinical stage T1c or T2a prostate cancer (",
"      <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"       table 1",
"      </a>",
"      ), a Gleason score &le;6, and a serum PSA &le;10",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13288/abstract/19\">",
"       19",
"      </a>",
"      ]. For patients over age 70 years, slightly less stringent criteria were applied (Gleason score &le;7 [3+4],",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PSA &le;15",
"      <span class=\"nowrap\">",
"       ng/mL).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are being managed with active surveillance, the optimal schedule for monitoring and the criteria for initiating therapy have not been defined (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Surveillance strategy'",
"      </a>",
"      above). Our approach includes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Measurement of the serum PSA at three month intervals, to calculate the PSA doubling time. We use a doubling time of three years or less as a criterion for active intervention.",
"     </li>",
"     <li>",
"      A repeat prostate biopsy is performed at one year, to rule out higher grade disease that may have been missed on the original biopsy. Following this, biopsies are repeated every four to five years to look for evidence of biologic progression to Gleason 4+3 or higher.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/1\">",
"      Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177:2106.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/3\">",
"      Dahabreh IJ, Chung M, Balk EM, et al. Active surveillance in men with localized prostate cancer: a systematic review. Ann Intern Med 2012; 156:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/4\">",
"      Klotz L. Active surveillance for favorable-risk prostate cancer: who, how and why? Nat Clin Pract Oncol 2007; 4:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/5\">",
"      Konety BR, Bird VY, Deorah S, Dahmoush L. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era. J Urol 2005; 174:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/6\">",
"      Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst 2005; 97:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/7\">",
"      Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/8\">",
"      Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 2008; 112:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/9\">",
"      Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/10\">",
"      Irwin MB, Trapasso JG. Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology 1994; 44:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/11\">",
"      Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995; 153:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/12\">",
"      Epstein JI, Chan DW, Sokoll LJ, et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998; 160:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/13\">",
"      Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001; 166:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/14\">",
"      Augustin H, Hammerer PG, Graefen M, et al. Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur Urol 2003; 43:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/15\">",
"      Anast JW, Andriole GL, Bismar TA, et al. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004; 64:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/16\">",
"      Eggener SE, Mueller A, Berglund RK, et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 2009; 181:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/17\">",
"      Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004; 101:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/18\">",
"      Lee MC, Dong F, Stephenson AJ, et al. The Epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy. Eur Urol 2010; 58:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/19\">",
"      Klotz L. Active surveillance for prostate cancer: trials and tribulations. World J Urol 2008; 26:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/20\">",
"      Steyerberg EW, Roobol MJ, Kattan MW, et al. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007; 177:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/21\">",
"      Roemeling S, Roobol MJ, Kattan MW, et al. Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations. Cancer 2007; 110:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/22\">",
"      Kattan MW, Cuzick J, Fisher G, et al. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer 2008; 112:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/23\">",
"      Albertsen P. Predicting survival for men with clinically localized prostate cancer: what do we need in contemporary practice? Cancer 2008; 112:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/24\">",
"      Loeb S, Roehl KA, Helfand BT, Catalona WJ. Complications of open radical retropubic prostatectomy in potential candidates for active monitoring. Urology 2008; 72:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/25\">",
"      Margel D, Yap SA, Lawrentschuk N, et al. Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. J Urol 2012; 187:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/26\">",
"      Choo R, Do V, Sugar L, et al. Comparison of histologic grade between initial and follow-up biopsy in untreated, low to intermediate grade, localized prostate cancer. Can J Urol 2004; 11:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/27\">",
"      Patel MI, DeConcini DT, Lopez-Corona E, et al. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004; 171:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/28\">",
"      Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/29\">",
"      Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet 2012; 379:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/30\">",
"      Shappley WV 3rd, Kenfield SA, Kasperzyk JL, et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009; 27:4980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/31\">",
"      Duffield AS, Lee TK, Miyamoto H, et al. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol 2009; 182:2274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/32\">",
"      van den Bergh RC, Roemeling S, Roobol MJ, et al. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men. BJU Int 2009; 103:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/33\">",
"      van As NJ, Norman AR, Thomas K, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008; 54:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/34\">",
"      Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol 2007; 178:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/35\">",
"      Dall'Era MA, Konety BR, Cowan JE, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008; 112:2664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/36\">",
"      Khatami A, Ali K, Aus G, et al. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007; 120:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/37\">",
"      Stattin P, Holmberg E, Bratt O, et al. Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol 2008; 180:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/38\">",
"      Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/39\">",
"      Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367:203.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.clinicaltrials.gov/ (Accessed on October 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/41\">",
"      Hayes JH, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010; 304:2373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/42\">",
"      Latini DM, Hart SL, Knight SJ, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol 2007; 178:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/43\">",
"      Bailey DE, Mishel MH, Belyea M, et al. Uncertainty intervention for watchful waiting in prostate cancer. Cancer Nurs 2004; 27:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13288/abstract/44\">",
"      Fujita K, Landis P, McNeil BK, Pavlovich CP. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009; 182:2664.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6922 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_62_13288=[""].join("\n");
var outline_f12_62_13288=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITION OF TERMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATIENT SELECTION FOR ACTIVE SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SURVEILLANCE STRATEGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H696570543\">",
"      Evidence of progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H696570550\">",
"      Prevention of progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Observational studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Randomized trials of active surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/6922\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6922|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/19/41277\" title=\"table 1\">",
"      TNM staging prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/43/10941\" title=\"table 2\">",
"      TNM group prostate CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=related_link\">",
"      Chemoprevention strategies in prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=related_link\">",
"      Initial approach to low-risk clinically localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=related_link\">",
"      Interpretation of prostate biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/15/3315?source=related_link\">",
"      Patient information: Choosing treatment for low-risk localized prostate cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=related_link\">",
"      Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=related_link\">",
"      Prostate cancer: Risk stratification, other prognostic factors, and predictive tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=related_link\">",
"      Radical prostatectomy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=related_link\">",
"      Risk factors for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/8/42122?source=related_link\">",
"      Screening for prostate cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_62_13289="Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency";
var content_f12_62_13289=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/62/13289/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13289/contributors\">",
"     Bertil Glader, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/62/13289/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13289/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13289/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/62/13289/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13289/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/62/13289/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose 6-phosphate dehydrogenase (G6PD) deficiency, an X-linked disorder, is the most common enzymatic disorder of red blood cells in humans, affecting more than 400 million people worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The clinical expression of G6PD variants encompasses a spectrum of hemolytic syndromes. Affected patients are most often asymptomatic, but many patients have episodic anemia, while a few have chronic hemolysis.",
"   </p>",
"   <p>",
"    With the most prevalent G6PD variants (G6PD A- and G6PD Mediterranean), hemolysis is induced in children and adults by the sudden destruction of older, more deficient erythrocytes after exposure to drugs having a high redox potential (including the antimalarial drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    and certain sulfa drugs) or to fava beans, selected infections, or metabolic abnormalities (",
"    <a class=\"graphic graphic_table graphicRef74254 \" href=\"UTD.htm?19/22/19821\">",
"     table 1",
"    </a>",
"    ). However, in the neonate with G6PD deficiency, decreased bilirubin elimination may play an important role in the development of jaundice (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Jaundice in neonates'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal enzyme function and the genetics and pathophysiology of G6PD deficiency, including its possible role in protecting against severe malaria, will be reviewed here. The clinical manifestations, diagnosis, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A historical review of the discovery of this defect, its clinical manifestations, detection, population genetics, and molecular biology, written by Dr. Ernest Beutler, a pioneer in the understanding of this disorder, is available [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FUNCTION OF G6PD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose-6-phosphate dehydrogenase catalyzes the initial step in the hexose monophosphate (HMP or pentose phosphate) shunt, oxidizing glucose-6-phosphate to 6-phosphogluconolactone and reducing nicotinamide adenine dinucleotide phosphate (NADP) to NADPH (",
"    <a class=\"graphic graphic_figure graphicRef77081 \" href=\"UTD.htm?18/40/19085\">",
"     figure 1",
"    </a>",
"    ). The HMP shunt is the only red cell source of NADPH, a cofactor important in glutathione metabolism.",
"   </p>",
"   <p>",
"    The main function of the HMP shunt is to protect red blood cells against oxidative injury via the production of NADPH. Red blood cells contain relatively high concentrations of reduced glutathione (GSH), a sulfhydryl-containing tripeptide that functions as an intracellular reducing agent, thereby protecting against oxidant injury. Oxidants, such as superoxide anion (O2-) and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , are formed within red cells via reactions of hemoglobin with oxygen and can also be produced by exogenous factors such as drugs and infection. If these oxidants accumulate within red cells, hemoglobin and other proteins are oxidized (see below), leading to loss of function and cell death.",
"   </p>",
"   <p>",
"    Under normal circumstances, oxidant accumulation does not occur, since these compounds are rapidly inactivated by GSH in conjunction with glutathione peroxidase. These reactions result in the conversion of GSH to oxidized glutathione (GSSG). GSH levels are restored by glutathione reductase which catalyzes the reduction of GSSG to GSH. This reaction requires the NADPH generated by G6PD.",
"   </p>",
"   <p>",
"    Thus, tight coupling of the HMP shunt to glutathione metabolism is responsible for protecting intracellular proteins from oxidative injury. Almost all hemolytic episodes related to altered HMP shunt and glutathione metabolism are due to G6PD deficiency. Rarely, hemolysis results from deficiencies in GSH synthetic enzymes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5399?source=see_link\">",
"     \"Related disorders of the hexose monophosphate shunt and glutathione metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS OF G6PD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene for G6PD is located on the X chromosome (band X q28) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/8\">",
"     8",
"    </a>",
"    ] and has been cloned and sequenced [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Even though females have two X chromosomes per cell, normal males and females have the same enzyme activity in their red cells because one of the X chromosomes in each cell of the female embryo is inactivated and remains inactive throughout subsequent cell divisions (Lyon hypothesis) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    G6PD deficiency is expressed in males carrying a variant gene, while heterozygous females are usually clinically normal. However, the mean red blood cell enzyme activity in heterozygous females may be normal, moderately reduced, or grossly deficient depending upon the degree of lyonization and the degree to which the abnormal G6PD variant is expressed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/13\">",
"     13",
"    </a>",
"    ]. A heterozygous female with 50 percent normal G6PD activity has 50 percent normal red cells and 50 percent G6PD-deficient red cells. The deficient cells are as vulnerable to hemolysis as the enzyme-deficient red blood cells in males.",
"   </p>",
"   <p>",
"    It is of interest that the incidence of G6PD deficiency in Chinese females &ge;80 years of age was several-fold greater than what was expected from population screening at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/14\">",
"     14",
"    </a>",
"    ]. It is thought that this is due to the skewed X-inactivation that occurs with aging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     G6PD and its variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The monomeric form of G6PD contains 515 amino acids, but the active form of G6PD is a dimer that contains tightly bound NADP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Amino acid 205 is the binding site for glucose-6-phosphate, while amino acids 386 and 387 may be involved in binding to NADP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/15,17\">",
"     15,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The normal or wild-type enzyme is called G6PD B, although over 400 variant enzymes have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/15,16,18,19\">",
"     15,16,18,19",
"    </a>",
"    ]. By international agreement, standardized methods have been used to characterize these enzyme variants, which differ on the basis of their biochemical properties, such as kinetic activity and the Michaelis constant for its substrate glucose-6-phosphate and cofactor NADP [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, differences between some variants are subtle and may not represent true enzyme differences.",
"   </p>",
"   <p>",
"    The variants are almost all missense point mutations, although a few deletions have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. Large deletions or frame shift mutations have not been identified, suggesting that complete absence of G6PD may be lethal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/15\">",
"     15",
"    </a>",
"    ]. Most class I variants that are associated with chronic hemolytic anemia have abnormalities in the glucose-6-phosphate binding or NADP binding site of the enzyme (",
"    <a class=\"graphic graphic_figure graphicRef66818 \" href=\"UTD.htm?28/29/29149\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Classification of G6PD variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization has classified the different G6PD variants according to the magnitude of the enzyme deficiency and the severity of hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/22\">",
"     22",
"    </a>",
"    ]. Classes IV and V are of no clinical significance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Class I variants, which are rare, have severe enzyme deficiency (less than 10 percent of normal) and have chronic hemolytic anemia",
"     </li>",
"     <li>",
"      Class II variants also have severe enzyme deficiency, but there is usually only intermittent hemolysis associated with infection, drugs, or chemicals",
"     </li>",
"     <li>",
"      Class III variants have moderate enzyme deficiency (10 to 60 percent of normal) with intermittent hemolysis usually associated with infection, drugs, or chemicals",
"     </li>",
"     <li>",
"      Class IV variants have no enzyme deficiency or hemolysis",
"     </li>",
"     <li>",
"      Class V variants have increased enzyme activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Wild-type enzyme",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal wild-type enzyme, G6PD B, is found in most Caucasians, Asians, and a majority of Blacks. It has normal catalytic activity and is not associated with hemolysis (class IV). A common variant is G6PD A+ which is found in 20 to 30 percent of Blacks from Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/23\">",
"     23",
"    </a>",
"    ]. It differs from G6PD B by the substitution of a single amino acid, an asparagine for aspartate at the amino acid 126 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/24\">",
"     24",
"    </a>",
"    ], and has much faster electrophoretic mobility (the letters A and B refer to relative electrophoretic mobilities). G6PD A+ has normal catalytic properties and does not cause hemolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     G6PD A- variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another common variant, G6PD A-, is the enzyme responsible for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    sensitivity in Blacks, and is the most common variant associated with mild to moderate hemolysis (class III). It is found in 10 to 15 percent of African-Americans, with similar frequencies in western and central Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    G6PD A- has an electrophoretic mobility identical to that of G6PD A+. However, G6PD A- is an unstable enzyme and its catalytic activity, which is nearly normal in bone marrow cells and reticulocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/26\">",
"     26",
"    </a>",
"    ], decreases markedly in older red cells due to increased catabolism (the \"+\" and \"-\" denote enzyme activity) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All cases of G6PD A- have a mutation at nucleotide 376 (A&mdash;&gt;G), which also is the nucleotide substitution characteristic of G6PD A+ [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/15,28,29\">",
"     15,28,29",
"    </a>",
"    ]. However, the G6PD A- variants have a second mutation, which is usually at nucleotide 202 (G&mdash;&gt;A) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/15,28\">",
"     15,28",
"    </a>",
"    ] and, less often, at nucleotide 680 (G&mdash;&gt;T) or at nucleotide 968 (T&mdash;&gt;C) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although initially thought to be a single homogeneous mutation in Africans, G6PD A- represents at least three different genotypes and a number of G6PD variants originally described in non-Africans have one of the known G6PD A- mutations. As examples, some patients with G6PD Betica, a Spanish variant, or G6PD Matera, an Italian variant, have base substitutions at nucleotides 376 and 202, identical to the more common G6PD A- variant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     G6PD Mediterranean variant",
"    </span>",
"    &nbsp;&mdash;&nbsp;G6PD Mediterranean is the most common abnormal variant found in Caucasians, particularly those whose origins are in the Mediterranean region [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/32\">",
"     32",
"    </a>",
"    ]. It is also found throughout the Mid-East. The electrophoretic mobility of G6PD Mediterranean is identical to that of G6PD B, but it is synthesized at a reduced rate, its catalytic activity is markedly reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/26\">",
"     26",
"    </a>",
"    ], and hemolysis can be severe (class II). G6PD Canton is a variant enzyme seen in Asians; its biochemical properties are very similar to those of G6PD Mediterranean [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although G6PD Mediterranean involves many different ethnic groups, most subjects have the same genetic defect, a single base substitution (C&mdash;&gt;T) at nucleotide 563 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Many biochemical variants have the same molecular defect as G6PD Mediterranean [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY OF G6PD DEFICIENCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22470979\">",
"    <span class=\"h2\">",
"     Hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of G6PD for red cell integrity was first recognized following the observation that some African-American soldiers taking the antimalarial drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"     primaquine",
"    </a>",
"    developed acute hemolytic anemia with hemoglobinuria. Subsequently, the activity of G6PD, one of the enzymes needed to maintain adequate GSH levels, was shown to be deficient in affected red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of developing hemolysis and the severity of disease are determined by the biochemical characteristics of the G6PD variant. In normal subjects, the activity of G6PD falls exponentially as red cells age, as the normal enzyme (G6PD B) has an in vivo half-life of 62 days [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/26\">",
"     26",
"    </a>",
"    ]. However, normal old red blood cells still contain sufficient G6PD activity to maintain GSH levels in the face of oxidant stress. In contrast, the half-life is much shorter in the G6PD variants associated with hemolysis. As an example, the enzymatic activity of G6PD A- is normal in reticulocytes, but declines rapidly thereafter with a half-life of 13 days [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/26,37\">",
"     26,37",
"    </a>",
"    ]. G6PD Mediterranean is even more unstable, with a half-life measured in hours [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings correlate with the clinical degree of hemolysis after oxidant stress. Patients with G6PD A- usually have hemolysis that is mild and limited to older deficient erythrocytes (class III). In contrast, red cells of all ages are grossly deficient in G6PD Mediterranean (class II). Thus, the entire red blood cell population of subjects with G6PD Mediterranean is susceptible to oxidant-induced injury, which can lead to severe hemolytic anemia. However, in the absence of oxidant stress, G6PD Mediterranean red cells have a survival in the circulation that is only modestly shorter than that of normal red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    G6PD-deficient erythrocytes that are exposed to oxidants (eg, drugs, infection) become depleted of GSH; this change is followed by oxidation of other sulfhydryl-containing proteins with the following consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxidation of the sulfhydryl groups on hemoglobin leads to the formation of methemoglobin and then denatured globin or sulfhemoglobin, which form insoluble masses that attach to the red cell membrane (called Heinz bodies) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/40\">",
"       40",
"      </a>",
"      ]. This oxidative denaturation of hemoglobin leads to its crossbonding; as a result, hemoglobin is no longer free to flow in the cytosol, producing the puddling of hemoglobin and bite or hemiblister cells in the peripheral smear (",
"      <a class=\"graphic graphic_picture graphicRef73790 \" href=\"UTD.htm?25/28/26054\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"       \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oxidation of membrane sulfhydryl groups leads to the accumulation of membrane polypeptide aggregates, presumably due to disulfide bond formation between spectrin dimers and between spectrin and other membrane proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/39,41,42\">",
"       39,41,42",
"      </a>",
"      ]. The number of aggregates increases with the fall in red cell GSH [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The net effect is that the deficient red cells become rigid and nondeformable, making them susceptible to stagnation and destruction by reticuloendothelial macrophages in the marrow, spleen and liver [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Although this type of hemolysis is predominantly extravascular, intravascular hemolysis also occurs, leading to hemoglobinemia and hemoglobinuria.",
"   </p>",
"   <p>",
"    Hemolysis occurring after oxidant injury is usually due to G6PD deficiency. However, a similar sequence can occur with hemoglobin H and some unstable hemoglobinopathies, since these abnormal hemoglobins are highly susceptible to mild oxidant stress. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/616?source=see_link\">",
"     \"Unstable hemoglobin variants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link&amp;anchor=H33#H33\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\", section on 'Hemoglobin H disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Jaundice in neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonates who are deficient in G6PD have a higher incidence of neonatal jaundice. The clinical picture of neonatal jaundice in this setting differs from classic Rh-related neonatal jaundice in two main respects. First, G6PD deficiency related neonatal jaundice is rarely present at birth; the peak incidence of clinical onset is between days two and three [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/45\">",
"     45",
"    </a>",
"    ]. Second, there is more jaundice than anemia, and the anemia is rarely severe [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/46\">",
"     46",
"    </a>",
"    ]. The severity of jaundice varies widely, from being subclinical to imposing the threat of kernicterus if it is not treated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\", section on 'Neonatal hyperbilirubinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of this type of neonatal jaundice remains uncertain. Some believe that decreased hepatic bilirubin elimination is a key factor [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/5,15\">",
"     5,15",
"    </a>",
"    ], while others maintain that increased hemolysis causes the hyperbilirubinemia and that there is no need to invoke liver involvement over and above the normal immaturity of the neonatal bilirubin-conjugating mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study compared the incidence of severe jaundice (ie, bilirubin &gt;15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or &gt;257",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    among infants with varying combinations of G6PD deficiency and the variant Gilbert polymorphism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/48\">",
"     48",
"    </a>",
"    ]. Neither G6PD deficiency nor presence of the variant Gilbert polymorphism alone increased the incidence of hyperbilirubinemia (incidence: 7 to 15 percent) over subjects with normal alleles at these two loci (incidence: 10 percent), but both defects in combination did (incidence: 32 to 50 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=see_link&amp;anchor=H4#H4\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     G6PD in other hematopoietic cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocyte and platelet G6PD is regulated by the same gene as that in red cells; as a result, deficient individuals have reduced enzyme activity in these cells, particularly patients with more severe enzyme deficiency such as G6PD Mediterranean [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/36,49-51\">",
"     36,49-51",
"    </a>",
"    ]. However, this abnormality is rarely associated with functional impairment of leukocytes and platelets due to their normally short survival. As an example, phagocytic and bactericidal activity of granulocytes are typically normal in deficient subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rare kindreds with severe enzymatic deficiency of G6PD (ie, &lt;5 percent of normal) may have decreased respiratory burst activity due to a lack of NADPH production in phagocytes, leading to symptoms of chronic granulomatous disease and increased susceptibility to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=see_link&amp;anchor=H22#H22\">",
"     \"Neutrophil functions other than movement\", section on 'Respiratory burst'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY OF G6PD DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;G6PD deficiency is global in its distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/54\">",
"     54",
"    </a>",
"    ]. It occurs most often in the tropical and subtropical zones of the Eastern Hemisphere [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/15,55\">",
"     15,55",
"    </a>",
"    ]. As examples, G6PD deficiency is present in approximately 20 percent of South African black males [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/56\">",
"     56",
"    </a>",
"    ], 8 percent in Brazilian blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/57\">",
"     57",
"    </a>",
"    ], 20 to 35 percent in the lowlands of Sardinia and Greece (with a much lower prevalence at higher altitudes) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], as high as 60 to 70 percent in Kurdish Jews [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/32\">",
"     32",
"    </a>",
"    ], and, in Asia, 5.5 percent in South China [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/60\">",
"     60",
"    </a>",
"    ], 2.6 percent in India [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/61\">",
"     61",
"    </a>",
"    ], and less than 0.1 percent in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, G6PD deficiency is present in about 12 percent in African-American men [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. In addition, as many as 20 percent of African-American women are heterozygous for G6PD mutants [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/65\">",
"     65",
"    </a>",
"    ] and as many as 1 percent are homozygous. G6PD deficiency is rare among Native Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Possible protection against malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of its high prevalence in areas in which malaria was once endemic, it has been proposed that G6PD deficiency may have conferred a selective advantage against infection by Plasmodium falciparum [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/1,67-69\">",
"     1,67-69",
"    </a>",
"    ]. This issue remains unresolved as some studies have shown conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/15,70\">",
"     15,70",
"    </a>",
"    ], but the following observations are in support of such a relationship. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20858?source=see_link&amp;anchor=H2#H2\">",
"     \"Protection against malaria in the hemoglobinopathies\", section on 'Review of malarial infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      G6PD deficiency in Sardinia is more common at sea level than at higher elevations, a pattern that parallels the endemicity of malaria [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It has been unclear whether both female heterozygotes and male hemizygotes are protected. In two case-control studies in African children, the common African form of G6PD deficiency (G6PD A-) was associated with a 46 to 58 percent reduction in the risk of severe malaria in the two groups [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/1\">",
"       1",
"      </a>",
"      ]. However, a mathematical model that considered the selective advantage against malaria suggested that there was a counterbalancing disadvantage of male hemizygotes that limited its prevalence in malaria endemic regions.",
"     </li>",
"     <li>",
"      In female heterozygotes who have both normal and G6PD deficient red cells, there are more malaria parasites in normal compared with G6PD-deficient cells [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/71\">",
"       71",
"      </a>",
"      ]. This is compatible with the demonstration that invasion is normal but in vitro growth of malarial parasites is inhibited in G6PD-deficient red cells in female heterozygotes; there are conflicting data as to inhibition of parasite growth in male hemizygotes [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/72,73\">",
"       72,73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Somewhat different findings were noted in a study of the Mediterranean variant of G6PD-deficient red cells [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/74\">",
"       74",
"      </a>",
"      ]. With five different strains of P. falciparum, there were no significant differences in either invasion or maturation within deficient and normal red cells. However, among red cells that were parasitized at the ring stage (but not the more mature trophozoite stage), phagocytosis occurred 2.3 times more intensely in the G6PD-deficient cells in association with a marked reduction in reduced glutathione (GSH).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanisms responsible for inhibition of parasite growth or increased phagocytosis in G6PD-deficient red cells are not known. One possibility is that oxidant stress, which causes GSH instability and destroys the host red cells, also kills the parasite [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/75\">",
"     75",
"    </a>",
"    ]. Although the parasite may provide a small amount of G6PD activity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/75-77\">",
"     75-77",
"    </a>",
"    ], it is insufficient to compensate for the enzyme deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/75\">",
"     75",
"    </a>",
"    ]. Similarly, oxidant stress in the presence of diminished GSH in ring stage infected, G6PD-deficient cells may cause membrane damage that promotes phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/74,78,79\">",
"     74,78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative explanation is that infected, G6PD-deficient red cells are, due to the low levels of GSH, unable to generate the ribose derivatives needed by the parasite for nucleic acid synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13289/abstract/80\">",
"     80",
"    </a>",
"    ]. Such a defect would lead to inhibition of parasite growth and does not require oxidative destruction of the parasite.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/41/12946?source=see_link\">",
"       \"Patient information: Glucose-6-phosphate dehydrogenase deficiency (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22470651\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose 6-phosphate dehydrogenase (G6PD) deficiency, an X-linked disorder, is the most common enzymatic disorder of red blood cells in humans. Affected patients are most often asymptomatic, but many patients have episodic anemia, following exposure to infections, drugs, or chemicals, while a few have chronic hemolysis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucose-6-phosphate dehydrogenase catalyzes the initial step in the hexose monophosphate (HMP or pentose phosphate) shunt, oxidizing glucose-6-phosphate to 6-phosphogluconolactone and reducing nicotinamide adenine dinucleotide phosphate (NADP) to NADPH (",
"      <a class=\"graphic graphic_figure graphicRef77081 \" href=\"UTD.htm?18/40/19085\">",
"       figure 1",
"      </a>",
"      ). The main function of the HMP shunt is to protect red blood cells against oxidative injury via the production of NADPH. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Function of g6pd'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Pathophysiology of G6PD deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      G6PD has a number of variants, as follows (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics of g6pd'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Epidemiology of G6PD deficiency'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      G6PD B, the normal wild-type enzyme, is found in most Caucasians, Asians, and a majority of Blacks. It has normal catalytic activity and is not associated with hemolysis.",
"     </li>",
"     <li>",
"      G6PD A+ is found in 20 to 30 percent of Blacks from Africa. It has normal catalytic properties and does not cause hemolysis.",
"     </li>",
"     <li>",
"      G6PD A-, responsible for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/59/38837?source=see_link\">",
"       primaquine",
"      </a>",
"      sensitivity in Blacks, is found in 10 to 15 percent of African-Americans, with similar frequencies in western and central Africa. Patients usually have mild hemolysis limited to older red cells.",
"     </li>",
"     <li>",
"      G6PD Mediterranean is the most common abnormal variant found in Caucasians. Catalytic activity is markedly reduced in red cells of all ages. Thus, the entire red blood cell population is susceptible to oxidant-induced injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are a number of consequences of G6PD deficiency. These include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Neonatal jaundice. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Jaundice in neonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Episodic or chronic Heinz body hemolytic anemia. (See",
"      <a class=\"local\" href=\"#H22470979\">",
"       'Hemolytic anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased susceptibility to infection in kindreds with severe enzymatic deficiency, due to a lack of NADPH production in phagocytes. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'G6PD in other hematopoietic cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Possible protection against malaria. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Possible protection against malaria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/1\">",
"      Ruwende C, Khoo SC, Snow RW, et al. Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature 1995; 376:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/2\">",
"      Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008; 371:64.",
"     </a>",
"    </li>",
"    <li>",
"     Glader B. Hereditary hemolytic anemias due to red blood cell enzyme disorders. In: Wintrobe's Clinical Hematology, Greer JP, Foerster J, Rodgers GM, et al. (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2009. p.933.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/4\">",
"      Mason PJ, Bautista JM, Gilsanz F. G6PD deficiency: the genotype-phenotype association. Blood Rev 2007; 21:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/5\">",
"      Kaplan M, Hammerman C. Severe neonatal hyperbilirubinemia. A potential complication of glucose-6-phosphate dehydrogenase deficiency. Clin Perinatol 1998; 25:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/6\">",
"      Kaplan M, Hammerman C. Glucose-6-phosphate dehydrogenase deficiency: a hidden risk for kernicterus. Semin Perinatol 2004; 28:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/7\">",
"      Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood 2008; 111:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/8\">",
"      KIRKMAN HN, HENDRICKSON EM. Sex-linked electrophoretic difference in glucose-6-phosphate dehydrogenase. Am J Hum Genet 1963; 15:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/9\">",
"      Martini G, Toniolo D, Vulliamy T, et al. Structural analysis of the X-linked gene encoding human glucose 6-phosphate dehydrogenase. EMBO J 1986; 5:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/10\">",
"      Persico MG, Viglietto G, Martini G, et al. Isolation of human glucose-6-phosphate dehydrogenase (G6PD) cDNA clones: primary structure of the protein and unusual 5' non-coding region. Nucleic Acids Res 1986; 14:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/11\">",
"      Takizawa T, Huang IY, Ikuta T, Yoshida A. Human glucose-6-phosphate dehydrogenase: primary structure and cDNA cloning. Proc Natl Acad Sci U S A 1986; 83:4157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/12\">",
"      BEUTLER E, YEH M, FAIRBANKS VF. The normal human female as a mosaic of X-chromosome activity: studies using the gene for C-6-PD-deficiency as a marker. Proc Natl Acad Sci U S A 1962; 48:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/13\">",
"      Hsia YE, Miyakawa F, Baltazar J, et al. Frequency of glucose-6-phosphate dehydrogenase (G6PD) mutations in Chinese, Filipinos, and Laotians from Hawaii. Hum Genet 1993; 92:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/14\">",
"      Au WY, Lam V, Pang A, et al. Glucose-6-phosphate dehydrogenase deficiency in female octogenarians, nanogenarians, and centenarians. J Gerontol A Biol Sci Med Sci 2006; 61:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/15\">",
"      Beutler E. G6PD deficiency. Blood 1994; 84:3613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/16\">",
"      Mason PJ. New insights into G6PD deficiency. Br J Haematol 1996; 94:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/17\">",
"      Hirono A, Kuhl W, Gelbart T, et al. Identification of the binding domain for NADP+ of human glucose-6-phosphate dehydrogenase by sequence analysis of mutants. Proc Natl Acad Sci U S A 1989; 86:10015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/18\">",
"      Miwa S, Fujii H. Molecular basis of erythroenzymopathies associated with hereditary hemolytic anemia: tabulation of mutant enzymes. Am J Hematol 1996; 51:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/19\">",
"      Beutler E. The genetics of glucose-6-phosphate dehydrogenase deficiency. Semin Hematol 1990; 27:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/20\">",
"      Nomenclature of glucose-6-phosphate dehydrogenase in man. Am J Hum Genet 1967; 19:757.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Scientific Group. Standardization of procedures for the study of glucose-6-phosphate dehydrogenase. WHO Tech Rep Ser 366, Geneva 1967.",
"    </li>",
"    <li>",
"     Beutler E. The molecular biology of enzymes of erythrocyte metabolism. In: The Molecular Basis of Blood Disease, Stamatoyannopoulos G, Nienhus AW, Majerus PW, et al. (Eds), WB Saunders, Philadelphia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/23\">",
"      BOYER SH, PORTER IH, WEILBACHER RG. Electrophoretic heterogeneity of glucose-6-phosphate dehydrogenase and its relationship to enzyme deficiency in man. Proc Natl Acad Sci U S A 1962; 48:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/24\">",
"      Yoshida A. A single amino Acid substitution (asparagine to aspartic Acid) between normal (b+) and the common negro variant (a+) of human glucose-6-phosphate dehydrogenase. Proc Natl Acad Sci U S A 1967; 57:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/25\">",
"      Reys L, Manso C, Stamatoyannopoulos G. Genetic studies on southeastern Bantu of Mozambique. I. Variants of glucose-6-phosphate dehydrogenase. Am J Hum Genet 1970; 22:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/26\">",
"      Piomelli S, Corash LM, Davenport DD, et al. In vivo lability of glucose-6-phosphate dehydrogenase in GdA- and GdMediterranean deficiency. J Clin Invest 1968; 47:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/27\">",
"      Morelli A, Benatti U, Gaetani GF, De Flora A. Biochemical mechanisms of glucose-6-phosphate dehydrogenase deficiency. Proc Natl Acad Sci U S A 1978; 75:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/28\">",
"      Hirono A, Beutler E. Molecular cloning and nucleotide sequence of cDNA for human glucose-6-phosphate dehydrogenase variant A(-). Proc Natl Acad Sci U S A 1988; 85:3951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/29\">",
"      Beutler E, Kuhl W, Vives-Corrons JL, Prchal JT. Molecular heterogeneity of glucose-6-phosphate dehydrogenase A-. Blood 1989; 74:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/30\">",
"      Beutler E. Glucose-6-phosphate dehydrogenase: new perspectives. Blood 1989; 73:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/31\">",
"      Vulliamy TJ, D'Urso M, Battistuzzi G, et al. Diverse point mutations in the human glucose-6-phosphate dehydrogenase gene cause enzyme deficiency and mild or severe hemolytic anemia. Proc Natl Acad Sci U S A 1988; 85:5171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/32\">",
"      Oppenheim A, Jury CL, Rund D, et al. G6PD Mediterranean accounts for the high prevalence of G6PD deficiency in Kurdish Jews. Hum Genet 1993; 91:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/33\">",
"      McCurdy PR, Kirkman HN, Naiman JL, et al. A Chinese variant of glucose-6-phosphate dehydrogenase. J Lab Clin Med 1966; 67:374.",
"     </a>",
"    </li>",
"    <li>",
"     Glader BE. Glucose-6-phosphate dehydrogenase deficiency and related disorders of hexose monophosphate shunt and glutathione metabolism. In: Wintrobe's Clinical Hematology, 10th ed, Lee GR, Foerster J, Lukens J, et al. (Eds), Williams &amp; Wilkins, Baltimore 1176.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/35\">",
"      Cappellini MD, Martinez di Montemuros F, De Bellis G, et al. Multiple G6PD mutations are associated with a clinical and biochemical phenotype similar to that of G6PD Mediterranean. Blood 1996; 87:3953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/36\">",
"      ALVING AS, CARSON PE, FLANAGAN CL, ICKES CE. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 1956; 124:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/37\">",
"      Yoshida A, Stamatoyannopoulos G, Motulsky AG. Negro variant of glucose-6-phosphate dehydrogenase deficiency (A-) in man. Science 1967; 155:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/38\">",
"      Corash L, Spielberg S, Bartsocas C, et al. Reduced chronic hemolysis during high-dose vitamin E administration in Mediterranean-type glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 1980; 303:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/39\">",
"      Arese P, De Flora A. Pathophysiology of hemolysis in glucose-6-phosphate dehydrogenase deficiency. Semin Hematol 1990; 27:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/40\">",
"      Jacob HS. Mechanisms of Heinz body formation and attachment to red cell membrane. Semin Hematol 1970; 7:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/41\">",
"      Allen DW, Flynn TP, Johnson GJ. Erythrocyte membrane protein changes in glucose-6-phosphate dehydrogenase mutants with chronic hemolytic disease: an example of postsynthetic modification of membrane proteins. Prog Clin Biol Res 1982; 97:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/42\">",
"      Coetzer T, Zail S. Membrane protein complexes in GSH-depleted red cells. Blood 1980; 56:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/43\">",
"      Rifkind RA. Heinz body anemia: an ultrastructural study. II. Red cell sequestration and destruction. Blood 1965; 26:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/44\">",
"      Tizianello A, Pannacciulli I, Ajmar F, Salvidio E. Sites of destruction of red cells in G-6-PD deficient Caucasians and in phenylhydrazine treated patients. Scand J Haematol 1968; 5:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/45\">",
"      DOXIADIS SA, VALAES T. THE CLINICAL PICTURE OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE DEFICIENCY IN EARLY INFANCY. Arch Dis Child 1964; 39:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/46\">",
"      Meloni T, Costa S, Cutillo S. Haptoglobin, hemopexin, hemoglobin and hematocrit in newborns with erythrocyte glucose-6-phosphate dehydrogenase deficiency. Acta Haematol 1975; 54:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/47\">",
"      Valaes T. Severe neonatal jaundice associated with glucose-6-phosphate dehydrogenase deficiency: pathogenesis and global epidemiology. Acta Paediatr Suppl 1994; 394:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/48\">",
"      Kaplan M, Renbaum P, Levy-Lahad E, et al. Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: a dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia. Proc Natl Acad Sci U S A 1997; 94:12128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/49\">",
"      RAMOT B, FISHER S, SZEINBERG A, et al. A study of subjects with erythrocyte glucose-6-phosphate dehydrogenase deficiency. II. Investigation of leukocyte enzymes. J Clin Invest 1959; 38:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/50\">",
"      Miller DR, Wollman MR. A new variant of glucose-6-phosphate dehydrogenase deficiency hereditary hemolytic anemia, G6PD Cornell: erythrocyte, leukocyte, and platelet studies. Blood 1974; 44:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/51\">",
"      Schilir&ograve; G, Russo A, Mauro L, et al. Leukocyte function and characterization of leukocyte glucose-6-phosphate dehydrogenase in Sicilian mutants. Pediatr Res 1976; 10:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/52\">",
"      Vives Corrons JL, Feliu E, Pujades MA, et al. Severe-glucose-6-phosphate dehydrogenase (G6PD) deficiency associated with chronic hemolytic anemia, granulocyte dysfunction, and increased susceptibility to infections: description of a new molecular variant (G6PD Barcelona). Blood 1982; 59:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/53\">",
"      van Bruggen R, Bautista JM, Petropoulou T, et al. Deletion of leucine 61 in glucose-6-phosphate dehydrogenase leads to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections. Blood 2002; 100:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/54\">",
"      Nkhoma ET, Poole C, Vannappagari V, et al. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis 2009; 42:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/55\">",
"      Beutler E. Glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 1991; 324:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/56\">",
"      Bienzle U. Glucose-6-phosphate dehydrogenase deficiency. Part 1: Tropical Africa. Clin Haematol 1981; 10:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/57\">",
"      Saldanha PH, N&oacute;brega FG, Maia JC. Distribution and heredity of erythrocyte G6PD activity and electrophoretic variants among different racial groups at S&atilde;o Paulo, Brazil. J Med Genet 1969; 6:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/58\">",
"      Siniscalco, M, et al. Favism and thalassemia in Sardinia and their relationship to malaria. Nature 1961; 190:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/59\">",
"      Stamatoyannopoulos G, Panayotopoulos A, Motulsky AG. The distribution of glucose-6-phosphate dehydrogenase deficiency in Greece. Am J Hum Genet 1966; 18:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/60\">",
"      Chan TK, Todd D. Characteristics and distribution of glucose-6-phosphate dehydrogenase-deficient variants in South China. Am J Hum Genet 1972; 24:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/61\">",
"      Panich V. Glucose-6-phosphate dehydrogenase deficiency. Part 2. Tropical Asia. Clin Haematol 1981; 10:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/62\">",
"      Nakatsuji T, Miwa S. Incidence and characteristics of glucose-6-phosphate dehydrogenase variants in Japan. Hum Genet 1979; 51:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/63\">",
"      Heller P, Best WR, Nelson RB, Becktel J. Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients. N Engl J Med 1979; 300:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/64\">",
"      Chinevere TD, Murray CK, Grant E Jr, et al. Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel. Mil Med 2006; 171:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/65\">",
"      TARLOV AR, BREWER GJ, CARSON PE, ALVING AS. Primaquine sensitivity. Glucose-6-phosphate dehydrogenase deficiency: an inborn error of metabolism of medical and biological significance. Arch Intern Med 1962; 109:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/66\">",
"      Lisker R, Linares C, Motulsky AG. Glucose-6-phosphate dehydrogenase Mexico. A new variant with enzyme deficiency, abnormal mobility, and absence of hemolysis. J Lab Clin Med 1972; 79:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/67\">",
"      Luzzatto L. Genetics of red cells and susceptibility to malaria. Blood 1979; 54:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/68\">",
"      Nagel RL, Roth EF Jr. Malaria and red cell genetic defects. Blood 1989; 74:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/69\">",
"      Tishkoff SA, Varkonyi R, Cahinhinan N, et al. Haplotype diversity and linkage disequilibrium at human G6PD: recent origin of alleles that confer malarial resistance. Science 2001; 293:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/70\">",
"      Ruwende C, Hill A. Glucose-6-phosphate dehydrogenase deficiency and malaria. J Mol Med (Berl) 1998; 76:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/71\">",
"      Luzzatto L, Usanga FA, Reddy S. Glucose-6-phosphate dehydrogenase deficient red cells: resistance to infection by malarial parasites. Science 1969; 164:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/72\">",
"      Luzzatto L, Sodeinde O, Martini G. Genetic variation in the host and adaptive phenomena in Plasmodium falciparum infection. Ciba Found Symp 1983; 94:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/73\">",
"      Roth EF Jr, Raventos-Suarez C, Rinaldi A, Nagel RL. Glucose-6-phosphate dehydrogenase deficiency inhibits in vitro growth of Plasmodium falciparum. Proc Natl Acad Sci U S A 1983; 80:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/74\">",
"      Cappadoro M, Giribaldi G, O'Brien E, et al. Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. Blood 1998; 92:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/75\">",
"      Roth EF Jr, Schulman S, Vanderberg J, Olson J. Pathways for the reduction of oxidized glutathione in the Plasmodium falciparum-infected erythrocyte: can parasite enzymes replace host red cell glucose-6-phosphate dehydrogenase? Blood 1986; 67:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/76\">",
"      Usanga EA, Luzzatto L. Adaptation of Plasmodium falciparum to glucose 6-phosphate dehydrogenase-deficient host red cells by production of parasite-encoded enzyme. Nature 1985; 313:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/77\">",
"      Yoshida A, Roth EF Jr. Glucose-6-phosphate dehydrogenase of malaria parasite Plasmodium falciparum. Blood 1987; 69:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/78\">",
"      Giribaldi G, Ulliers D, Mannu F, et al. Growth of Plasmodium falciparum induces stage-dependent haemichrome formation, oxidative aggregation of band 3, membrane deposition of complement and antibodies, and phagocytosis of parasitized erythrocytes. Br J Haematol 2001; 113:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/79\">",
"      Griffiths MJ, Ndungu F, Baird KL, et al. Oxidative stress and erythrocyte damage in Kenyan children with severe Plasmodium falciparum malaria. Br J Haematol 2001; 113:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13289/abstract/80\">",
"      Roth EF Jr, Ruprecht RM, Schulman S, et al. Ribose metabolism and nucleic acid synthesis in normal and glucose-6-phosphate dehydrogenase-deficient human erythrocytes infected with Plasmodium falciparum. J Clin Invest 1986; 77:1129.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7109 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-3B792D9370-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_62_13289=[""].join("\n");
var outline_f12_62_13289=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22470651\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FUNCTION OF G6PD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS OF G6PD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      G6PD and its variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Classification of G6PD variants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Wild-type enzyme",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - G6PD A- variant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - G6PD Mediterranean variant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PATHOPHYSIOLOGY OF G6PD DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22470979\">",
"      Hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Jaundice in neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      G6PD in other hematopoietic cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EPIDEMIOLOGY OF G6PD DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Possible protection against malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22470651\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7109\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7109|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/40/19085\" title=\"figure 1\">",
"      Physiology of G6PD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/29/29149\" title=\"figure 2\">",
"      G6PD mutations and class",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7109|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/28/26054\" title=\"picture 1\">",
"      Heinz body hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7109|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/22/19821\" title=\"table 1\">",
"      Drugs and G6PD deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=related_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=related_link\">",
"      Neutrophil functions other than movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=related_link\">",
"      Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/41/12946?source=related_link\">",
"      Patient information: Glucose-6-phosphate dehydrogenase deficiency (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20858?source=related_link\">",
"      Protection against malaria in the hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5399?source=related_link\">",
"      Related disorders of the hexose monophosphate shunt and glutathione metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/616?source=related_link\">",
"      Unstable hemoglobin variants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_62_13290="Treatment of insomnia";
var content_f12_62_13290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of insomnia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/62/13290/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13290/contributors\">",
"     Michael H Bonnet, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13290/contributors\">",
"     Donna L Arand, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/62/13290/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13290/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13290/contributors\">",
"     Ruth Benca, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/62/13290/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/62/13290/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/62/13290/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insomnia was previously viewed as a transient problem secondary to a medical condition, psychiatric illness, sleep disorder, or medication, that would improve with treatment of the underlying disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/1\">",
"     1",
"    </a>",
"    ]. However, evidence has accumulated over the past 20 years that indicates that this view is incorrect.",
"   </p>",
"   <p>",
"    It is now recognized that insomnia may be an independent disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Insomnia may occur in the absence of coexisting conditions and, when coexisting conditions exist, may persist despite successful treatment of the coexisting condition. Treatment directed at the insomnia, rather than the comorbidity, may be necessary. Since insomnia can precipitate, exacerbate, or prolong comorbid conditions, treatment of insomnia may improve comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of insomnia is described in this topic review. The definition, types, epidemiology, clinical features, consequences, and diagnostic evaluation of insomnia are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4758?source=see_link\">",
"     \"Overview of insomnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9561?source=see_link\">",
"     \"Types of insomnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41541?source=see_link\">",
"     \"Clinical features and diagnosis of insomnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with insomnia should receive therapy for any medical condition, psychiatric illness, substance abuse, or sleep disorder that may be precipitating or exacerbating the insomnia. They should also receive counseling about sleep hygiene (",
"    <a class=\"graphic graphic_table graphicRef71116 \" href=\"UTD.htm?6/3/6203\">",
"     table 1",
"    </a>",
"    ) and stimulus control (",
"    <a class=\"graphic graphic_table graphicRef77189 \" href=\"UTD.htm?3/54/3947\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For patients who continue to have insomnia that is sufficiently burdensome to warrant an intervention, reasonable approaches include behavioral therapy, medication, or both:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Behavioral therapies include relaxation, sleep restriction therapy, cognitive therapy, and cognitive behavioral therapy. These therapies are not available in all medical centers. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Behavioral therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Medications used to treat insomnia include benzodiazepines, nonbenzodiazepine sedatives, and melatonin agonists. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Medications'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Combination therapy involves initially prescribing both cognitive behavioral therapy and a medication (usually for six to eight weeks), then tapering the medication off or to an as-needed schedule while continuing cognitive behavioral therapy. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Combination therapy'",
"      </a>",
"      below.) The use of medication prior to the initiation of behavioral therapy appears to be less effective [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice among these approaches should be individualized according to the patient's values and preferences, the availability of advanced behavioral therapies, the severity and impact of the insomnia, and the potential benefits versus the risks, costs, and inconveniences.",
"   </p>",
"   <p>",
"    In clinical practice, initial treatment typically involves sleep hygiene instruction and stimulus control procedures. If follow-up indicates that further treatment is needed, then more formal cognitive behavioral therapy alone or in combination with a medication may be used for six weeks. For patients who respond to therapy (ie, report both improved sleep at night and improvement of daytime deficits), the medication can be tapered or used as needed while continuing the cognitive behavioral therapy. Patients whose symptoms recur after discontinuation of therapy may require re-evaluation for referral for polysomnography or additional cognitive behavioral therapy, with or without pharmacologic therapy. An exception to this approach is patients who have acute insomnia due to a self-limited stressor; such patients may benefit from short-term medication alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BEHAVIORAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral therapies for insomnia include sleep hygiene education, stimulus control, relaxation, sleep restriction therapy, cognitive therapy, and cognitive behavioral therapy. Patients whose insomnia has been successfully treated by behavioral therapy are likely to report decreased daytime symptoms and improvement of daytime function, quality of life, and comorbidities. Behavioral therapy has not been reported to cause side effects, but can be inconvenient and costly. In addition, it is not readily available in many places.",
"   </p>",
"   <p>",
"    Behavioral therapy can be prescribed by any clinician. All behavioral therapies except sleep hygiene counseling should be implemented over a series of approximately 6 to 10 sessions. The evidence suggests that the success of the therapy is related to the experience of the individual implementing it [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sleep hygiene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep hygiene refers to actions that tend to improve and maintain good sleep (",
"    <a class=\"graphic graphic_table graphicRef71116 \" href=\"UTD.htm?6/3/6203\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sleep as long as necessary to feel rested (usually 7 to 8 hours for adults) and then get out of bed",
"     </li>",
"     <li>",
"      Maintain a regular sleep schedule",
"     </li>",
"     <li>",
"      Try not to force sleep",
"     </li>",
"     <li>",
"      Avoid caffeinated beverages after lunch",
"     </li>",
"     <li>",
"      Avoid alcohol near bedtime (eg, late afternoon and evening)",
"     </li>",
"     <li>",
"      Avoid smoking or other nicotine intake, particularly during the evening",
"     </li>",
"     <li>",
"      Adjust the bedroom environment as needed to decrease stimuli (eg, reduce ambient light, turn off the television or radio)",
"     </li>",
"     <li>",
"      Resolve concerns or worries before bedtime",
"     </li>",
"     <li>",
"      Exercise regularly for at least 20 minutes, preferably more than four to five hours prior to bedtime",
"     </li>",
"     <li>",
"      Avoid daytime naps, especially if they are longer than 20 to 30 minutes or occur late in the day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sleep hygiene alone has not been directly compared to no intervention or a sham intervention. However, numerous clinical trials used sleep hygiene alone as the control intervention, demonstrating improvement of sleep following the initiation of sleep hygiene [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Stimulus control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with insomnia may associate their bed and bedroom with the fear of not sleeping or other arousing events, rather than the more pleasurable anticipation of sleep. The longer one stays in bed trying to sleep, the stronger the association becomes. This perpetuates the difficulty falling asleep.",
"   </p>",
"   <p>",
"    Stimulus control therapy is a strategy whose purpose is to disrupt this association by enhancing the likelihood of sleep (",
"    <a class=\"graphic graphic_table graphicRef77189 \" href=\"UTD.htm?3/54/3947\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients should not go to bed until they are sleepy and should use the bed primarily for sleep (and not for reading, watching television, eating, or worrying). They should not spend more than 20 minutes in bed awake. If they are awake after 20 minutes, they should leave the bedroom and engage in a relaxing activity, such as reading or listening to soothing music. Patients should not engage in activities that stimulate them or reward them for being awake in the middle of the night, such as eating or watching television. In addition, they should not return to bed until they are tired and feel ready to sleep. If they return to bed and still cannot sleep within 20 minutes, the process should be repeated. An alarm clock should be set to wake the patient at the same time every morning, including weekends. Daytime naps are not allowed.",
"   </p>",
"   <p>",
"    Patients may not improve immediately. However, accumulating sleepiness will facilitate sleep during successive nights.",
"   </p>",
"   <p>",
"    Stimulus control therapy has improved sleep in randomized trials and its effects may be long-lasting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. One study suggested that stimulus control therapy is more effective among patients who are not already receiving medications for insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Relaxation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relaxation therapy may be implemented before each sleep period. There are two common techniques for relaxation therapy: progressive muscle relaxation and the relaxation response.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive relaxation is based upon the theory that an individual can learn to relax one muscle at a time until the entire body is relaxed. Beginning with the muscles in the face, the muscles are contracted gently for one to two seconds and then relaxed. This is repeated several times. The same technique is used for other muscle groups, usually in the following sequence: jaw and neck, upper arms, lower arms, fingers, chest, abdomen, buttocks, thighs, calves, and feet. This cycle is repeated for approximately 45 minutes, if necessary.",
"     </li>",
"     <li>",
"      The relaxation response begins by lying or sitting comfortably. The eyes are closed and relaxation is allowed to spread throughout the body. A relaxed, abdominal breathing pattern is established. Thoughts are redirected away from everyday thoughts and toward a neutral mental focusing device, such as a peaceful word or image.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One trial randomly assigned 57 patients with insomnia to receive progressive relaxation therapy or no therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/19\">",
"     19",
"    </a>",
"    ]. Progressive relaxation therapy improved measures of sleep, but not daytime function. Another randomized trial similarly found improvement in sleep measures among patients who received relaxation therapy compared to a sham therapy, but the improvement was modest and smaller than that achieved with cognitive behavioral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/20\">",
"     20",
"    </a>",
"    ]. Relaxation therapy is sometimes combined with biofeedback to reduce somatic arousal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sleep restriction therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with insomnia stay in bed longer to try to make up for lost sleep. This causes a circadian shift and a reduction in the homeostatic drive that makes sleep onset the following night more difficult and results in the need to stay in bed even longer. Sleep restriction therapy counteracts this tendency by limiting the total time allowed in bed, including naps and other sleep periods outside of bed, in order to increase the drive to sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/21\">",
"     21",
"    </a>",
"    ]. This consolidates sleep and improves sleep efficiency (the percentage of time in bed that the patient is asleep).",
"   </p>",
"   <p>",
"    Sleep restriction therapy begins by decreasing the time spent in bed to the same amount of time that the patient reports sleeping (usually determined from sleep diaries or logs completed by the patient), but not less than five hours per night (",
"    <a class=\"graphic graphic_table graphicRef69303 \" href=\"UTD.htm?8/33/8731\">",
"     table 3",
"    </a>",
"    ). On a daily basis, the patient reports the amount of sleep obtained the previous night and the amount of time spent in bed. The clinician then computes the sleep efficiency, which is the reported time asleep divided by the reported time in bed. The time in bed is increased by 15 to 30 minutes once the sleep efficiency exceeds 85 percent. This process is repeated until the patient reports improved sleep without residual daytime sleepiness. Naps are not permitted.",
"   </p>",
"   <p>",
"    To improve compliance, the rationale for the therapy needs to be carefully explained to patients and some care needs to be used to determine and schedule the time in bed in a manner that maximizes the ability to sleep and is acceptable to the patient. Older patients tend to have more difficulty maintaining sleep even when restricted; therefore, they are given more lenient criteria.",
"   </p>",
"   <p>",
"    A trial randomly assigned 21 patients with insomnia to receive sleep hygiene education alone or sleep restriction plus sleep hygiene education [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/22\">",
"     22",
"    </a>",
"    ]. The group that received sleep restriction had a greater improvement in sleep efficiency. A more recent systematic review with meta-analysis of the various behavioral therapies for insomnia confirmed that sleep restriction improves sleep, compared to various controls [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cognitive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are awake at night commonly become concerned that they will perform poorly the next day if they do not obtain adequate sleep. This worry can exacerbate their difficulty falling asleep, creating a vicious cycle of wakefulness and concern. A person may begin to blame all negative events in their life on poor sleep. During cognitive therapy, a person works with a therapist to deal with their anxiety and catastrophic thinking, while establishing realistic expectations related to insomnia and the need for sleep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cognitive behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive behavioral therapy (CBT) is a strategy that combines several of the previously described approaches over several weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/24\">",
"     24",
"    </a>",
"    ]. A sample 8-session CBT program may include an introductory education session, followed by two sessions that focus on stimulus control and sleep restriction. These may be followed by two sessions that focus on cognitive therapy and then a session on sleep hygiene. Finally, there may be a session that reviews and integrates the previous session and a session that addresses future problems, such as stress and relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients are encouraged to complete sleep logs as they learn and apply the various strategies. This allows improvement to be measured.",
"   </p>",
"   <p>",
"    The advantage of the educational nature of CBT is that it provides patients with tools to apply in the future. Disadvantages of CBT include the duration of therapy and the relatively few clinicians who are skilled at all of its components. The benefit of CBT may be reduced when it is administered by less experienced clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CBT has proven efficacious in moderate to high-quality randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/1\">",
"     1",
"    </a>",
"    ]. This was best illustrated by a meta-analysis of behavioral therapies for insomnia that found that CBT (sleep hygiene, relaxation, stimulus control, plus sleep restriction) improved subjective sleep quality and decreased subjective wake time during the night [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/23\">",
"     23",
"    </a>",
"    ]. The benefits of CBT appear to persist well beyond the termination of active treatment and there is little evidence of any adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CBT is particularly recommended for use in situations where medications are contraindicated or may be more likely to produce side effects, such as older adults, pregnant women, and patients with renal, hepatic, or pulmonary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications that are commonly used to treat insomnia include benzodiazepines, nonbenzodiazepine sedatives, and melatonin agonists. Patients whose insomnia has been successfully treated with pharmacologic therapy are likely to report improvement of daytime function, better quality of life, and fewer comorbidities (eg, depressed mood). Risks of pharmacologic therapy include side effects, as well as physical and psychological addiction with long-term use. These risks may be increased in certain clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy &ndash; Sedative-hypnotics may increase the risk of fetal malformations if used during the first trimester.",
"     </li>",
"     <li>",
"      Alcohol consumption &ndash; Sedative-hypnotics should not be combined with alcohol because there is a risk of excessive sedation whenever central nervous system suppressants are combined.",
"     </li>",
"     <li>",
"      Renal or hepatic disease &ndash; Most sedative-hypnotic medications undergo hepatic and renal clearance. Metabolic clearance may be delayed in patients who have renal or hepatic disease, leading to accumulation and excessive sedation.",
"     </li>",
"     <li>",
"      Pulmonary disease or sleep apnea &ndash; Many sedative-hypnotics are respiratory suppressants that can worsen obstructive sleep apnea or hypoventilation.",
"     </li>",
"     <li>",
"      Nighttime decision makers &ndash; Sedative-hypnotics should not be taken by individuals who may be called upon to make important decisions during the night (eg, clinicians on-call or single parents responsible for the care of young children) because they can cause excess sedation and impair decision-making.",
"     </li>",
"     <li>",
"      Older adults &ndash; The risk of adverse effects is increased in older adults, especially those who are older than 75 years. This is a consequence of multiple comorbidities and central nervous system changes associated with aging.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines are a class of sleep promoting medications that bind several gamma-aminobutyric acid (GABA) type A receptor subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/26\">",
"     26",
"    </a>",
"    ]. They reduce the time to the onset of sleep, prolong stage 2 sleep, prolong total sleep time, and may slightly reduce the relative amount of rapid eye movement (REM) sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, they decrease anxiety, impair memory, and have anticonvulsive properties. The pharmacologic properties of the benzodiazepines are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=see_link\">",
"     \"Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Benzodiazepines commonly used for the treatment of insomnia include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/49/23319?source=see_link\">",
"     triazolam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/15/22774?source=see_link\">",
"     estazolam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27334?source=see_link\">",
"     temazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/3/27703?source=see_link\">",
"     flurazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/39/30326?source=see_link\">",
"     quazepam",
"    </a>",
"    . A primary difference among these medications is their duration of action. Triazolam is short-acting; estazolam, lorazepam, and temazepam are intermediate-acting; flurazepam and quazepam are long-acting (",
"    <a class=\"graphic graphic_table graphicRef65653 \" href=\"UTD.htm?39/16/40205\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/27\">",
"     27",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     Diazepam",
"    </a>",
"    is also long-acting, but is generally not used to treat insomnia because it has a long duration of effect and can lead to the accumulation of active metabolites. The long-acting benzodiazepines should be avoided in older adults because there is increased risk for adverse effects in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meta-analyses of randomized, placebo-controlled trials indicate that benzodiazepines decrease sleep latency and the number of awakenings, while improving sleep duration and sleep quality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. Typical changes associated with these medications include decreases in the duration to sleep onset by approximately 10 minutes and increases in the total sleep time of 30 to 60 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The side effects of benzodiazepines are described below. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nonbenzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;A newer class of sleep promoting medications has also been approved for the treatment of insomnia. These medications have a structure that is different from the benzodiazepines and includes more targeted action at one GABA type A receptor. A consequence of their greater specificity is less anxiolytic and anticonvulsant activity. The pharmacologic properties of such nonbenzodiazepine sedative-hypnotics are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=see_link\">",
"     \"Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonbenzodiazepines appear to improve both subjective and objective sleep outcomes. Specifically, meta-analyses of randomized, placebo-controlled trials indicate that nonbenzodiazepines decrease sleep latency and the number of awakenings, while improving sleep duration and sleep quality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. Nonbenzodiazepines also increase adverse events compared to placebo.",
"   </p>",
"   <p>",
"    Nonbenzodiazepines commonly used to treat insomnia include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/61/15318?source=see_link\">",
"     zaleplon",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/11/15542?source=see_link\">",
"     eszopiclone",
"    </a>",
"    , and zolpidem extended release (",
"    <a class=\"graphic graphic_table graphicRef83292 \" href=\"UTD.htm?16/43/17085\">",
"     table 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/61/15318?source=see_link\">",
"       Zaleplon",
"      </a>",
"      has a very short half-life of about one hour. As a result, it is effective for patients who have difficulty falling asleep (ie, sleep onset insomnia), but may not be effective for patients who have difficulty maintaining sleep (ie, sleep maintenance insomnia) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/34\">",
"       34",
"      </a>",
"      ]. Neither persistent sleepiness (ie, hangover effects) nor rebound insomnia is associated with zaleplon. Occasional side effects include headache, dizziness, nausea, abdominal pain, and somnolence [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/26\">",
"       26",
"      </a>",
"      ]. Zaleplon is not indicated for long-term use.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"       Zolpidem",
"      </a>",
"      has a half-life of approximately 1.5 to 2.4 hours. It is indicated for the short-term treatment of insomnia characterized by difficulty with sleep initiation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/35\">",
"       35",
"      </a>",
"      ]. Neither hangover effects nor rebound insomnia are associated with zolpidem. The most common side effects are headache, dizziness, and somnolence. Zolpidem is not approved for long-term use. Zolpidem is also available in a dissolvable tablet and as an oral spray for patients who have difficulty swallowing a pill. A dissolvable tablet (1.75 to 3.5 mg) can be taken in the middle of the night for sleep maintenance insomnia, with the requirement that at least four hours be available to sleep after administration and at least five hours be available prior to driving. In January of 2013, the US Food and Drug Administration (FDA) issued a safety announcement recommending use of a lower dose in women than had been previously recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/36\">",
"       36",
"      </a>",
"      ]. This should also be considered in men. (See",
"      <a class=\"local\" href=\"#H947212\">",
"       'Nonbenzodiazepines'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"       Zolpidem",
"      </a>",
"      extended release also has a half-life of about 1.5 to 2.4 hours, but is released over a longer duration. It was developed to improve both sleep onset insomnia and sleep maintenance insomnia while avoiding hangover effects, although it has never been directly compared to regular zolpidem [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/37\">",
"       37",
"      </a>",
"      ]. Side effects of zolpidem extended release are relatively few, with the most common being headache, somnolence, and dizziness [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/26\">",
"       26",
"      </a>",
"      ]. In January of 2013, the FDA recommended use of a lower dose in women than had been previously recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/36\">",
"       36",
"      </a>",
"      ]. This lower dose should also be considered for men. Sleep may be worse during the first night following discontinuation of this medicine. Zolpidem extended release is not limited to short-term use and there is little evidence for abuse or dependence in most patients. In theory, however, such medications could be habit forming with long-term use. (See",
"      <a class=\"local\" href=\"#H947212\">",
"       'Nonbenzodiazepines'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/11/15542?source=see_link\">",
"       Eszopiclone",
"      </a>",
"      has the longest half-life of the approved nonbenzodiazepines, approximately five to seven hours. This may extend to nine hours in elderly patients. Eszopiclone is effective for both sleep onset insomnia and sleep maintenance insomnia [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/38\">",
"       38",
"      </a>",
"      ]. It has not been associated with hangover effects, but may have an unpleasant metallic taste. Other reported side effects include somnolence, headache, dizziness, and unpleasant dreams [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/26,39\">",
"       26,39",
"      </a>",
"      ]. Sleep may be worse on the first night after discontinuation of this medication. Eszopiclone is not limited to short-term use and there is little evidence for abuse or dependence in most patients. In theory, however, such medications could be habit forming with long-term use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most clinical trials evaluated short-term therapy (eg, seven days), although a few longer clinical trials have been performed. In one randomized trial, patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/11/15542?source=see_link\">",
"     eszopiclone",
"    </a>",
"    for six months had improved quality of life, decreased work limitation, and improved sleep compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/40\">",
"     40",
"    </a>",
"    ]. This persisted throughout the trial and the subsequent six month open label extension. In another randomized trial of 1018 patients with insomnia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    extended release taken for up to six months improved sleep onset, sleep maintenance, morning sleepiness, next-day concentration, and work performance compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects associated with the nonbenzodiazepines are similar to those associated with benzodiazepines. This is discussed below. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Melatonin agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15125?source=see_link\">",
"     Ramelteon",
"    </a>",
"    is a melatonin agonist. It binds with much higher affinity than melatonin to melatonin receptors expressed in the suprachiasmatic nucleus and has a half-life of 1.5 to 5 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Ramelteon is metabolized by the liver and should be used with caution in patients with hepatic insufficiency. It is contraindicated in patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    , since fluvoxamine may decrease the metabolism of ramelteon [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/45\">",
"     45",
"    </a>",
"    ]. Ramelteon provides the most benefit to patients who have sleep onset insomnia.",
"   </p>",
"   <p>",
"    A trial randomly assigned 107 patients with chronic insomnia to receive 4 mg, 8 mg, 16 mg, and then 32 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15125?source=see_link\">",
"     ramelteon",
"    </a>",
"    sequentially, followed by placebo with a washout period of 5 to 12 days between each treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/46\">",
"     46",
"    </a>",
"    ]. The treatment was administered 30 minutes prior to the patient's usual bedtime. All doses of ramelteon decreased sleep onset latency by 10 to 15 minutes and increased total sleep time by 10 to 15 minutes without adverse effects, as measured by polysomnography. Subsequent randomized trials demonstrated subjective benefit, persistence of the effect for at least six months, and improvement in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. Subjective efficacy extended to one year in an open label trial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15125?source=see_link\">",
"     ramelteon",
"    </a>",
"    is approved in the United States, the European Medicines Agency (EMA) concluded in 2008 that there was inadequate evidence that the drug was effective for insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/53\">",
"     53",
"    </a>",
"    ]. It did not approve ramelteon for use.",
"   </p>",
"   <p>",
"    Adverse effects associated with melatonin agonists are generally milder than those associated with benzodiazepines and nonbenzodiazepines. (See",
"    <a class=\"local\" href=\"#H947384\">",
"     'Melatonin agonists'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous other medications have a sedating effect, but are not recommended for routine use in patients with insomnia. These include antidepressants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , antipsychotics, and barbiturates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    ) are sedating because of central anticholinergic or antihistaminergic activity. Such antidepressants may be useful in the management of patients who have insomnia associated with depression.",
"   </p>",
"   <p>",
"    Sedating antidepressants have also been evaluated in patients with insomnia who are not depressed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial that randomly assigned 240 older adult patients with insomnia to receive low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"       doxepin",
"      </a>",
"      (1 or 3 mg) or placebo for 12 weeks, patients who received the 3 mg dose of doxepin had a reduction of wake time after sleep onset, increased total sleep time, increased sleep efficiency, and increased self-reported sleep quality when compared to placebo. Patients who received the 1 mg dose of doxepin had inconsistent improvement of some outcomes measures at several time points [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/54\">",
"       54",
"      </a>",
"      ]. Based on these and other data [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/55\">",
"       55",
"      </a>",
"      ], doxepin has been approved at doses of 3 and 6 mg by the United States Food and Drug Administration primarily for the treatment of sleep maintenance insomnia.",
"     </li>",
"     <li>",
"      Another trial randomly assigned 306 nondepressed patients with insomnia to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"       zolpidem",
"      </a>",
"      , or placebo for two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/56\">",
"       56",
"      </a>",
"      ]. After one week of therapy, trazodone improved subjective sleep latency, sleep duration, wake time after sleep onset, and number of awakenings, compared to placebo. However, after two weeks, the trazodone group did not differ significantly from the placebo group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite their sleep-promoting effects, the routine use of sedating antidepressants other than low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    to treat insomnia in patients who are not depressed has not been recommended because the sedating effect tends to be short-lived and other side effects are common [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/1,57\">",
"     1,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Diphenhydramine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many over-the-counter sleep aids contain",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (a sedating antihistamine) or a combination of diphenhydramine plus pain relievers. There is little evidence that diphenhydramine improves insomnia and it may cause sedation the next day (due to its long half-life). Additional side effects include decreased alertness, diminished cognitive function, delirium, dry mouth, blurred vision, urinary retention, constipation, and increased intraocular pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/1\">",
"     1",
"    </a>",
"    ]. Routine use of diphenhydramine to treat insomnia is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antipsychotics have been used to treat insomnia. However, there are few trials that demonstrate effectiveness of these medications and all have potentially significant adverse effects. The routine use of antipsychotics to treat insomnia in patients without psychosis is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Barbiturates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barbiturates have similarly been used to treat insomnia. However, there is little evidence that these medications improve insomnia and all have potentially significant adverse effects. Routine use of barbiturates to treat insomnia is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Over-the-counter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herbal products, hormones, and alcoholic beverages have been used as sleep aids by patients with insomnia. These agents are not regulated by the FDA.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Valerian &ndash; Valerian is one of the 10 most popular herbal products sold in the United States. It is commonly used in an effort to treat insomnia. A meta-analysis of 18 studies found that Valerian decreased objective sleep latency by less than one minute compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/58\">",
"       58",
"      </a>",
"      ]. Valerian may also produce hepatotoxic effects [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/1\">",
"       1",
"      </a>",
"      ]. Contamination with undesirable substances poses a problem for many such natural remedies.",
"     </li>",
"     <li>",
"      Melatonin &ndash; Melatonin is a hormone that is normally secreted by the pineal gland. It does not appear to be beneficial as a treatment for insomnia in most patients with two exceptions: it may be useful in patients who have delayed sleep phase syndrome and in a subgroup of patients with low melatonin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/1,59-64\">",
"       1,59-64",
"      </a>",
"      ]. It appears to be safe when used short-term (three months or less) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/61\">",
"       61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9561?source=see_link&amp;anchor=H19#H19\">",
"       \"Types of insomnia\", section on 'Sleep disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alcohol &ndash; Alcohol is commonly self-prescribed as a sleep aid because it decreases the time required to fall asleep, at least in the short-term. However, alcohol can promote sleep disturbances later in the night and promotes upper airway instability and sleep apnea. These negative effects, coupled with the significant risk of dependence and interaction with other medications, preclude the use of alcohol to treat insomnia [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H947205\">",
"    <span class=\"h3\">",
"     Common to all hypnotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse effects associated with the benzodiazepines and nonbenzodiazepines are residual daytime sedation, drowsiness, dizziness, lightheadedness, cognitive impairment, motor incoordination, and dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/1,29-31\">",
"     1,29-31",
"    </a>",
"    ]. Long-term use may be habit forming and rebound insomnia may occur when some short-acting medications are discontinued. Less common adverse effects include complex sleep-related behaviors (eg, sleep walking, driving, making telephone calls, eating, having sex while not fully awake), anterograde amnesia (particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/49/23319?source=see_link\">",
"     triazolam",
"    </a>",
"    or when used with alcohol), aggressive behavior, and severe allergic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/27,66\">",
"     27,66",
"    </a>",
"    ]. Lethal overdose is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/67\">",
"     67",
"    </a>",
"    ], unless there is concurrent use of alcohol or another central nervous system depressant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H947212\">",
"    <span class=\"h3\">",
"     Nonbenzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generally speaking, the adverse effects associated with the nonbenzodiazepines are similar to those associated with the benzodiazepines, but their frequency and severity may be less [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. This is probably related to their shorter half-lives. Most of the complex sleep-related behaviors that have been reported in patients taking nonbenzodiazepines were related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    , but it is unknown whether this reflects the widespread use of zolpidem or an association between the agent and the side effect [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/27\">",
"     27",
"    </a>",
"    ]. Other side effects that have been reported in patients taking nonbenzodiazepines include an unpleasant taste (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/11/15542?source=see_link\">",
"     eszopiclone",
"    </a>",
"    ) and hallucinations (zolpidem). The incidence of infection (eg, upper respiratory, otitis media, urinary tract, conjunctivitis, others) may also be increased among patients taking a nonbenzodiazepine, according to one meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/68\">",
"     68",
"    </a>",
"    ]. The cause of this observation is uncertain.",
"   </p>",
"   <p>",
"    In January of 2013, the FDA published a safety communication that the recommended dose for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    be set at the lowest dose (5 mg for all except zolpidem extended release, which is now 6.25 mg) for women and also be considered for men [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/36\">",
"     36",
"    </a>",
"    ]. These recommendations were based on studies showing that blood levels of zolpidem above about 50",
"    <span class=\"nowrap\">",
"     ng/ml",
"    </span>",
"    appeared capable of impairing driving sufficiently to increase the risk of an accident. This blood level was found in about 15 percent of women and 3 percent of men eight hours after administration of 10 mg of zolpidem. Eight hours after use of the extended-release formulation of zolpidem, 33 percent of women and 25 percent of men still had this elevated blood level. While the FDA announcement was specific to zolpidem-based products, it has long been known that there is variability in metabolism for sedative hypnotic medications but dosing recommendations have been based on group statistical effects rather than individual responses. This new safety announcement suggests a shift in sensitivity to medication side effects that should probably also be applied to this class of medications in general.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H947384\">",
"    <span class=\"h3\">",
"     Melatonin agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15125?source=see_link\">",
"     Ramelteon",
"    </a>",
"    has fewer side effects than the nonbenzodiazepines or benzodiazepines [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/69\">",
"     69",
"    </a>",
"    ]. It is not associated with hypnotic side effects (eg, next day residual performance deficits), withdrawal, or rebound insomnia, and it does not appear to be habit forming [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/51,69\">",
"     51,69",
"    </a>",
"    ]. Ramelteon has little abuse potential and is the only approved sedative-hypnotic medication that is not a scheduled substance with the United States Drug Enforcement Administration (DEA). The most common side effects are somnolence, dizziness, nausea, fatigue, and headache [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]. Elevated prolactin levels and decreased testosterone levels may occur, but routine monitoring of either is not indicated in the absence of other clinical indications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H947219\">",
"    <span class=\"h3\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older adults have a particularly high risk of adverse effects, including excessive sedation, cognitive impairment, delirium, night wandering, agitation, postoperative confusion, balance problems, fall and fractures, and impaired performance of daily activities [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. In a meta-analysis of 24 randomized trials (2417 patients) that evaluated the impact of pharmacotherapy in adults older than 60 years with insomnia, there was an improvement of sleep quality, total sleep time, and frequency of nighttime awakening [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/73\">",
"     73",
"    </a>",
"    ]. However, the magnitude of these benefits was relatively small compared to the two- to fivefold increase in adverse cognitive or psychomotor events. This suggests that additional caution is necessary when deciding whether pharmacotherapy is indicated for an older patient with insomnia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H947253\">",
"    <span class=\"h3\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the adverse effects described above are well established, one study (that included evidence for the frequently prescribed agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27334?source=see_link\">",
"     temazepam",
"    </a>",
"    ) suggested that hypnotic drugs could be associated with the development of cancer and death, even at prescription levels of less than 18 doses per year over a 2.5 year duration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/74\">",
"     74",
"    </a>",
"    ]. It is important to emphasize, however, that this evidence is observational and, therefore, does not indicate causality. It is plausible that the cause of the symptoms for which the hypnotic agent was prescribed (including all psychiatric diagnoses, which were not controlled for) was responsible for the outcomes, rather than the hypnotic agent itself. A prospective investigation of long-term hypnotic use compared with placebo and behavioral treatment needs to be done.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11704147\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concurrent use of any sleeping medication and alcohol (or another central nervous system depressant) increases the risk of central nervous system depression and, therefore, is contraindicated.",
"   </p>",
"   <p>",
"    Most benzodiazepines (except",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"     oxazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27334?source=see_link\">",
"     temazepam",
"    </a>",
"    ) and nonbenzodiazepines are metabolized by the CYP3A4 system [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/27\">",
"     27",
"    </a>",
"    ]. Inhibitors of the CYP3A4 system (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ) increase the risk of toxicity related to benzodiazepines and nonbenzodiazepines, while inducers of the CYP3A4 system (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ) may decrease the effectiveness of benzodiazepines and nonbenzodiazepines.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15125?source=see_link\">",
"     Ramelteon",
"    </a>",
"    is metabolized by the CYP1A2 system and, to a lesser extent, the CYP2C9 and CYP3A4 systems [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/27\">",
"     27",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     Fluvoxamine",
"    </a>",
"    is a potent inhibitor of the CYP1A2 system and should not be used with ramelteon because it markedly increases serum concentrations of ramelteon. Other inhibitors of the CYP1A2 (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ), CYP2C9, or CYP3A4 systems may also increase the risk of ramelteon toxicity, while inducers of the CYP systems (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ) may decrease the effectiveness of ramelteon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11704037\">",
"    <span class=\"h2\">",
"     Choice of an agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials directly comparing the effect of different medications on insomnia are rare. Indirect comparisons of benzodiazepines and nonbenzodiazepines suggest that these classes of medication have a similar impact on sleep onset latency (ie, they decrease objective sleep onset latency by approximately 10 minutes and subjective sleep onset latency by 15 to 20 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/29\">",
"     29",
"    </a>",
"    ]. However, the benzodiazepines are more likely to prolong total sleep time, perhaps because they tend to have longer half-lives [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of the few trials that directly compared different medications, 382 patients with primary insomnia received each of six interventions in random order for two nights each, with a three to seven day washout period in between [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/75\">",
"     75",
"    </a>",
"    ]. The agents included placebo,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/11/15542?source=see_link\">",
"     eszopiclone",
"    </a>",
"    (1, 2, 2.5, and 3 mg), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    (10 mg). Compared to placebo, eszopiclone at doses of 2.5 and 3 mg decreased the median wake time after sleep onset, but zolpidem and eszopiclone at doses of 1 and 2 mg did not. The wake time after sleep onset refers to the amount of time that the patient is awake between sleep onset and the final morning arising time. There were no differences in any of the objective sleep outcomes when eszopiclone (2 and 3 mg) and zolpidem were compared directly.",
"   </p>",
"   <p>",
"    Most clinicians select a sedative-hypnotic on the basis of the type of insomnia (ie, sleep onset or sleep maintenance) and the duration of effect:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with sleep onset insomnia, a short-acting medication is a reasonable choice for an initial trial of pharmacologic therapy. This may improve the insomnia with less residual somnolence the following morning. Examples of short-acting medications (duration of effect &le;8 hours) include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/61/15318?source=see_link\">",
"       zaleplon",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"       zolpidem",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/49/23319?source=see_link\">",
"       triazolam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15125?source=see_link\">",
"       ramelteon",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      For patients with sleep maintenance insomnia, a longer-acting medication is preferable for an initial trial of pharmacologic therapy. Examples of longer-acting medications include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"       zolpidem",
"      </a>",
"      extended release,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/11/15542?source=see_link\">",
"       eszopiclone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27334?source=see_link\">",
"       temazepam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/15/22774?source=see_link\">",
"       estazolam",
"      </a>",
"      , and low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"       doxepin",
"      </a>",
"      . However, these medications may increase the risk for hangover sedation and patients must be warned about this possibility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other issues to be considered when prescribing a medication for insomnia include cost and adverse effects. The benzodiazepines and off-patent nonbenzodiazepines (specifically,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/61/15318?source=see_link\">",
"     zaleplon",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    ) tend to be less expensive than the other nonbenzodiazepines and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15125?source=see_link\">",
"     ramelteon",
"    </a>",
"    . The adverse effects are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     COMBINATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy involves prescribing both cognitive behavioral therapy (CBT) and a medication, usually for six to eight weeks. The medication is then tapered off or to an as-needed schedule, while continuing the CBT.",
"   </p>",
"   <p>",
"    Two trials from the same investigators illustrate the effects of combination therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first trial randomly assigned 78 patients with persistent insomnia to receive CBT alone,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27334?source=see_link\">",
"       temazepam",
"      </a>",
"      alone, CBT plus temazepam, or placebo for eight weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/76\">",
"       76",
"      </a>",
"      ]. At the end of the treatment phase, all of the therapies had significantly decreased the wake time after sleep onset compared to placebo, although there were no significant differences when the treatment groups were compared to each other. Two years following the completion of treatment, only the CBT alone group had maintained its reduction in the wake time after initial sleep onset.",
"     </li>",
"     <li>",
"      The second trial randomly assigned 160 patients with persistent insomnia to receive CBT plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"       zolpidem",
"      </a>",
"      or CBT alone for six weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/77\">",
"       77",
"      </a>",
"      ]. Both groups had decreased sleep onset latency, decreased wake time after sleep onset, and increased sleep efficiency when compared to baseline after six weeks. However, there was no significant difference in the remission rate when the groups were compared to each other (44 versus 39 percent). The patients then underwent secondary randomization. Patients in the CBT alone group were randomly assigned to no treatment or maintenance CBT, while patients in the CBT plus zolpidem group were randomly assigned to either maintenance CBT or maintenance CBT plus as-needed zolpidem. The improvement of sleep latency, wake time after sleep onset, and sleep efficiency was maintained in all groups at six months, when compared to baseline. The remission rate was higher at six months among the groups that had received CBT plus zolpidem during the initial six weeks of the trial, than among the groups that had initially received CBT alone (56 versus 43 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, the evidence indicates that CBT alone, drug therapy alone, and combination therapy all improve measures of insomnia (eg, wake time after sleep onset) within weeks of initiating the therapy. Continuing CBT alone after the completion of initial therapy appears to be the best option for maintaining improvement long-term. CBT also increases the likelihood that the medication can eventually be tapered [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence is insufficient to justify combination therapy as routine initial management for insomnia patients. Many patients will improve with CBT alone, without pharmacologic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the treatment is successful, patients will report both improved sleep at night and improvement of daytime deficits. Discontinuation of the medication should be considered in any patient who is receiving pharmacologic therapy alone or combination therapy.",
"   </p>",
"   <p>",
"    Patients who have little improvement during the initial trial of cognitive behavioral therapy, pharmacologic therapy, or combination therapy may have other causes of poor sleep. Adherence with the prescribed therapy should be confirmed and then additional diagnostic evaluation performed. Such patients often require referral to a sleep disorders center to be evaluated for sleep apnea or other underlying causes. Such an evaluation is indicated earlier (ie, prior to the failure of routine therapy) if there is clinical suspicion that sleep apnea or another etiology exists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41541?source=see_link\">",
"     \"Clinical features and diagnosis of insomnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5744619\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Insomnia related to circadian rhythm disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have insomnia associated with a circadian rhythm disorder may benefit from phototherapy or chronotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to bright light when awakening is an effective therapy for patients whose sleep onset insomnia is due to delayed sleep phase syndrome, a condition in which the onset of sleep is delayed because the individual's sleep-wake rhythm is longer than 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9561?source=see_link&amp;anchor=H19#H19\">",
"     \"Types of insomnia\", section on 'Sleep disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients undergoing phototherapy sit in front of 10,000 lux light box (or a window with sunlight) for 30 to 40 minutes upon awakening (average indoor lighting is 300 to 500 lux, average sunny summer day is 100,000 lux). In addition, they markedly reduce their exposure to bright light in the evening (eg, they may keep their shades down and indoor lights dim). A response to therapy is generally evident after two to three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/79\">",
"     79",
"    </a>",
"    ]. Indefinite treatment is frequently necessary to maintain the benefits. In less severe cases, consistent awakening at a given time in the morning, followed by physical activity with exposure to outdoor light (eg, a walk outside, sitting next to a window with the shades and curtains open), may be sufficient even on a cloudy day.",
"   </p>",
"   <p>",
"    Phototherapy may also be beneficial to patients whose insomnia is due to advanced sleep phase syndrome, a condition in which the individual desires sleep early and awakens early because their sleep-wake rhythm has shifted earlier. In this situation, exposure to bright light in the evening can help delay sleep onset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Chronotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronotherapy is a behavioral strategy that can be used in patients with circadian rhythm disorders. It refers to the intentional delay of sleep onset by two to three hours on successive days until the desired bedtime has been achieved. After this, the patient strictly enforces this sleep-wake schedule. One study reported a high success rate among patients with delayed sleep phase syndrome, even when the disorder had been present for many years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronotherapy requires close monitoring of schedules. Patients must continue to delay their sleep times until the desired bedtime has been achieved, which means adhering to several afternoon and evening bedtimes. This is an arduous schedule that is sometimes implemented in the inpatient setting. In addition, patients generally become less adherent to their schedule after the initial adjustment, lapsing into their original sleep habits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31065860\">",
"    <span class=\"h2\">",
"     Cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insomnia is common among patients with cirrhosis. The evaluation of insomnia in patients with advanced liver disease should include an assessment for hepatic encephalopathy, since it may be a contributing factor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hepatic encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with cirrhosis who have insomnia, behavioral therapies should be used first. For those who do not respond, we would consider pharmacological therapy for those with mild cirrhosis. However, we would use the lowest possible dose of medication and carefully follow the patient because there is potential for the medications to precipitate changes in liver function and hypnotic side effects. Increased sedation may be less of an issue with a medication such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15125?source=see_link\">",
"     ramelteon",
"    </a>",
"    , which does not have a specific dose response curve. Ramelteon was associated with some improvement in liver function in an animal model of acute liver shock [",
"    <a class=\"abstract\" href=\"UTD.htm?12/62/13290/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11704216\">",
"    <span class=\"h2\">",
"     Jet lag",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jet lag is a common cause of insomnia, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35861?source=see_link\">",
"     \"Jet lag\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9561?source=see_link&amp;anchor=H5#H5\">",
"     \"Types of insomnia\", section on 'Jet lag'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/16/2306?source=see_link\">",
"       \"Patient information: Insomnia (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/24/28035?source=see_link\">",
"       \"Patient information: Insomnia treatments (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients with insomnia should receive therapy for any medical condition, psychiatric illness, substance abuse, or sleep disorder that may be precipitating or exacerbating the insomnia. They should also receive general behavioral suggestions, particularly advice regarding sleep hygiene (",
"      <a class=\"graphic graphic_table graphicRef71116 \" href=\"UTD.htm?6/3/6203\">",
"       table 1",
"      </a>",
"      ) and stimulus control (",
"      <a class=\"graphic graphic_table graphicRef77189 \" href=\"UTD.htm?3/54/3947\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who continue to have insomnia that is severe enough to require an intervention, we suggest cognitive behavioral therapy (CBT) as the initial therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). An alternative type of behavioral therapy is reasonable if CBT is not available. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Behavioral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients whose insomnia continues to be severe enough to require an intervention despite behavioral therapy, we suggest the addition of a medication to the behavioral therapy, rather than changing to a strategy of medication alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who require medication for sleep onset insomnia, we suggest a short-acting medication, rather than a longer-acting agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11704037\">",
"       'Choice of an agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who require medication for sleep maintenance insomnia, we suggest a longer-acting medication, rather than a short-acting agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Alternatively, a new formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"       zolpidem",
"      </a>",
"      has been approved for use in the middle of the night. Patients should be warned about the risk for daytime drowsiness, impaired driving, dizziness, and lightheadedness. (See",
"      <a class=\"local\" href=\"#H11704037\">",
"       'Choice of an agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients given behavioral plus pharmacologic therapy should continue for six to eight weeks. In patients who respond to therapy, the medication can be tapered while continuing the behavioral therapy. Patients whose symptoms recur may require evaluation in a sleep disorders center, prior to the institution of long-term therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term medication alone is not the optimal initial treatment strategy for patients with insomnia. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/1\">",
"      National Institutes of Health. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005; 28:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/2\">",
"      Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med 1998; 158:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/3\">",
"      Krystal, AD. Psychiatric comorbidity: the case for treating insomnia. Sleep Med Clin 2006; 1:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/4\">",
"      Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006; 59:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/5\">",
"      Roehrs T, Hyde M, Blaisdell B, et al. Sleep loss and REM sleep loss are hyperalgesic. Sleep 2006; 29:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/6\">",
"      Tashjian RZ, Banerjee R, Bradley MP, et al. Zolpidem reduces postoperative pain, fatigue, and narcotic consumption following knee arthroscopy: a prospective randomized placebo-controlled double-blinded study. J Knee Surg 2006; 19:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/7\">",
"      Sack RL, Auckley D, Auger RR, et al. Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. An American Academy of Sleep Medicine review. Sleep 2007; 30:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/8\">",
"      Valli&egrave;res A, Morin CM, Guay B. Sequential combinations of drug and cognitive behavioral therapy for chronic insomnia: an exploratory study. Behav Res Ther 2005; 43:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/9\">",
"      Espie CA, MacMahon KM, Kelly HL, et al. Randomized clinical effectiveness trial of nurse-administered small-group cognitive behavior therapy for persistent insomnia in general practice. Sleep 2007; 30:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/10\">",
"      Stepanski EJ, Wyatt JK. Use of sleep hygiene in the treatment of insomnia. Sleep Med Rev 2003; 7:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/11\">",
"      Guilleminault C, Clerk A, Black J, et al. Nondrug treatment trials in psychophysiologic insomnia. Arch Intern Med 1995; 155:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/12\">",
"      Edinger JD, Sampson WS. A primary care \"friendly\" cognitive behavioral insomnia therapy. Sleep 2003; 26:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/13\">",
"      Chen HY, Chiang CK, Wang HH, et al. Cognitive-behavioral therapy for sleep disturbance in patients undergoing peritoneal dialysis: a pilot randomized controlled trial. Am J Kidney Dis 2008; 52:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/14\">",
"      Bootzin RR, Perlis ML. Nonpharmacologic treatments of insomnia. J Clin Psychiatry 1992; 53 Suppl:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/15\">",
"      Pallesen S, Nordhus IH, Kvale G, et al. Behavioral treatment of insomnia in older adults: an open clinical trial comparing two interventions. Behav Res Ther 2003; 41:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/16\">",
"      Espie CA, Lindsay WR, Brooks DN, et al. A controlled comparative investigation of psychological treatments for chronic sleep-onset insomnia. Behav Res Ther 1989; 27:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/17\">",
"      Engle-Friedman M, Bootzin RR, Hazlewood L, Tsao C. An evaluation of behavioral treatments for insomnia in the older adult. J Clin Psychol 1992; 48:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/18\">",
"      Riedel B, Lichstein K, Peterson BA, et al. A comparison of the efficacy of stimulus control for medicated and nonmedicated insomniacs. Behav Modif 1998; 22:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/19\">",
"      Means MK, Lichstein KL, Epperson MT, Johnson CT. Relaxation therapy for insomnia: nighttime and day time effects. Behav Res Ther 2000; 38:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/20\">",
"      Edinger JD, Wohlgemuth WK, Radtke RA, et al. Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial. JAMA 2001; 285:1856.",
"     </a>",
"    </li>",
"    <li>",
"     Spielman, AJ, Yang, et al. Insomnia: Sleep restriction therapy. In: Insomnia Diagnosis and Treatment, Sateia, MJ, Buysse, DJ (Eds), Informa UK Ltd, London 2010. p.277.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/22\">",
"      Hoch CC, Reynolds CF 3rd, Buysse DJ, et al. Protecting sleep quality in later life: a pilot study of bed restriction and sleep hygiene. J Gerontol B Psychol Sci Soc Sci 2001; 56:P52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/23\">",
"      McCurry SM, Logsdon RG, Teri L, Vitiello MV. Evidence-based psychological treatments for insomnia in older adults. Psychol Aging 2007; 22:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/24\">",
"      Smith MT, Neubauer DN. Cognitive behavior therapy for chronic insomnia. Clin Cornerstone 2003; 5:28.",
"     </a>",
"    </li>",
"    <li>",
"     Morin, CM. Insomnia Psychological Assessment and Management, The Guilford Press, New York 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/26\">",
"      Lieberman JA. Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care. Prim Care Companion J Clin Psychiatry 2007; 9:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/27\">",
"      Drugs for insomnia. Treat Guidel Med Lett 2009; 7:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/28\">",
"      Bloom HG, Ahmed I, Alessi CA, et al. Evidence-based recommendations for the assessment and management of sleep disorders in older persons. J Am Geriatr Soc 2009; 57:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/29\">",
"      Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 2007; 22:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/30\">",
"      Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000; 162:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/31\">",
"      Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997; 278:2170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/32\">",
"      Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev 2009; 13:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/33\">",
"      Huedo-Medina TB, Kirsch I, Middlemass J, et al. Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration. BMJ 2012; 345:e8343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/34\">",
"      Elie R, R&uuml;ther E, Farr I, et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group. J Clin Psychiatry 1999; 60:536.",
"     </a>",
"    </li>",
"    <li>",
"     Ambien (zolpidem tartrate) prescribing information file://products.sanofi-aventis.us/ambien/ambien.html (Accessed on June 27, 2009).",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm334738.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/37\">",
"      Hindmarch I, Legangneux E, Stanley N, et al. A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers. Br J Clin Pharmacol 2006; 62:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/38\">",
"      Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005; 6:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/39\">",
"      Ancoli-Israel S, Krystal AD, McCall WV, et al. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep 2010; 33:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/40\">",
"      Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007; 30:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/41\">",
"      Krystal AD, Erman M, Zammit GK, et al. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008; 31:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/42\">",
"      Erman M, Guiraud A, Joish VN, Lerner D. Zolpidem extended-release 12.5 mg associated with improvements in work performance in a 6-month randomized, placebo-controlled trial. Sleep 2008; 31:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/43\">",
"      Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med 2004; 5:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/44\">",
"      Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005; 48:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/45\">",
"      Cajochen C. TAK-375 Takeda. Curr Opin Investig Drugs 2005; 6:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/46\">",
"      Erman M, Seiden D, Zammit G, et al. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med 2006; 7:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/47\">",
"      Mini LJ, Wang-Weigand S, Zhang J. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. Am J Geriatr Pharmacother 2007; 5:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/48\">",
"      Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007; 3:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/49\">",
"      Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007; 23:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/50\">",
"      Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006; 7:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/51\">",
"      Mayer G, Wang-Weigand S, Roth-Schechter B, et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009; 32:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/52\">",
"      Richardson GS, Zammit G, Wang-Weigand S, Zhang J. Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. J Clin Psychiatry 2009; 70:467.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.emea.europa.eu/htms/human/opinion/opinion.htm (Accessed on January 28, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/54\">",
"      Krystal AD, Durrence HH, Scharf M, et al. Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep 2010; 33:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/55\">",
"      Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2008; 69:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/56\">",
"      Walsh, JK, Erman, M, Erwin, CW, et al. Subjective hypnotic efficacy of trazadone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 1998; 13:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/57\">",
"      Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005; 66:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/58\">",
"      Fern&aacute;ndez-San-Mart&iacute;n MI, Masa-Font R, Palacios-Soler L, et al. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med 2010; 11:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/59\">",
"      Almeida Montes LG, Ontiveros Uribe MP, Cort&eacute;s Sotres J, Heinze Martin G. Treatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study. J Psychiatry Neurosci 2003; 28:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/60\">",
"      Baskett JJ, Wood PC, Broad JB, et al. Melatonin in older people with age-related sleep maintenance problems: a comparison with age matched normal sleepers. Sleep 2001; 24:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/61\">",
"      Buscemi N, Vandermeer B, Hooton N, et al. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med 2005; 20:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/62\">",
"      Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004; 116:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/63\">",
"      Zhdanova IV, Wurtman RJ, Regan MM, et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001; 86:4727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/64\">",
"      van Geijlswijk IM, Korzilius HP, Smits MG. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep 2010; 33:1605.",
"     </a>",
"    </li>",
"    <li>",
"     Mendelson, WB. Hypnotic medications: mechanisms of action and pharmacologic effects. In: Principles and practice of sleep medicine, Kryger, M, Roth, T, Dement, WC (Eds), Saunders, Philadelphia 2005. p.444.",
"    </li>",
"    <li>",
"     FDA requests label change for all sleep disorder drug products. FDA News. Released on March 14, 2007 file://www.fda.gov/bbs/topics/NEWS/2007/NEW01587.html (Accessed on February 26, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/67\">",
"      Buckley NA, Dawson AH, Whyte IM, O'Connell DL. Relative toxicity of benzodiazepines in overdose. BMJ 1995; 310:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/68\">",
"      Joya FL, Kripke DF, Loving RT, et al. Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem. J Clin Sleep Med 2009; 5:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/69\">",
"      Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 2005; 66 Suppl 9:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/70\">",
"      Gray SL, LaCroix AZ, Hanlon JT, et al. Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc 2006; 54:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/71\">",
"      Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003; 17:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/72\">",
"      Kudoh A, Takase H, Takahira Y, Takazawa T. Postoperative confusion increases in elderly long-term benzodiazepine users. Anesth Analg 2004; 99:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/73\">",
"      Glass J, Lanct&ocirc;t KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005; 331:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/74\">",
"      Kripke DF, Langer RD, Kline LE. Hypnotics' association with mortality or cancer: a matched cohort study. BMJ Open 2012; 2:e000850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/75\">",
"      Erman MK, Zammit G, Rubens R, et al. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J Clin Sleep Med 2008; 4:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/76\">",
"      Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999; 281:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/77\">",
"      Morin CM, Valli&egrave;res A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA 2009; 301:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/78\">",
"      Baillargeon L, Landreville P, Verreault R, et al. Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial. CMAJ 2003; 169:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/79\">",
"      Chesson AL Jr, Littner M, Davila D, et al. Practice parameters for the use of light therapy in the treatment of sleep disorders. Standards of Practice Committee, American Academy of Sleep Medicine. Sleep 1999; 22:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/80\">",
"      Czeisler CA, Richardson GS, Coleman RM, et al. Chronotherapy: resetting the circadian clocks of patients with delayed sleep phase insomnia. Sleep 1981; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/62/13290/abstract/81\">",
"      Mathes AM, Kubulus D, Waibel L, et al. Selective activation of melatonin receptors with ramelteon improves liver function and hepatic perfusion after hemorrhagic shock in rat. Crit Care Med 2008; 36:2863.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7691 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.28.111.102-85BFFBD9BA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_62_13290=[""].join("\n");
var outline_f12_62_13290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BEHAVIORAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sleep hygiene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Stimulus control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Relaxation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sleep restriction therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cognitive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cognitive behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nonbenzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Melatonin agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Diphenhydramine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Barbiturates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Over-the-counter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H947205\">",
"      - Common to all hypnotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H947212\">",
"      - Nonbenzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H947384\">",
"      - Melatonin agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H947219\">",
"      - Older adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H947253\">",
"      - Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11704147\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11704037\">",
"      Choice of an agent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      COMBINATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5744619\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Insomnia related to circadian rhythm disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Phototherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Chronotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31065860\">",
"      Cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11704216\">",
"      Jet lag",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7691\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7691|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/3/6203\" title=\"table 1\">",
"      Rules for good sleep",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/54/3947\" title=\"table 2\">",
"      Bootzins stimulus control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/33/8731\" title=\"table 3\">",
"      Sleep restriction rules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/16/40205\" title=\"table 4\">",
"      Pharmacology benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/43/17085\" title=\"table 5\">",
"      Pharmacology nonbenzodiazepines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41541?source=related_link\">",
"      Clinical features and diagnosis of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/22/34153?source=related_link\">",
"      Clinical manifestations and diagnosis of hepatic encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35861?source=related_link\">",
"      Jet lag",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4758?source=related_link\">",
"      Overview of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/16/2306?source=related_link\">",
"      Patient information: Insomnia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/24/28035?source=related_link\">",
"      Patient information: Insomnia treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=related_link\">",
"      Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9561?source=related_link\">",
"      Types of insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_62_13291="Indications for nonobstetric surgery during pregnancy";
var content_f12_62_13291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for nonobstetric conditions requiring surgery during pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incidence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Appendicitis",
"       </td>",
"       <td>",
"        1:1500 pregnancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholecystitis",
"       </td>",
"       <td>",
"        1:1500-1:10,000 pregnancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bowel obstruction",
"       </td>",
"       <td>",
"        1:1500-1:3500 pregnancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adnexal torsion",
"       </td>",
"       <td>",
"        1:3000-1:4000 pregnancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breast or cervical disease",
"       </td>",
"       <td>",
"        1:3000-1:5000 pregnancies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma",
"       </td>",
"       <td>",
"        Variable (trauma complicates 4-8 percent of all pregnancies, but the incidence of severe life-threatening trauma possibly requiring surgery is 0.3-0.4 percent)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_62_13291=[""].join("\n");
var outline_f12_62_13291=null;
var title_f12_62_13292="Gastrointestinal peptides used in clinical practice";
var content_f12_62_13292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Gastrointestinal peptides used in clinical practice",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Peptide",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical utility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        Somatostatin",
"       </td>",
"       <td>",
"        Gastrointestinal hormone secreting tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnostic radiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Variceal hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bleeding ulcers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV-associated diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other chronic diarrheal syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reducing fistula output",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Secretin",
"       </td>",
"       <td>",
"        Diagnosis of Zollinger-Ellison syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnostic radiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic function testing",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Cholecystokinin",
"       </td>",
"       <td>",
"        Diagnostic radiology (biliary scintigraphy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic function testing",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Glucagon",
"       </td>",
"       <td>",
"        Therapeutic endoscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnostic radiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment of severe hypoglycemia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Pentagastrin",
"       </td>",
"       <td>",
"        Quantitation of gastric acid output",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnosis and monitoring of medullary thyroid cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnosis of carcinoid syndrome",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        GLP-1-like agents",
"       </td>",
"       <td>",
"        Treatment of diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Motilin-like agents",
"       </td>",
"       <td>",
"        Treatment of gastroparesis, dysmotility",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HIV: human immunodeficiency virus.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_62_13292=[""].join("\n");
var outline_f12_62_13292=null;
var title_f12_62_13293="Causes of TEN";
var content_f12_62_13293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of toxic epidermal necrolysis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alka-Seltzer&reg;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Allopurinol*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amiodarone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antibiotics, esp. tetracyclines and penicillin*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anticonvulsants*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antipyrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Barbiturates*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Brompheniramine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chlorpromazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dapsone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethambutol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fansidar",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fenoprofen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gold",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Griseofulvin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ipecac",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isoniazid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            NSAIDs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pentamidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenolphthalein",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Quinine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Streptomycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfonamides*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tolbutamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trimethoprim",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aspergillosis (pulmonary)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Escherichia coli (septicemia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes simplex virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Measles virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Varicella zoster virus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Miscellaneous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Graft-versus-host disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Idiopathic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neoplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hodgkin's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leukemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Non-Hodgkin's lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Vaccinations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            BCG",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diphtheria toxoid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Measles",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Poliomyelitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tetanus antitoxin",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Most commonly associated with toxic epidermal necrolysis (TEN).",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Sanders, CV. Diagnosis of the patient with fever and rash. In: The Skin and Infection: A Color Atlas and Text, Sanders, CV, Nesbitt, LT (Eds), Williams &amp; Wilkins, Baltimore, 1995. With permission from Rohrer, TE, Ahmed, AR. Toxic epidermal necrolysis. Int J Dermatol 1991; 30:457.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_62_13293=[""].join("\n");
var outline_f12_62_13293=null;
var title_f12_62_13294="LT inhibitors in asthma";
var content_f12_62_13294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Benefit of leukotriene inhibitors in asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 232px; background-image: url(data:image/gif;base64,R0lGODlhsgHoAOYAAP///4CAgAAAAEBAQMDAwAAzmf8AAICZzNDQ0BAQEEBmszAwMHBwcBBAn/9AQKCgoMDN5v/AwP+goFBQUCAgIPDz+eDg4FBzufDw8P+AgKCz2WBgYGCAv+Dm85CQkJCm07CwsP8QENDZ7CBNpjBZrP/Q0P/w8LDA33CNxv8gIP9wcP8wMP9QUP9gYP+wsP/g4P+QkI9AQI8wMI9DSe8DCQ8vj0BNZoApXJ8yWV9fn+/T2e/j6T8sRp8TOe9jac8JHIBgYK8PLwAfX4BwcICDiX9pnL8GE98GE18/f+8AAD8mcu8yOe+jqX8ZTAAvj98AAICJvIBJfAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACyAegAAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/QtwgEhSABARbR2tvc3YYWDwkCgxgLAgsL1N7r7O3GAQLxgxsCHu73+Pm88oLiA+fZABC4RjCAOn0IKWEgwJChBQQDHgAYwCBhPn4A4hGgt0HQwIIDAiha2JBAQEMBBkQcgMAQRUQPWFoERiCeTWwGMw54BO/gTGMYxQkUsPPQNUU1bQoQaeiBgAkGsRkiiqhnJKo/G02rdu3kI5LwBICwkBMrgQkUMQB4wJSthX8b/yQi2JAWAFkQDEJmvWUhqUkA9AIErsoUEdh4IADkHbABwVsBGxhKDfAAgUiqA7NltuohwEK0A+wBmDtgwgOnFKTuPQROqKBy59JRsiBOZM3LO0E8ZfB04jjfCCicY0B7QYAEC4YSFSdx9ayw8URimBCvImFGtJcKSs0gAYXg59gKoCZA3DiqVnuqFyBRcEr2Fs4JnsA7gUznhaDPq2cJ9gSP2lFF3TXC+SbIPwBwJpZiAkyjnW6F4UfMUSOZ859HeQmV3ngZJScIehyuB09HAGDgwQTmBICAABQw4IFaWEk41W8A+AOQRwVd41Mh1C2g1lC4+VaQgQZuSE1PtwEpY/8xFCbS44+6TQCCOQmGyGGMIB45HjzCFbVAAh548OAA4iQX45KDYKQRRziCFCEhYkJ2zQNJUiXmBASA0BF19Gm4FAEr4klBAkomiaYwTR4S5wZzwhMACAUaqVOaO4lpnHADiUWdPSwSwJtBG4BAQAKEdurVkkGNU1NRKL05CHTxDFBnUQEI1xt4KI5jgXD/PSDcAi0laeihwCSKklJEwUZBpFaSxypVGPyzAHWZEoCBOAg4RdRSFphzTkthtYRmXxplE9hgRrlK7LqCGMvuL7BKR50A1qX77r3tqovvM+7uu2S//jYDcMDODUxwMgYf/FPCCjOpb8MLPwyxwxNLyHD/xcVKjHE+F2/cS8cec/ORXiEfA3LJ0YysMcq7nMxyNC5zAoEGHbxMScw2v/JAvZngrIkCJBRAwgEi5MzTyka30ldJdHHiMyYdNFABACdwMEIDHJwwddLXcW0LrLE6jfQnKHBQiAgHBH3BBzV7/erYbp8yqn0qUcBqz3B3MgIEiFSgwQUNkIBC0V4/HTcoeb16NyaGV3LCCI2cgMLVHGiwtc2NH97JQ4Nwvknmk6wNiQgfBK0A2y+DrnkmIDzw4yeqQ1JBAW1H4jcHDYyAAt9ZeY736rHAk0BjsOetyQcXYALB5FhbblFKmKgMPCwWeGArBS+KrQoJGmzSwQcKCP0B/+HexKRS3YtPIv30sSDQ3ZmMG4+JCA18cnvuKJzQDdjwWxI7+5aYiz+0hwoOoGAUIkABCRpwAedFYwDpYEjTNPE/AEaCLLZ6yo4uUUFGNIB8o/jeBYRGtGfsbBAnpKD8LEjBeGDvVIbYymvYohp7nUIDJFBFBaqWu6wt43XFY+EqPBAZ7ISDRtBJAAzzhYoGugJtajsABHg3odQsMX5CzIV+PJKNAXWtFB0owOVc0QENoABoBSiAAhRwAClScRdHfEpzPrfCLPpvHAyoiEoSgZH9NOcjBCFZKQ5gtltUAAInOMAZR1CABijgAgf4AARASIsHzAtMdLQjKuAxkZ3sEf8RfRzNOQYByGsIkhQj0N8vOjAzQiqAkY6EpAYgULtXgCd9leigJhPByT1+8hB9DIePeFlHSUAAcshg5QcOcAEFNKAAI1AABw4wy1qOAgOWtAmJfuc1v73RFfzDJbnGkw0xJYABlPniKKYZDRFAYJnNTCMJFICCA5wAAmPURByHJy4VJs1vI7zAN1sRTqMoRST/sAkuE1RM2dGuHVNs4xrlSc+BTgIeEQniywBagAbmcxu6NIQGFDATREoxE44JRUh/wlGP3iIma5kjAUfBvY3B9DSK4RkHGyqjljoQF71c6E5JETWPBbWTmZyYTz96i6N6YqWDKJtRx+FLoUoCquz/WGqxlrKsOc00FB+cKpnsYx9EyLBENLwiQwmmVUQhq3/+4ykjHheyghaiNUi0iRLVya62EqOUXk1qKETnsaWVpJ+vsgkpu6gdG67LrzKCahiZ2rCBjAaxwKSRH/kqIciiCarIK5lT+ahZUXpIIDk6pXM8SyyoplK0VLVqRjQrzNcBVrVZOUFAf4qvlYoAmXUdDzoYglm7+KWc5UGnTAmB1WJE7QOUfYaJCLLcoYLCgCizK3MP6huFcnYm9GxHQsMm2E5UoAHWxMQhLXqI8FZipJSshfnO9xJ/MmK9jnAvJeDrirRFFxrnaEhx1WdKuSICh55AQRpVaQgIFOAAgqCm/yTCF+ECsHd/SFNwARhcCAdDGAASjgSFQWzhVkAgrO0wTifW5wkFdE9vaSwkACDAAWmKgANqhDA1KyDhDtgTAB2oMQdAeMwHQ+AABfhAjVUJgWaiYGoaOMD3WNnM00VYA+CDMNr4duT4PgdpjCyAjGlsYxyzEcSW6/GPg2xjQhRZikhWsgKY7GQoS5ltTV7jB66cZQBsecYlPEQFRrBndzAgNYG1byei9t9JnCDJz5yag4fGxqBFEwBqBMDVAPCBAtAscAdoQP0GoYFnuhjJjkxjBx59AQUnL3zPPPI0w9e9RqJghGzrKABGmN4vzxXSYpwxCSsNTZJmetOd/vTQRP9NiFKrMcqNDB/tWO1qAMDawoQ8AK0x3YBbJzmMyeM1Ii6QvHuMF665NLAhpNoJHAfZ07t+KJA9LIhMI1m3Uuv0rEs8iBEjmW8KbvKDD8BIawcbABVAXtAgnOnZkTR84NYFw9yN4+6Je94PrjdJ7w24hItZ2/wWhL9LHPARtrHg4dtawi+wcEyT1OEGj/ghPjCCRkdjGgL+6ib2Zt40vlJoBndzxl0OZDGLmcTTbGMtR863f4evjW0MuiAW+IFOM5ykRNeA0DYscY3NTo2MzOGIBUFvoocRx2ZDctKlTAimkxgCT4e61AFAdasTPetb5/Ag6Oflg3WQrp3Q98kLQDr/MR9Zih3VX6bpnka+iUBo9xxc2zeMthL/u9MCrdrcobm8jAuNxklG+DNHjYk4ovuiGhM8wQmv78M7+AKKx3rQSvx4EkQehOE7QeWbbmHMI9JsY+e8ghlOAtDv+byNFPTQ8DGec8s2Eh1kZyeCtjUFH3D1DdAfrO+udeCeYPYkqOUJnrlMy1s+zK8uAKl97nlRF+CAgsAx/DHhD5XoNK6LoL4grA9iWGo/+YvXfYPwffIkfuT3b2/Xf2mUfuunRu33TPMnf4dQY/nAEothfzqnXvJmEYtHCEHTa5NwThrlDB04CB9oCONnc/5SQaH1EyXoZy9oCQywTRmoDC/4eFhH/whRo3cVU0E1ZTTOV174IDjZpW6CQD9cc4H1xU35kDYs8z8oMH+71AjNpQsn1nfugAF5gQBSUoOVgGI2Y4H0dX/plg/n9WIWMS8bcSGKhgkIZjTNpxTPdzT5QG5ZUQ+yAj1CaAmENYWOUIW3QHMquA5iISul0QjYFADZQ0yaMFl+SIfu8HhYiA8bQCrCUV2GABv/kABAlB/qRkiPCIlZRQKFlhXTkVyNUBPJ8Q8b9Daa8FqhiBQF5g4UKCEpxQiwsQAUQIO3ZWDHdDjWQBYDFgks5g2lNojiFSrxMIyEgAGV+Cu2lVoGJn1ewxvjMQE0aF3eEDUXhhCFSAELkI2Kov8dXvRdtoNecTM86aCHTNgNRIgf4zE87JgITpEO5oCJTHQJI3U4zbcRc/iHRsgLCiQjulgPE7QI75MaipA5P+g2EEQBm7KH0HBiIDgTo7IAtCEabTgJjHY4CGAew7SR0HCGcdM47KY5gNIJgPgK0oQmpvePAHkJYOg2NEQQzAh9AYkLgogmy7Ic4oh/jgNccXNuGtGOzyCJhyIWePSTZVgJfTiUHsAQFAGRRtkMg1aKqEIAxoEWXtgIs4OMIbMgCRISMLmQOVkLHFBuhxKOYUGGTTkJLag5gxIA3QEVZcmI0HCM9xImKllMsKg5IGAeCeA+GgmUzkA/3egcwagiXbn/CEg4PSTRl9CwfOxijWfBlDdTR9gFPNOVaFjkDAP5Luo4EHe5CDhzXhWZNEEoksgwfqkJjwQgKwdZlY3whsATYMQlkcZwXjx4KA8Zkbq5CC7GPir2FWyxiOZYDC2JLx8ZDyF5CcXoCI44PYdGXYugieXRicx1lv1FAmC5GimpCdHZCKDIPquZCKroG62Yj8mAlPvyS5IZCTzHPjiXmxVyDrtICL2oDFcZMPPYmIcAeABUnzdZIs94DtHoJspghwHDG+fjlpkZCdRInXK4CGIiEuXoWMagATVHMOdJm4kwO6/JNfbBVRAqCPWoleyBl8aAmAfTFyViLQBaCH/DQuMh/wAYEABsmAgJKTErCQoVQJkEMy0lkp/BeQgNyT6FiCKlyaLEcEYNwyFjOaN7R3oAhE66saKs6Qtog44Kg0kAMAE7+pmNcJJChAAFipPBQDqAw0C9uS/0gA5auqWHMJP0CRpLSKa6wKaitjaTuC/OiIpUCgC2aUEZdHpXxZ2awKcMND6xuJ2O8JQA1BtPpaiVwKh+ajNc+KBUOp0sRB8j+ETI06eOmjSHCpPToFZrxQhKJkQq8SWcSqekgKml6jaUCgnN6aNg9qaa81aIqqaoQKt/mjOgGgneoquM8IuPCqKdIKwsVImxaprn1FhtEkgrs5lZhCJ2kQBGCFX41qjDev84H2pWYuEo+imNi4CamiSWiSOrmKA74bqsVcJdySkI+7iuiaEYTVqv+iiUmoQNNZlOi7A0HKFWCZOkQjQB58QbhamNnjACaLhLcehdf0itGmoIHalJ4IGgR2oJHBqK1lKf4SmrZqpJI+uulQCx8goKBjMC8bqypsmdHwuzlZoIAkqzkjCemfCXOEunktqzjqCz+piDsXiLt7ilIuqHdCIIIJCvzJqyickLJRABKiAB7EAy/+mwhBCXu0Qy7fq0k3CvvzC1GaACDpACBpACDtACBmC13AAR3qESZaWbPJtFSaEUY2qYrxi1rkC2Zou2aqsCGRABJUAIEtC2IoMsCeD/tLT5mLsEt3ZTGmkqipkAPoTgAhmQAS4QAZxbuKfgt2ebtg4guITLCIfrttvAAPiop4OArVO4tDWrCedFRSaQAoLrALgbugawuyuQuyyQuZm7uZ37CKALuKM7uJ4rCafbDQRag3aqsXh6osCaCdpGCGa7CJzLuRIAvBmQu7rLu76buX8ruqSbvJmwvNpgjeQlkoU6hafasY8wu4NQAgbwAp2QvRGwvZlbuqOAvgDGrZ7JutYWsVN4q4PKCNU7CA6QAc3gv86gkKFadN+pOcUan5cgv4IgASlgAs7gwMyQFzkXPbNICOUZitCKgShLnjloAiEQAdDgwcowrpQQnfMZ/4oy/JaVgMEA0AIsoA0wjAwBu7qo52b+CrQ4TAkJDAAREAL268OI2wyLObmUO6GPqIUs0YUprAg6vAIMzA0/XAyWiY0zlbSPqoYbkLdHLAlJDAMrsA5fPAyjmbWGKbaxiIekCb9a3AC8w8Iu7MZPjAz9OJtkirCPWIixicYRWglJzAItUAr4q8AqQAkl4ACoq7x/bAy/yR9J5biPWoneMaeLkKpmmcMotsQcTAq7u7shULgG4ACUEAEG0MWU8Ma/0Jwcm1QlG4qnKIJaURujjMQylgIwYAq7CwAwYAA93MoA8AItgLsqcMoSwAKjawIm0L0s4AJKbAAq0MzYDAAl0P/Mz9wItPwLJ2tfz/uI1mAXjMkIx/rLkqCuANC9p1DMsOzKyhwBC8y2jZwByJwBKRABKxACGbACBjC1aTvQBf0CIcDFC+0I47wL2kobAXkU3wezEHyI0vop56qgk1CeCm2+o7C7CG21ygwAEtDMyhwCKSAIJlDPGcC2gxvLAOACsXzM2KwCBe3QlxwM7Lqv1/GzoSilckwIK2INFruf7+ylo4sKu4u7bqvMOK0C9QwAJZ3NC7y/sMzAWc3PLszVj/DQuNDTYuOpy7qLGFAOmNkuyPIwOMNuLhACp0zMBlAIyuwABuACh+vKLGAAMBABLLDEISABEQADgm0ALQDQBU3/v3+dAiEQCWBtCwqbR5qsQly7rLCynp0jQZBhsPITRjVTu5VcCsVMCMpcAiHQyspsAi1w2inwAiWw12m7uQZw2oGdwWi7AiAtzjvdCxv7nHhTtyXT0oPLCTGBxVRosa0iCRxQSPK8Go9dC+U8EmzhOgtpA0U8MS0NA2Z72mvbx5mAU7H7CJ7tzfWLH88dC/DZCOYgLQspBFKoMIO93a3cAoPbxJ3AleHtCMstCAssI+f9CkONCFESpmJ5CETgBCO6JPnbvbf9uy5g36LgKyEMtoUw3hoc1+a927jgoCi8kNphrtV6DTMQBfdSAtsbuivg4LldCjecyPptNizczUvy/9+s0OLbJRIgjloFEQNJEMkyUgKYywIErbYZIAErrgpBjMeCMN4q0MPEQuO8ICYVwbC8BAQrsAIQjhAvEORDvsCCjQsLEeZKDgD7bdpZPuMaTgsIYA4EgD3Y0SnCwdkAoAIhIOPt8AIR8NJ2HQKj29e9oC1aKb2Q0DHjzcX3AuWn8CUJ4Clz6CssIsQU8tY+3g0uIM2z3ecRgOG+AI4UcMdZvN8wsNL4guilYMgBPsSC8AIOgNvbYAIsINCZDsixyeh47Nl87C+kPgpgMgCQktaJWggZUNuV8Mj8PemRMMmhbQlvzQKabgy7aBy8TOFkbjYt0MgBk+sqpRSYjeqEsP/ELdDsjpDKs83KrjwJWZ0Jrl7nUKxXqjq9icBopnww2A4KHlAajEubJrDqR74IxXzMyezKzOzM0CzNz1zNDnDN2bzNDtDN3zzNjvDW3/4MluEB7e7uiMBOwtww8w4vDxPsyc4I9KzM95zPhh3P/fzPAY3QBp0CKq/QDN3Gi6Dq//wMZIGcHctoAz0xG68J9cGdBuPt4J4IIk3QJF3uJ23XrqzSLO3SMH3uNJ0BNj3nOZ0IMBAC4ewM2ZGdFnzxB6DQ3q3xH78KWVqUW38I+c7q4d7KlCwIUK3NU13VLo3VMr3VBtDVdY8IMv/1zSDlVN6YjMYCxm7EzEUBZw3BVOr/8WlP165s13itzHvd138dAoE92IV92ARdAoodAYyNCFV/9dCgh7iltYXARm8d9EYcABEUjtGtt4oA9CA/16TtyqaN2q6s2qzt2rCdArJN226rwQaA9oSQ99xwHHJrN4JOuR3WADuQAmEv+Nol7SzNAimw77HQ+abPDM8/wyPcXgfQ3IJ/CPMVrdA/CMc8zLYg/N5gWBNeCUJ7Yjow9d+vCjFTAinA7LRQ9Rlw/e8CMGwECA4ZAISFhoeIiYqLjI2Oj5CRkpOUlZaJAQGVJiwpJZegiCUrK5+hp6ipqZmJEA1MKSaqs7S1tre4hgSZA5qWMAYwuY8ZBoPDyMmUrIgK/1AhLsrS09TVkbsBvaAlKSyy1aOl1uPUzIauPg7k6+ztuOaWnJ7Uxcfu97TwhApFIS/4AAMKXKTvVzBl4UwNXLjMVyFXS+wxnEjRWkFL3LwNq1exoyN9Cm6k8Eiy5K2L8VqEiHArocmXheBBqEGDJcybOCWhvCQhhERUJjKEEJbTJDwFPVgUXcoU0c5Loxx8OxUhhYN/TT2ag6DEX9avRZ9eMqHS5lgVQ8FqdajgB1G1cEuKBdXzp6SqV+NWZAahyQq9gDvO3bZC6iQTaN8GXsgsR83FkAcOBkV2ZSS8WCNL1nQiSAvNoO9NDlXXEeK0oTcDQBJiaurX5RwOi5oZEf9m2AIzaTgiAbdvVRYIICAoGxnaaIcqI/+NDMODAA8wMMqEQx3z65YwLBAwgDg1FyFUGAKvEfuw7QMELJjOw4BC8/AdMRDA3Tu1F6RecIIWPxcIARMAMIEAIBBkhHj9JagIAQIEUJ8io9GCVgjlKViLg5pgWAg2mQQwwxNDdCjiiCSWaOKJKKao4oostuiiiQTARB93GFDAAIPdEcIhL7286OOJMsjw45BEFplijBY1CICGOo4YQwxGpjhAj1GaOGWVVlKJ5YjavETAlwgwOOODO2aj5ZYsXommi2qumWZx0nggAAMAzOeBfSfBOUuEk/DZp54lYfClnAsMhwmgyfj/qYqiqyA6jAUCUEAABQJYgKctjEKS6UeOnrIpQDheGhs5n4JS6iUPUErBA9N1Gsqpou7pqqmzMgVrJbc2RGqt6+TqFK+4AvtnLr4yVGwkx2oqrKx7LauTs8hC+0iyhFAbkLWNYNvqrhV9mYu3uIBri7jjIrkYudSgO4260rBr4bvwxivvvPTWa++9+OY7i3PQSXeLcLiAkIm5qiDgQb+3hGkpYPxGV40FB3vgbzUKW8OvtMmgp54tCDiYYy1i0lfgLGN+PAsCCSgJmMbrUZMefS1Tg7LK08w8AAUM/RfggCPP8rLJswQHgJxAn8IqpALYsh3NcOksIIHUgIBBjQIQ/6zM0hhbQqmhxirJJC2h5vKAABuAPF/WmCRwNmAafk0NpQtLE4DaTCeDQKSUBsiY13WnEvYtNSYQtyoPpEfnyQS6rVbbfScj5+HS3C1w49+qR8B2rA70eJ0C3AnygxxTkADXtaRn9atjUs7U5nZWM1/Z5aSOtiR3d6c4PpBKCnctBls+sSoEpLxBrpcHMF+lQX+5AdmDg5X7pMhPMyAFA08THAHLb9A8MpSCsN3p+KQaaea0vEwf+KiPGfTSFPScj+pNib9qNbInOfskCGyXAPn69u///wAMoAAHSMACGvCACEygAhfIwAY68IEQbIegDBUmQgRne4lAwAD4F8GOhP9JOoJamLsQwYCiddAWGKAPIbYGgPS4bxEMut8Jk7G2sQWIQTFrRHpmiIzvIe1O9JEOASYwAAaAMBsTKFAMASCw4XhgSgzAIA/H8Z/uLC8BS5oTADCAxJFZYAMD2MBwdsjFOyEAjBPg4BRx1TlCTSBUOptPgBaQgABsJ0wNYlDZlscAO6JvjfTDYgLuaDoA0NGOAkCABQY5NyzucACjg9QCArABvQHSEgyaABEZkAA5aWJAmdgadyiZxzkNUjoDmkAA/njJaaRnbP/xQMoAUDtSBkBOwzNdehzEqrvZSGKtvEQCKBWA/7Bwlx3CUTIZlIBmgnADS3thMKkhJ0oZMm+lAFDmwBw0vExYID3EJAQIILmxaVJiQIkEAH2wODQAEQAEZWvmAwjggXnOSU4B2oAHCNA6c1rjbgDKYucIIU96PuBuCwABPzVYqa1hT6HN9Ock5MTOVMaEUgFFADrbt8T0HCxlapPoOFJmRvpQcKMF8h7Mvpk0BlEgfzAjnUhnStOa2vSmOM2pTnfK05769KdADapQh0rUohr1qEhNqlKXytSmHjUQADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of the leukotriene synthesis inhibitor zileuton (left panel) and the LTD4 receptor antagonist zafirlukast (right panel) on FEV1 in patients with mild to moderate asthma. Both drugs significantly improved the FEV1 compared to placebo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Israel, E, Rubin, P, Kemp, JP, et al, Ann Intern Med 1993; 119:1059 and Spector, SL, Smith, LJ, Glass, M, et al, Am J Respir Crit Care Med 1994; 150:618.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_62_13294=[""].join("\n");
var outline_f12_62_13294=null;
var title_f12_62_13295="Serum T conc 3 preps";
var content_f12_62_13295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Serum testosterone concentrations during the course of chronic administration of three different testosterone preparations to hypogonadal men",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 559px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) During 14 days following the injection of 200 mg of testosterone enanthate. B) During the 24 hours after application of one or two testosterone patches that deliver approximately 5 mg of testosterone each. C) During the 24 hours after application of a testosterone gel containing 50 or 100 mg of testosterone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Snyder, PJ, Lawrence, DA. J Clin Endocrinol Metab 1999; 51:1335. Dobs, AS, Meikle, AW, Arver, S, et al. J Clin Endocrinol Metab 1999; 84:3469. Swerdloff, RS, Wang, C, Cunningham, G, Dobs, A. J Clin Endocrinol Metab 2000; 85:4500.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_62_13295=[""].join("\n");
var outline_f12_62_13295=null;
